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1. Summary 
Gene therapy has been considered as a viable therapeutic option for life limiting genetic 
diseases (e.g. Cystic Fibrosis (CF) and ß-Thalassemia) lacking conventional therapy. Over the 
last three decades a shift of opinion was observed in the scientific community regarding gene 
therapy, from US Food and Drug Administration (FDA) halting all gene therapy-based trails in 
1996 to approving 9 clinical trials in the last 5 years. A similar trend can be observed for RNA. 
After the discovery of mRNA in 1961 it was kept almost untouched by scientists till the 21st 
century and 2016 saw the first mRNA based clinical trial. Originally, RNA was known for its 
instability and for being immunogenic. RNA can activate immune responses by interacting 
with various pattern recognition receptors (PRRs) like toll-like receptors (TLR3, TLR7 and 
TLR8) and RNA dependent Protein Kinase R (PKR). In recent years around 150 post 
transcriptional chemical modifications of RNA have been reported that allow for a greater 
variety of the 4 basic ribonucleotides. These modifications can influence both intramolecular 
(more stability or flexibility) and intermolecular interactions (with PRRs, less immunogenicity).  
 
Studies conducted during my PhD provide an overview of how mRNAs can be improved for 
gene supplementation or gene correction therapy by introducing chemical modifications and 
sequence optimization. For gene supplementation therapy, cystic fibrosis transmembrane 
conductance regulator (CFTR) mRNA was in vitro transcribed with 2-Thiouridine (s2U), 5-
Methylcytidine (m5C) and N1-Methylpseudouridine (m1Ψ). Chemically modified human CFTR 
mRNA (cmRNAhCFTR) showed significantly higher CFTR protein expression and channel 
functionality in CF bronchial epithelial cell line (CFBE41o-) compared to unmodified hCFTR 
mRNA (mRNAhCFTR) and plasmid DNA expressing hCFTR (pDNAhCFTR). In vivo (Cftr-/- mouse 
model), cmRNAhCFTR together with Chitosan-coated PLGA (poly-D, L-lactide-co-glycolide 
75:25 (Resomer RG 752H)) nanoparticles (NPs) can drastically improve the lung function. 
Forced expiratory volume (FEV, the most important parameter considered for CF patients to 
determine disease progression) was notably improved by cmRNAhCFTR compared to groups 
treated with pDNAhCFTR and unmodified mRNAhCFTR regardless the route of administration 
(intravenous (i.v.) and intratracheal (i.t.)). cmRNAhCFTR also exhibits reduced immune responses 
in ex vivo and in vivo experiments. 
 
The second study investigated mRNA encoding clustered regularly interspaced short 
palindromic repeat (CRISPR) associated protein 9 (Cas9) for gene correction of a common ß-
thalassemia splicing variant HBBIVS1-110. Cas9 was observed to be the superior programmable 
site-specific endonuclease in comparison to Zinc-finger nucleases (ZFNs) and Transcription 
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activator like effector nucleases (TALENs). Cas9 when delivered in a plasmid form did not 
achieve sufficient amount of double strand breaks to result in significant gene correction by 
homology directed repair (HDR). Chemically modified Cas9 mRNA (cmRNACas9) induced 
higher amount of double stranded breaks and subsequently HDR in K562 (immortalized 
myelogenous leukemia cell line) and bone marrow-derived CD34+ hematopoietic stem cells 
(HSCs).  
 
The final study provided a new angle on increasing efficiency and reducing immunogenicity 
of mRNA by taking advantage of the degeneracy of the genetic code to exchange specific 
nucleotides (especially depleting Uridine in the mRNA transcript) without altering the amino 
acid composition. Sequence engineering of Cas9 mRNA can increase the functionality of 
CRISPR/Cas system (by producing more double strand breaks in HBB gene) in CD34+ HSCs 
compared to non-sequence engineered Cas9 mRNAs. The reduction of immunogenicity was 
achieved by sequence engineering and introduction of 5-methoxyuridine (5moU) further 
decreased the level of measured cytokines.  
 
All the findings during the PhD thesis contributed towards a review article putting the 
outcomes into perspective of the current state of mRNA research. The article signifies the role 
of target specific components like route of administration and carriers of mRNA and how it 
can be formulated together. Finally, the review article reflects the importance of chemical 
modification and sequence engineering as milestones in development of mRNA therapeutics. 
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2. Zusammenfassung 
Die Gentherapie wird als mögliche Therapieoption lebensverkürzender Erkrankungen (wie 
z.B. Cystische Fibrose (CF) oder β-Thalassämie) erwogen, welche bisher als unheilbar gelten. 
In den letzten 30 Jahren hat sich die Meinung über Gentherapie in der wissenschaftlichen 
Gemeinschaft stark gewandelt, vom zeitweiligen Stopp aller gentherapie-basierten klinischen 
Studien durch die US Food and Drug Administration (FDA) bis hin zu 9 erfolgreichen klinischen 
Studien in den letzten 5 Jahren. Ähnliches kann auch zum Thema RNA beobachtet werden: 
nach ihrer Entdeckung im Jahre 1961 galt RNA lange Zeit als zu instabil und zu immunogen 
für therapeutische Anwendungen. In der Tat kann RNA Immunreaktionen durch die 
Aktivierung sog. Pattern Recognition Rezeptoren (PRRs) wie Toll-like Rezeptoren (TLR3, TLR7 
und TLR8) oder Protein Kinase R (PKR) hervorrufen. Hierzu wurden in letzten Jahren etwa 150 
posttranskriptionelle chemische Modifikationen der 4 Basen der RNA beschrieben, die für 
eine höhere Variabilität und Einsatzfähigkeit von RNA sorgen. Diese Modifikationen 
beeinflussen sowohl die Interaktionen innerhalb der RNA (erhöhte Stabilität oder Flexibilität) 
als auch Interaktionen mit anderen Molekülen, wie z.B. PRRs (geringere Immunogenität). Auf 
Grund dieser Weiterentwicklungen konnte im Jahr 2016 die erste mRNA-basierte klinische 
Studie durchgeführt werden.  
 
Die Untersuchungen im Rahmen meiner Doktorarbeit geben einen Überblick über die 
Möglichkeiten wie mRNA für Gensupplementtherapien und Genkorrektur eingesetzt und zu 
diesem Zweck angepasst (mittels chemischer Modifikation und Sequenzoptimierung) werden 
kann. Als Beispiel für Gensupplementtherapie wurde ein mRNA Transkript des Cystic Fibrosis 
Transmembrane Regulator (CFTR) Gens mithilfe von in vitro Transkription erstellt. Zusätzlich 
wurden Transkripte unter Verwendung von 2-Thiouridin (s2U), 5-Methylcytidin (m5C) und N1-
Methylpseudouridin (m1Ψ) chemisch modifiziert. Chemisch modifizierte hCFTR mRNA 
(cmRNAhCFTR) zeigte eine signifikant höhere CFTR Expression und Funktionalität in CF 
Bronchialepithelzellen (CFBE41o-) im Vergleich zu unmodifizierter mRNA (mRNAhCFTR) und 
Plasmid-DNA (pDNAhCFTR). Im in vivo Cftr-/- Mausmodell konnte cmRNAhCFTR in Verbindung mit 
Chitosan-beschichteten poly-D, L-lactide-co-glycolide 75:25 (Resomer RG 752H) (PLGA) 
Nanopartikeln (NPs) eine drastische Verbesserung der Lungenfunktion erzielen. Die 
Einsekundenkapazität (FEV, bei Mäusen 0,1s, einer der wichtigsten 
Lungenfunktionsparameter zur Verlaufskontrolle bei CF Patienten) konnte im Vergleich zu 
mRNAhCFTR und pDNAhCFTR durch cmRNAhCFTR deutlich gesteigert werden. Dabei spielte der 
Administrationsweg (intravenös (i.v.) oder intratracheal (i.t.)) keine Rolle. Wie erwartet konnte 
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außerdem eine Verminderung der Immunantwort bei cmRNAhCFTR in in vivo und ex vivo 
Experimenten beobachtet werden. 
 
In einer zweiten Studie wurden mRNA Transkripte vom Clustered Regularly Interspaced 
Palindromic Repeats (CRISPR) associated Protein 9 (Cas9) untersucht. CRISPR/Cas9 wurde 
hierbei zur Genkorrektur der Spleißvariante HBBIVS1-110 des β-Globin Gens, welche zur β-
Thalassämie führt, genutzt. Im Vergleich zu anderen sequenzspezifischen Endonukleasen, 
Zink-Finger-Nukleasen (ZFN) und Transcription activator-like effector nucleases (TALENs), 
konnte eine höhere Aktivität bei Cas9 gemessen werden. Auch wenn Cas9 in Form von 
Plasmid-DNA noch keinen ausreichenden Prozentsatz an DNA-Doppelstrangbrüchen 
induzieren konnte, um Genkorrektur durch homologe Rekombination zu ermöglichen, konnte 
eine Reparatur des Gendefekts mithilfe von cmRNACas9 in K562 Zellen (immortalisierte 
myeloische Leukämie Zelllinie) und CD34+ hämatopoetischen Stammzellen (HSCs) 
nachgewiesen werden. 
 
Der Einfluss von Modifikationen auf die Effizienz von Cas9 mRNA wurde in einer weiteren 
Studie tiefergehend beleuchtet. Unter Zuhilfenahme der Degeneration des genetischen 
Codes wurde eine Sequenzoptimierung und insbesondere eine Verminderung des 
Uridingehaltes innerhalb des Cas9 mRNA Transkriptes vorgenommen ohne dabei die 
Aminosäuresequenz des Proteins zu ändern. Die Sequenzoptimierung der Cas9 mRNA 
konnte die Induktion von DNA-Doppelstrangbrüchen im HBB Gen in CD34+ HSCs im 
Vergleich zur nicht-sequenzoptimierten Form weiter steigern. Außerdem konnte auch die 
Immunogenität der mRNA durch Sequenzoptimierung verringert und durch Verwendung von 
5-Methoxyuridin (5moU) noch weiter minimiert werden.  
Die Ergebnisse dieser Doktorarbeit konnten innerhalb eines Review-Artikels in den 
wissenschaftlichen Kontext eingeordnet werden. Darüber hinaus weist dieser Artikel auf 
weiter zu beachtenden Faktoren, wie Administrationsformen, Eigenschaften von 
Transportmolekülen (NPs) und deren Formulierung hin. Außerdem zeigt der Artikel in diesem 
Zusammenhang die Bedeutung von chemischen Modifikationen und Sequenzoptimierung 
von mRNA als wichtiger Meilenstein in der Entwicklung von mRNA-basierten Therapien auf. 
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3.5. Contribution to the publications in thesis 
Uridine Depletion and Chemical Modification Increase Cas9 mRNA Activity and 
Reduce Immunogenicity without HPLC purification. 
Prior to performing the experiments, the integrity of the Cas9 mRNA was analysed by 
Bioanalyzer. I collected serum from whole blood transfected with Cas9 mRNA and conducted 
various ex vivo human immunological assays (ELISA). Additionally, the mRNA in nanocarrier 
complex was tested in vivo by intravenous (i.v.) injection in murine model and blood collection 
for immunological study at various time points by me. I further contributed towards data 
analysis, graphical presentation of collected data and writing the paper.  
 
Chemically modified hCFTR mRNAs recuperate lung function in a mouse 
model of cystic fibrosis. 
I designed the outline of the paper, performed experiments, analyzed data, made graphics and 
wrote the manuscript with the help of other authors. In particular, the in vitro experiments 
including the production of cmRNAhCFTR followed by expression analysis of hCFTR protein by 
flow cytometry, Western blot and Immunofluorescence as well as the ex vivo whole blood 
assay to check the immunogenicity of the mRNAs were conducted by me. For the in vivo study, 
I treated the mouse model with cmRNAhCFTR by intratracheal and intravenous administration, 
collected saliva for determination of chloride concentration and measured the lung mechanics 
via FlexiVent with the help of Alexander Dewerth, Ngadhnjim Latifi and Georg R. Schweizer.  
 
Gene correction of HBB mutations in CD34+ hematopoietic stem cells using 
Cas9 mRNA and ssODN donors. 
The in vitro experiment to optimize K562 cell electroporation and compare different 
endonucleases for gene correction were performed together with Ngadhnjim Latifi. I 
contributed towards the meticulous preparation of the manuscript. 
 
Recent developments in mRNA-based protein supplementation therapy to 
target lung diseases. 
I contributed towards the literature research, designing graphics and writing the paper with 
emphasis on post transcriptional mRNA modifications. The paper structure was designed by 
Itishri Sahu, Brian Weidensee, Michael Kormann and me.  
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4. Introduction 
“Victory has 1000 fathers; defeat is an orphan.”-Count Ciano.  
4.1. Gene Therapy 
Forty-seven years ago, in 1972, Theodore Friedmann proposed a prophetic account 
regarding the potential advantages of gene therapy along with the downsides1. But “Gene 
therapy” was coined to separate the term from George Orwell’s proposed dystopia based on 
“human genetic engineering”. The term used by Orwell was influenced by “Genetic 
engineering”, which was first used at the Sixth International congress of Genetics held in 
19322. Gene therapy is by no means a new concept and the early history of gene therapy is a 
combination of missteps, attempt of experiments before the necessary tools were available, 
extravagant dreams of numerous dreamers. Just as the rudimentary flying machine made by 
Wright brothers led to the sophisticated supersonic jets, development of recombinant DNA 
technology by Herbert W. Boyer, Stanley N. Cohen, and Paul Berg opened a whole new 
chapter for curing untreatable conditions3. 
 
4.1.1. Molecular genetics and Gene therapy (Early age) 
Genes can be transferred as nucleic acid (in Pneumococci) was first observed by Avery, 
Macleod and McCarthy. This proves to be a vital point of reference for molecular genetics4. 
Further studies provided evidence of viruses containing the capacity to transmit genes5 and 
becoming an enduring part of cellular genome5,6. Rous sarcoma virus (RSV) can successfully 
transduce cells in culture to reproduce virus, providing the first evidence of viral gene 
mediated cell transduction. Similarly, Simian Virus 40 (SV40)can integrate viral DNA in SV40-
transduced cells7-9. Two more important discoveries, structure of DNA along with its function10 
and central dogma (genetic information flow; DNA to RNA to protein) provided fuel for 
advancement in the area of Gene therapy11. 
 
Arthur Kornberg achieved replication of DNA in a test tube12 which further helped Waclaw 
Szybalski transfer a mammalian gene for the first time13. From the late 1960s and early 1970, 
gene therapy became an important part of the scientific community. This lead Martin Cline of 
the University of California Los Angeles to conduct the first human gene therapy but without 
obtaining approval from any regulatory body. The recombinant DNA advisory committee 
(RAC) was already working with the US Food and Drug Administration (FDA) to regulate gene 
therapy and created a new committee called the Human Gene therapy working group (now 
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known as the Human Gene Therapy Subcommittee (HGTS)) to avoid unregulated gene 
therapy. In 1990, the HGTS approved the first T lymphocyte-directed gene therapy for two 
children with Adenosine deaminase (ADA) mediated severe combined immunodeficiency 
(SCID). The trial was not a success as transduced peripheral blood T cells cannot elevate the 
level of ADA significantly14. In 1993, Hematopoietic Stem cells (HSCs) based gene therapy 
was conducted by CellPro on ADA SCID patients with no significant outcome but this paved 
the way for stem cell therapy15. Stem cell-based gene therapies were conducted in 1999 on 
human immunodeficiency virus (HIV) patients and the study produced valuable insight on 
stem cell therapy but failed to be clinically significant16. 
 
The downsides of gene therapy were exposed when Jesse Gelsinger was reported dead 4 
days after being administered a high dose of Adenoviral vector for the treatment of ornithine 
transcarboxylase (OTC) deficiency17. Stem cell therapy also came under scrutiny when two of 
the ten children treated for X-linked SCID developed leukemia-like conditions18. FDA sent out 
the “March 6 letter” to all the investigator working on gene therapy to implement new scrutiny 
and Europe halted all gene therapy for re-review.  
 
4.1.2. A New age of Gene Therapy 
In 1996, the National Institute of Health (NIH) concluded that based on ongoing gene therapy 
trials, there is a lack of knowledge of the disease, the viral vector, target cells and tissues 
were the source of disappointing results19. But the last 10 years have been monumental for 
gene therapy as a better understanding and improvement of delivery vectors and gene 
expression resulted in significant clinical advancement. Till now, few gene therapies have 
received approval in the US and Europe (Table1) to be used as medicine. 
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Table 1: Approved gene therapies in western world 
Drug name Disease Vector/transgene Approval 
committee 
Year 
Glybera® -Familial lipoprotein lipase 
deficiency 
AAV based EMA 2012 
IMLYGIC® -Lesion in patients with 
melanoma 
Modified herpes simplex 
virus type I 
FDA 2015 
STRIMVELIS® -Adenosine deaminase 
(ADA) deficiency-SCID 
γ-retrovirus EMA 2016 
KYMRIAH® -Non-Hodgkin lymphoma CD-19 directed CAR-T cell FDA 2017 
YESCARTA® -Non-Hodgkin lymphoma 
-Lymphoblastic Leukemia 
CD-19 directed CAR-T cell FDA 2017 
LUXTURNA® -Retinal dystrophy AAV based FDA 2017 
AVXS-101 -Spinal muscular atrophy AAV based FDA 2016 
 
SCAAV2/8-LP1-HFIXCO -Hemophilia B AAV based FDA/EMA 2014/2017 
SPK-9001 
 
-Hemophilia B AAV based FDA/EMA 2016/2017 
AMT-061 -Hemophilia B AAV based FDA/EMA 2017/2017 
SB-FIX -Hemophilia B Zinc finger nuclease-
AAV2/6 
FDA 2017 
European Medicines Agency (EMA) 
US Food and Drug Administration (FDA) 
 
Along with the commercialized gene therapy, there are numerous clinical trials in progress for 
multiple diseases based on T cell, Hematopoietic Stem and Progenitor Cells (HSPCs) and in 
vivo administration (Supplement Table 2). Some of the trials gained FDA or EMA approval 
during different phases of clinical trial for orphan diseases lacking alternative cures.  
 
The advancement of Gene therapy is also based on better understanding of the cellular 
mechanism and establishment of three approach towards gene therapy; A) Gene 
supplementation, B) Gene suppression/inhibition and C) Gene correction (Figure 1).  
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Figure 1: The fundamental approach of Gene therapy 
Gene supplementation therapy restores function without alteration in genomic level. Gene inhibition by RNAi or 
Cas12 can reduce the expression of protein temporally. Gene editing or correction can have long lasting effects 
in stem cells. 
 
Gene supplementation restores normal cellular function without affecting the disease gene by 
providing a functional copy of gene in trans. Functional protein20, in vitro transcribed mRNA 
(IVT mRNA)21,22, and plasmid DNA23 have been studied for gene supplementation therapy and 
proved to be very efficient. Gene suppression or inhibition is used to reduce the expression 
of mutated genes to stop harmful accumulation of a faulty protein by RNA interference 
(example: Huntington’s disease)24 or anti-sense oligonucleotide25. Gene correction provides 
a site-specific correction by DNA double-strand break at the target site (by CRISPR/Cas9, 
ZFN or TALEN) and repair of the target site by homology directed repair (HDR) or Non-
homologous end joining26-28. Progressions in the field of gene therapy has made diseases like 
Cystic fibrosis and ß-Thalassemia perfect candidates to be investigated. 
 
4.2. Cystic Fibrosis (CF) 
CF is an autosomal-recessive disease, with limited therapeutic options available, affecting 
about 80,000 people worldwide29. It is caused by different mutations within the gene encoding 
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for the CF transmembrane and conductance regulator (CFTR). Those mutations result in 
compromised anion secretion and hyper-absorption of sodium ions across epithelia30,31 
(Figure 2). CFTR consists of 27 exons and is located on chromosome 7q31.232. The final 
transcript of CFTR (6.5 kb) has been reported for over 2000 mutations and CF can be 
connected to about 250 mutations33,34. Based on the impact on CFTR gene and protein, all 
the mutations have been categorized in six classes (Figure 2).  
 
Figure 2: Normal CFTR channel function and CFTR mutation classes 
Normal function of CFTR channel and effect of different mutation classes at the physiological level.  
 
4.2.1. CF Therapies 
CF therapy so far based on symptomatic control and consists of antibiotic treatment, 
supplementation of pancreatic enzymes and fat-soluble vitamins35. The symptomatic 
approach was inadequate and targeted therapy based on specific mutation of the CFTR was 
called for. Ivacaftor (Kalydeco®) was announced as a potentiator to increase the open 
possibility of CFTR channel and therefore an exclusive drug for patients with class III 
mutations. Patients with conductance mutation (class IV) also reported to have a beneficial 
effect36,37. Lumacaftor (VX-809) was the second line of potentiator but unfortunately can only 
be used as a combination therapy with ivacaftor (Trade name Orkambi®) for moderate 
improvement in lung function of patients with F508del mutation38. The approach using the 
potentiator is difficult to implement for each class of CFTR mutation and that makes mRNA-
based gene supplementation therapy a viable option for CF patients regardless of the 
mutation.   
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4.3. ß-Thalassemia 
Major adult hemoglobin (HbA) consists of α-globin chain (chromosome 16) and ß-globin chain 
(chromosome 11). Absence of partial or complete α-globin chain or ß-globin chain can result 
in α-Thalassemia or ß-Thalassemia, respectively39. Imbalance in α-globin and ß-globin chain 
determines the severity of disease and can result in erythropoietin overexpression which leads 
to bone marrow proliferation and variety of growth and metabolic abnormalities. Over 200 
mutations in ß-globin gene have been identified to cause disease ranging from no clinical 
symptoms (silent mutations) to complete absence of ß-globin chain synthesis40. 
 
4.3.1. Therapy for ß-Thalassemia 
Red blood cell (RBC) reduction is the main clinical symptom presented by ß-Thalassemia 
patients. Normal clinical therapy of chronic anemia patients is RBC transfusion and can 
heavily impair the quality of life of the patients. Iron overdose in the vital organs of the patients, 
recurring infections, and immune reactions caused by the transfusion can cause morbidity 
and mortality41. Removal of excess iron by iron chelators are in clinical use (Deferoxamine, 
Deferasirox and Deferiprone). However, these can cause adverse effects like nausea, 
abdominal pain, diarrhea, liver dysfunction, kidney dysfunction, neutropenia and 
agranulocytosis. The complications of the current clinical treatment call for gene therapy-
based applications.  
 
4.4. mRNA based therapy 
Recently, in vitro transcribed (IVT) messenger RNA came into focus as substantial efforts have 
been made for engineering mRNA with diverse pharmacokinetic properties26,42. Instability and 
immune response against IVT mRNA were the main issues. To avoid these downsides, 
modification of structural elements such as 5′ Cap, 5′- and 3′- untranslated region (UTR), 
poly(A) tail and the coding region were implemented21,43-46 (Figure 3). 
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Figure 3: IVT mRNA development timeline 
Adapted from Sahu I, Haque A, Weidensee B et al 2019 © Molecular Therapy publishing group. 
Overview of milestones in development of in vitro transcription of mRNA. White boxes: important milestones for 
development of mRNA therapy47. Blue boxes: evolution of different cap structures (Cap 0 and Cap 1)21,48,49. Red, 
green and grey boxes represent development in the area of 5′-UTR, 3′-UTR, poly(A) tail, respectively43,50,51. Yellow 
boxes represent nucleoside modifications and sequence optimizations in development for mRNA-based therapy52-
57. 
4.4.1. Chemical modifications to increase mRNA effectiveness 
RNA can be modified post-transcriptionally and over 150 chemical modifications are listed by 
different studies58. In mRNA, only a small subset of these naturally occurring modifications 
are reported to be capable of reducing innate immune responses and improving 
pharmacokinetic properties21,53,59. The first generation of modified IVT mRNAs contain 5-
Methylcytidine (m5C) or Pseudouridine (Ψ) to reduce innate immune responses and enhance 
translation22,60. TLR3, TLR7, TLR8, and retinoic acid-inducible gene I (RIG-I) activation was 
reduced by m5C, N6-methyladenosine (m6A), 5-Methyluridine (m5U), Ψ-UTP and 2-
Thiouridine (s2U) 21,22,53,61 modified nucleosides. RNA-dependent protein kinase (PKR) which 
mediates immune responses and translation inhibition (by phosphorylating the alpha subunit 
of translation initiation factor 2 (eIF-2α)) can be escaped using Ψ-UTP or m5C modified 
nucleosides62. m5C is explicitly recognized by the mRNA Aly/REF export factor (ALYREF) and 
increases mRNA-binding affinity and associated mRNA export out of the nucleus63. N1-
methylpseudouridine (m1Ψ) is the most used chemical modification in recent studies and 
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showed remarkable expression compared to Ψ substituted mRNA even when delivered by 
different routes in vivo55. m1Ψ initiates a tight binding to RIG-I and blocks RIG-I signaling61,64.  
 
4.4.2. Seqeunce engineering to increase mRNA effectiveness 
Codon optimization or sequence engineering of mRNA uses the flexibility of the genetic code 
to substitute specific nucleosides of a mRNA sequence without altering the resulting amino 
acid composition. Several recent studies have described codon optimization of unmodified 
and Ψ-UTP-modified mRNA through enriching guanosine/cytosine (G/C) can result in 
superior expression56,59.  
 
4.5. Programmable site-specific nucleases 
A new era for whole genome sequencing is paving the way towards revolutionizing basic 
science and personal medicine. Zinc-finger nuclease (ZFNs), transcription activator like 
effector nucleases (TALENs) and clustered regulatory interspaced short palindromic repeats 
(CRISPR) are advancing gene therapy based on the advancement of whole genome 
sequencing. The resourcefulness of ZFNs and TALENs gives the option to customize the DNA 
binding domain to identify practically any sequence65. On the other hand, the CRISPR/Cas 
system is distinct from ZFNs and TALENs as it can target any DNA sequence by CRISPR 
RNA (crRNA) and work as an RNA-guided DNA endonuclease. All the programmable site-
specific nucleases can be conducted by all RNA approach and various studies, including 
those from our lab, have shown that remarkable efficiency can be achieved21,26,27.  
 
4.5.1. Zinc-finger nuclease (ZFNs) 
Zinc finger (ZF) is composed of approximately 30 amino acids with a zinc atom bound to Cys2 
and His2. Klug et al. first described repetitive zinc-binding domains from Xenopus-oocytes
66. 
The Cys2-His2 domain is the most common type of DNA binding domain with a conserved bba 
configuration67. The a-helix structure of ZF can naturally contact 3 bp of major grove of DNA, 
however, the DNA recognition was advanced to 9-18 bp by constructing synthetic zinc finger 
protein (ZFP) with highly conserved linker sequences68. The attractive framework of providing 
tailor made sequence specificities by ZFPs was used to create designer nucleases. Two ZF 
proteins, Sp1-QNR and CP-QDR, were fused with the FokI cleavage domain of Sp1-QNF-FN 
and QDR-FN respectively and were termed zinc finger nucleases (ZFNs)
69(Figure 4).  
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4.5.2. Transcription activator like effector nucleases (TALENs) 
A recent discovery of TALE DNA binding motif (33-35 amino acids) from Xanthamonas 
bacteria provided an alternative platform for designing programable DNA binding proteins70,71. 
ZF can recognize 3-4 bases but TALE can recognize a single nucleotide by repeat variable 
diresidue (RVD, Amino acid NI recognize A, HD recognize C, NG and HG recognize T and NN 
recognize G or A). TALENs were designed by fusing FokI cleavage domain with TALE motifs 
and have been demonstrated to have similar cutting efficiency like ZFNs with lower 
cytotoxicity26,72(Figure 4). 
 
4.5.3. Clustered regulatory interspaced short palindromic repeats (CRISPR) 
Bacteria and Archaea have adapted a defense mechanism by integrating DNA fragment into 
clustered regularly interspaced short palindromic repeats (CRISPR) to fight against 
reoccurring viral and plasmid DNAs73. In the simplest form of the CRISPR system, CRISPR 
repeats are transcribed into long RNA that are further processed to contain a part of both the 
repeat sequence and a single spacer known as crRNA74-76. CRISPR locus also contain 
sequences to produce transactivating crRNA (tracrRNA). crRNA and tracrRNA complexes can 
associate with Cas9 protein. The tripartile structure can detect specific DNA targets by in 
proximity to a specific short sequence known as Protospacer-adjacent motif (PAM). The Cas9 
protein from Streptococcus pyogenes (most commonly used) contain two nuclease active 
sites and can initiate a double strand break 3 bp upstream of the PAM sequence77(Figure 4). 
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Figure 4: Programmable site-specific nucleases to achieve precise gene editing 
ZFN, TALEN and CRISPR/Cas9 based gene editing. Each of the programmable nuclease is comprised of different 
approach for targeting specific genomic areas and can produce double strand breaks to initiate gene correction 
by NHEJ or HDR.  
4.5.4. Gene editing by programmable site-specific nucleases 
Site specific nucleases possess a powerful system for generating a DNA double strand break. 
The double strand break gives an opportunity for gene editing to modify DNA at a specific 
locus on the basis of repair. Double strand breaks are repaired either by non-homologous 
end joining (NHEJ) or by homology directed repair (HDR). NHEJ occurs more frequently, no 
template is required and closes the break without adding to the DNA sequence78. NHEJ give 
programmable site-specific nucleases the ability to induce indels (insertion or deletion), to 
knockout specific genes by frameshift mutations or premature stop codon. On the contrary, 
HDR is based on homologous recombination. A homologous strand is needed and HDR can 
only occur in  S or G2 phase of the cell cycle79. HDR can repair a single mutation or insert a 
sequence of interest in targeted locus. For this purpose, the repair template can be given with 
non-integrating viral vectors (e.g. Adeno-associated viral vectors) or by using single-stranded 
oligodeoxynucleotides (ssODNs)26,27 (Figure 4).  
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5. Aim of the study 
Recent advancements in understanding the underlying mechanisms of gene therapy, in vitro 
transcribed (IVT) mRNA and CRISPR based correction system pave the way to study 
monogenetic diseases such as cystic fibrosis and ß-Thalassemia. The goal of the study was 
to obtain better insights about using chemical modifications and sequence optimization to 
improve IVT mRNA for efficient, less immunogenic gene therapy. 
 
One of the targets was to produce chemically modified hCFTR mRNA (cmRNAhCFTR) which 
can produce a functional CFTR protein and evade immunological response. Using various in 
vitro, ex vivo and in vivo models of cystic fibrosis, cmRNAhCFTR was tested rigorously and 
compared against wildtype CF models for restoration of functionality without immune 
response. The second target was to improve in vitro transcribed (IVT) Cas9 mRNA to achieve 
a high level of personalized gene-correction therapy for β-thalassemia. The study also 
includes a comparison of established programmable nucleases such as CRISPR/Cas9, 
TALENs, and ZFNs to identify the most promising gene correction approach. The first two 
studies indicated the potential IVT mRNA holds for protein supplementation and as a 
transiently expressed endonuclease for gene correction. This line of thought was extended 
by investigating different chemical modifications and sequence engineering to further 
enhance the usability of IVT mRNA. 
 
6. Results and Discussion 
6.1. Chemically modified hCFTR mRNAs recuperate lung function in 
a cystic fibrosis mouse model (paper 1) 
Though the underlying genetic defect of Cystic Fibrosis has been identified, restoration of 
robust CFTR function in patients suffering from cystic fibrosis remains unfulfilled. Small 
molecule agents (modulator/potentiator) such as Ivacaftor (for G551D mutation) or Orkambi 
(Lumacaftor-Ivacaftor, for F508del mutation) are available to CF patients but are limited to 
specific mutations in the CFTR gene. Unfortunately, Orkambi did not reach the predicted 
expectations for the benefit of patients with F508del mutations, the most common mutation 
among CF patients80. Attempts were made to supplement CFTR in the form of plasmid DNA 
providing promising data in vitro but exhibiting limitations in in vivo application23. In this study, 
cmRNAhCFTR was vigorously tested for mRNA therapy with a focus on restoring in vitro protein 
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expression and in vivo lung function. The unique formulation can be applied both targeted 
(intratracheally) and systemically (i.v.), having a profound effect on the lung function 
parameters.  
 
6.1.1. In vitro functional restoration and detection of CFTR protein in CFBE41o− 
and CFTR null A549 cells 
Cystic Fibrosis Bronchial Epithelium cells (CFBE41o-) are a well-documented cell line as in 
vitro CF model. The cell line was created from the bronchial epithelium of a CF patient 
homozygous for F508del mutation81. CFTR protein quantification by flow cytometry using a 
CFTR specific antibody (596) in CFBE41o- cells exhibits around 5-fold higher protein 
expression for cmRNAhCFTR, compared to unmodified mRNAhCFTR (24 hours). Flow cytometry 
data were substantiated by both Western blot and immunofluorescence analysis. Western 
blot image indicates a glycosylated band (160 kDa) after treatment with cmRNAhCFTR, a 
confirmation of functional CFTR protein. Immunofluorescence analysis also provides clear 
evidence of presence of CFTR protein when compared to untreated CFBE41o- cells. Halide-
sensitive Yellow fluorescent protein-based (YFP) assay in CFTR null A549 and CFBE41o− 
cells also corroborate the findings from flow cytometry and Western blot analyses by showing 
a significant increase in Iodide (I-) influx by functional CFTR channels and quenching of YFP 
48h post transfection.  
 
6.1.2. Ex vivo immune response 
The whole blood assay (WBA, ex vivo) was described by Coch and colleagues to have the 
potential to reflect broad aspects of in vivo cytokines and is used in various pre-clinical 
studies82. IFN-α, TNF-α and IL-8 levels were measured to predict activation of the immune 
system as reaction to RNA. pDNAhCFTR and unmodified mRNAhCFTR showed increased cytokine 
levels whereas cmRNAhCFTR did not show a significant elevation. This experiment provided the 
direction of eliminating unmodified mRNAhCFTR in mouse model as it potentially exhibits 
unnecessary immune responses. pDNAhCFTR (as it had been used in various study to produce 
functional CFTR) and two chemically modified CFTR mRNAs were used for further in vivo lung 
function restoration studies.  
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6.1.3. In vivo restoration and detection of CFTR protein in CF knockout mice to 
determine clinical potential of cmRNAhCFTR. 
Gut-corrected CFTR knock out mouse model (based on CFTRtm1Unc/J) is a useful mouse model 
for cystic fibrosis. Due to the promoter specific expression of CFTR in the intestine, the mouse 
model does not die from intestinal obstruction (ileum or large intestine). The mouse model 
does not demonstrate the typical lung phenotype seen in CF patients, however, various 
groups have reported findings such as the acid mucopolysaccharide on the bronchial surface 
by scanning electron microscopy, reduced airway compliance and increased resistance 
typical to CF in comparison to wild type mice83,84. The model is also reported to show similar 
symptoms of CF such as age dependent pulmonary inflammation, death of respiratory 
epithelial cells and severe persistent Pseudomonas aeruginosa infection85. The clinical 
potential of CFTR-encoded cmRNAs were tested in the mouse model by two different routes 
of administration. Intratracheal administration allows for a targeted delivery to the respiratory 
system while intravenous (i.v.) route was chosen for systemic delivery.  
  
To assess the impact of cmRNAhCFTR on lung function, an evaluation of clinically relevant lung 
mechanics was conducted using the FlexiVent® system. A significant difference was observed 
in three important parameters (airway compliance, resistance and FEV0.1) between Cftr
−/− and 
healthy wild-type mice. I.t. administration of cmRNAhCFTR improved the compliance 
significantly although relatively less than i.v. administration. Resistance was also improved 
significantly by both i.v. and i.t. administration of cmRNAhCFTR. FEV1 percentage (for mouse or 
small animal FEV0.1) is related to survival and the most important physiological parameter for 
CF patients. %FEV1 has become a significant parameter to check in clinical setup as a 
reduction of more than 30%FEV1 (compared to healthy individuals) can indicate mortality witin 
2 years86. A strong variance amid Cftr-/- controls and mock-treated Cftr-/- mice compared to 
homozygous wild-type mice (Cftr+/+) mice had been perceived in the case of FEV0.1. I.v. 
injection of 40 µg cmRNA
hCFTR
s2U0.25/m5C0.25
 significantly improved the FEV0.1 by 23 percentage 
points. pDNAhCFTR when administered via the i.t. route showed improving parameters of lung 
function measurements including FEV0.1, but in lower levels compared to cmRNA
hCFTR. 
Interestingly, it was observed that both i.v. and i.t. administration of cmRNA
hCFTR
s2U0.25/m5C0.25
 
positively compensated most of lung function parameters. 
 
Sweat chloride concentration is a recognized procedure to assess the treatment effects in CF 
patients. Based on this, salivary chloride assay has been described as an analogous method 
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in mice87. In our study, substantial decrease in salivary Chloride (Cl-) content of cmRNAhCFTR 
and pDNAhCFTR treated mice were observed regardless the route of administration, indicating 
a restoration of CFTR in the duct compartment of salivary glands and thus leading to an 
improved Cl- absorption.  
 
Along with the functional parameters, the expression of functional protein and disposition of 
cmRNAhCFTR in mouse lungs was tested by hCFTR ELISA and RT-qPCR. Both methods 
indicated that cmRNA
hCFTR
s2U0.25/m5C0.25
 lead to a higher protein expression and as well as mRNA 
disposition in the lung. The administration route of cmRNA
hCFTR
s2U0.25/m5C0.25
 had little effect on 
the ability to express functional protein. The special role of this chemical modification has to 
be further investigated for improving most of the lung function parameters including its effects 
on kinetics and expression patterns of mRNA.  
 
An extensive in vivo immune assay has been conducted to rule out immune reactions caused 
by either NPs (Chitosan-coated PLGA (poly-D, L-lactide-co-glycolide 75:25 (Resomer RG 
752H)) or the cmRNAhCFTR itself. Positive control (E. coli total mRNA) provided 
immunostimulatory effects in vivo but a response from NPs or the cmRNAhCFTR was not 
detectable at the endpoint analysis which is in line with our previous data26. Systemic delivery 
has also been reported to have no impact on proinflammatory cytokine secretion88. 
 
This study is the first proof of concept for the efficient application of NPs-cmRNAhCFTR in vivo 
to restore lung function in a Cftr-deficient mouse model with undetected immune responses 
in vivo and ex vivo. CFBE41o- cells when transfected with cmRNAhCFTR efficiently produced 
functional protein which can be detected by Western blot, flow cytometry, 
immunofluorescence and YFP assay. cmRNAhCFTR could efficiently restore lung function in 
Cftr-/-mice. In addition, the study produced a comprehensive comparison of two well-known 
mRNA modifications with pDNAhCFTR and of two different delivery routes, demonstrating that 
systemic administration of cmRNAhCFTR targets lung cells more efficiently at lower dosages. 
This study provides a strong base for cmRNAhCFTR transcript supplementation therapy for CF 
patients independent of CFTR mutations. 
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6.2. Gene correction of HBB mutation in CD34+ hematopoietic stem 
cells using Cas9 mRNA (paper 2) 
Studies had been conducted by various groups to target HBB gene using CRISPR/Cas9 
system in HSCs and mostly focused on HBB gene addition or targeting sickle cell disease 
mutations89,90. To best of our knowledge, this study is the first study to target the common ß-
thalassemia splicing variant HBBIVS1-110. The knowledge gathered from our previous study 
about optimization of expression by chemical modification of mRNAs was implemented to 
design a Cas9 mRNA to achieve higher indel induction and correction efficiency. 
 
6.2.1. Comparing ZFNs, TALENs and CRISPR/Cas9 
ZFNs, TALENs and CRISPR/Cas9 were designed to target splicing variant HBBIVS1-110 and 
efficacy was determined by T7 endonuclease-I (T7EI) assay in HEK293 cells. CRISPR/Cas9 
displayed an indel efficiency of approximately 60% in comparison to TALENs with an 
efficiency of about 35-40% and ZFNs reaching not over 10%. Interestingly, CRISPR/Cas9 
yielded similar amounts of indels regardless of the tested concentrations.  
 
6.2.2. Plasmid vs. all-RNA approach of CRISPR/Cas9 
A modified pX330 plasmid (pX330.sg HBBIVS1-110) encoding sgRNA sequence (to guide Cas9 
protein to specific mutation site) and SpCas9 was designed. Several ssODNs (to produce 
homology directed repair, HDR) were designed with homology arms varying in length and 
symmetry around the mutation site. pX330.sg HBBIVS1-110 based CRISPR/Cas9 system in K562 
cells provided a mean indel frequencies of 44±18% for target loci and resulted in around 20% 
HDR. In bone marrow-derived CD34+ hematopoietic stem cells (HSCs) this combination of 
pX330.sg HBBIVS1-110 and ssODNs produced relatively low indel and HDR rates (~30% indel 
and 3% HDR, determined by TIDE analysis). To increase the effectiveness of correction, 
pX330.sg HBBIVS1-110 was substituted with an all-RNA approach. Chemically modified Cas9 
mRNA (cmRNACas9) and sgRNAs were synthesized to increase the protein expression of Cas9 
and induction of indels as reported earlier57,91,92. The all-RNA approach yielded higher indels 
ranging from 65% to 87% and up to 11% HDR in CD34+ HSCs. Absolute quantification of 
NheI tag integration by next generation sequencing (NGS) reached around 8% when 
chemically modified Cas9 mRNA, sgRNA and ssODNs were used. These results indicate the 
potential of RNA-based CRISPR/Cas9 systems for ex vivo gene correction in CD34+ HSCs. 
Furthermore, the flexibility CRISPR/Cas9 is advantageous and yields higher efficiency over 
other site-specific endonucleases like ZFNs and TALENs. Although gene correction of 8% in 
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CD34+ HSCs was achieved a further improvement of HDR could result in translation into 
clinics. 
 
6.3. Uridine depletion and chemical modification increase Cas9 
mRNA activity and reduce immunogenicity without HPLC 
purification (paper 3) 
In both studies concerning cystic fibrosis and ß-thalassemia chemical modifications of IVT 
mRNA helped to increase the efficacy of gene supplementation and gene correction. To 
further optimize IVT mRNA, we investigated three design parameters to improve the activity 
of Cas9 protein. These parameters cover sequence engineering by Uridine depletion, HPLC 
purification and testing of different Cap structures.  
 
6.3.1. Sequence engineering (Uridine Depletion) improve Cas9 activity and 
reduce immunogenicity  
In order to replace particular nucleotides (especially Uridine), the degeneracy of the genetic 
code was utilized. Sequence engineering of the mRNA could be performed without changing 
the amino acid configuration. The Uridine-depleted Cas9 mRNA (with or without chemical 
modifications) yielded higher indel rates (77%-87%) compared to first generation chemically 
modified Cas9 mRNA (approximately 60%). The indel formation by Cas9 Ribonucleoprotein 
(RNP), which is used frequently by various groups for higher indel efficiency, provided 67% 
indel activity at the same target. Chemical modification of sequence engineered Cas9 mRNA 
did not play any significant role in elevating the indel activity. On the contrary, chemical 
modification (5moU and Ψ) played an important role in immune evasion. Uridine depletion 
alone can successfully reduce TNF-α and IL-6 level compared to most of the chemically 
modified Cas9 mRNA. Addition of 5moU and Ψ on the sequence engineered Cas9 mRNA 
lowered the level of TNF-α and IL-6 to a non-detectable level in whole blood assay.  
 
6.3.2. Influence of High-performance liquid chromatography (HPLC) purification 
on Cas9 mRNA 
Uridine depletion in combination with chemical modification could reduce IL-6 and TNF-α 
responses but was not successful in reducing IFN responses (U-depleted wild type and U- 
depleted Ψ Cas9 mRNAs). HPLC purification of mRNA had been reported to reduce dsRNA 
impurities and hence can avoid activation of innate immune sensors (TLRs, PKR, or MDA5)93. 
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HPLC purification effectively reduced IFN responses of U-depleted wild type and U-depleted 
Ψ Cas9 mRNAs. In the context of functionality of Cas9, HPLC purification played no 
significant role with the exception of unmodified Cas9 mRNA (wt).  
 
6.3.3. Capping strategy to influence Cas9 mRNA activity and immunogenicity 
mRNA contains a 5’ capping system which initiates translation by binding with eIF4E and 
eIF4G (eukaryotic translation initiation factors) and reduces deterioration by binding with 
Dcp1, Dcp2 and DcpS (mRNA decapping proteins)94,95. The natural occurring 5’-Cap is a 7-
methylguanosine (m7G) connected by a 5’-to-5’ triphosphate bridge with the first nucleotide 
(Cap 0). A modification of Cap 0, Cap 1, (2′-ribose position of the first cap-proximal nucleotide 
is 2′O-methylated) is used to reduce immune responses as previously reported96,97. Cap 1 
and Cap 0 structures for U-depleted Cas9 mRNA with 5moU modification were compared 
and no significant difference was observed in indel induction or levels of tested cytokine 
expressions.  
 
The testing of diverse modalities of Cas9 mRNA modifications showed a vast difference in 
functionality. Among these, Uridine depletion came up as the promising candidate by 
inducing up to 87% indel rate, a significant accomplishment towards achieving gene 
correction. Unfortunately, both HPLC purification and methylation on the 2′-ribose position 
of the first cap-proximal nucleotide could not increase the indel induction by Cas9. Chemical 
modifications (5moU and Ψ) reduce immune response measured by IL-6, IL-12 and TNF-α. 
Moreover, the combination of chemical modification of Uridine and Uridine depletion taken 
together surpassed the results of 5moU or Ψ alone and can be recommended for further gene 
correction studies.  
 
6.4. Recent Developments in mRNA-Based Protein 
Supplementation Therapy to Target Lung Diseases (paper 4) 
The study focusses on three aspects: respiratory diseases, barriers of the lung for drug 
delivery, and recent advancement in IVT mRNA therapies. Understanding the complexity of 
these aspects is the key towards a clinically relevant protein supplementation therapy for the 
lung. The various cell populations which are associated with different lung diseases play a 
vital role in establishing a therapeutic target. Especially differentiated cells, like ionocytes and 
ATII cells, or stem cells like bronchioalveolar stem cells (BASC) and myoepithelial cells (MEC) 
provide a strong target for mRNA therapy. Based on the selected target, nanocarriers need 
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to be designed with specific properties for delivery to specific cells and resistance against 
defense systems like respiratory mucus and alveolar fluids. The substantial size and charge 
of naked mRNA limits the cellular uptake, but nanocarriers can also here facilitate the 
transport across the cellular membrane. Finally, chemical modifications and sequence 
engineering of the mRNA itself improve the therapeutic ability by reducing immunogenicity 
and increasing protein expression. This study provides a critical overview of how to find a 
formulation considering the aspects of target, delivery and modification of mRNA.  
 
7. Concluding remarks 
mRNA has been sidelined for a long time as an unstable molecule. Recent advancements in 
the field of mRNA bring the true potential of this molecule to light. In three separate studies 
we could show the potential of cmRNA in protein supplementation therapy for cystic fibrosis, 
its potential for gene correction using CRISPR/Cas9 for ß-thalassemia and strategies to 
further customize IVT mRNA technology. I believe that these studies could contribute towards 
the advancement in the field of mRNA therapy and bring it a step further to clinical translation. 
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10. Supplement 
Table 2: Gene therapy-based product development land marks for ex vivo and in vivo therapies 
 
Therapy type Disease Vector/transgene Clinical trials 
Hematopoietic Stem and 
Progenitor Cells (HSPCs) 
 
ß-Thalassemia -Lentivirus (LV) ß-
hemoglobin 
-NCT02453477 
-NCT01639690 
Wiskott-Aldrich syndrome 
(WAS) 
-Lentivirus WAS -NCT01515462 
 
Adenosine deaminase 
deficiency (ADA) 
-Lentivirus ADA -NCT02999984 
Human Immunodeficiency 
virus (HIV) 
-Zinc finger nuclease 
CCR5 electroporated (ex 
vivo) 
-NCT02500849 
Metachromatic 
leukodystrophy 
-Lentivirus Arylsulfatase A 
(ARSA) 
-NCT01560182 
Adrenoleukodystrophy -Lentivirus ABCD1 -NCT03727555 
Sickle cell anemia -Lentivirus anti-sickling ß-
hemoglobin 
-NCT02151526 
-NCT02140554 
-NCT02247843 
T cell Acute /chronic 
Lymphoblastic Leukemia 
(ALL/CLL) 
-UCART19 
-γ-Retrovirus CD19 (CD28) 
CAR-T 
-NCT02746952 
-NCT02348216  
 
Multiple myeloma -γ-Retrovirus BCMA (CD28) 
CAR-T 
-γ-Retrovirus BCMA (4-1BB) 
CAR-T 
-Lentivirus-BCMA CAR-T 
-NCT02215967 
-NCT03070327 
-NCT03090659 
Human Immunodeficiency 
Virus (HIV) 
--Zinc finger nuclease 
CCR5 electroporated (ex 
vivo) 
NCT00842634 
 
In vivo Hemophilia A 
 
 
AAV5-Factor VIII NCTO2576795 
Retinal dystrophy AAV2-RPE65 NCT00643747 
 
Parkinson’s disease AAV2-AADC NCT03562494 
 
Aromatic I-amino acid 
decarboxylase deficiency 
AAV2-AADC NCT02926066 
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Chemically modified hCFTR mRNAs 
recuperate lung function in a mouse 
model of cystic fibrosis
A. K. M. Ashiqul Haque1, Alexander Dewerth1, Justin S. Antony  1,7, Joachim Riethmüller2, 
Georg R. Schweizer  1, Petra Weinmann1, Ngadhnjim Latifi1, Hanzey Yasar3, 
Nicoletta Pedemonte  4, Elvira Sondo4, Brian Weidensee1, Anjali Ralhan5, 
Julie Laval5, Patrick Schlegel1, Christian Seitz1, Brigitta Loretz3, Claus-Michael Lehr3,6, 
Rupert Handgretinger1,7 & Michael S. D. Kormann  1
Gene therapy has always been a promising therapeutic approach for Cystic Fibrosis (CF). However, 
numerous trials using DNA or viral vectors encoding the correct protein resulted in a general low 
efficacy. In the last years, chemically modified messenger RNA (cmRNA) has been proven to be a highly 
potent, pulmonary drug. Consequently, we first explored the expression, function and immunogenicity 
of human (h)CFTR encoded by cmRNAhCFTR in vitro and ex vivo, quantified the expression by flow 
cytometry, determined its function using a YFP based assay and checked the immune response in 
human whole blood. Similarly, we examined the function of cmRNAhCFTR in vivo after intratracheal 
(i.t.) or intravenous (i.v.) injection of the assembled cmRNAhCFTR together with Chitosan-coated PLGA 
(poly-D, L-lactide-co-glycolide 75:25 (Resomer RG 752 H)) nanoparticles (NPs) by FlexiVent. The 
amount of expression of human hCFTR encoded by cmRNAhCFTR was quantified by hCFTR ELISA, and 
cmRNAhCFTR values were assessed by RT-qPCR. Thereby, we observed a significant improvement of lung 
function, especially in regards to FEV0.1, suggesting NP-cmRNAhCFTR as promising therapeutic option for 
CF patients independent of their CFTR genotype.
Cystic fibrosis (CF), the most common life-limiting autosomal-recessive disease in the Caucasian population 
(1/2,500 newborns), affects more than 80,000 people worldwide1. It is caused by different mutations within the 
gene encoding for the CF transmembrane conductance regulator (CFTR). Those mutations result in impaired 
anion secretion and hyper-absorption of sodium ions across epithelia2,3. Chronic lung disease and slow lung 
degradation are the major contributing factors to both mortality and strongly reduced quality of life4,5. With cur-
rently available therapies, the mean survival is between 35 and 45 years6,7. Since the CFTR gene was first cloned 
in 1989, many efforts have been made to deal with the mutations at a cellular and genetic level8,9. Gene therapy 
approaches made it quickly to the clinic aiming to deliver viral CFTR-encoding vectors (such as adenoviruses 
(Ad) or adeno-associated viruses (AAV)) to CF patients10. However, none of the clinical studies and current 
treatments seem to provide sufficient human (h)CFTR expression to prevent the ultimately lethal CF symptoms 
in the respiratory tract of CF patients. Furthermore, repeated administration of viral vectors or DNA may lead to 
the development of unwanted immune reactions, mainly due to viral capsids and vector-encoded proteins10–12.
Newly designed viral vectors circumvent those problems and can be administered repeatedly, but from a 
clinical perspective, the field is still in need of a therapeutic tool that combines efficient expression in lungs and 
other (affected) organs and cells while avoiding immunogenicity and genotoxicity completely13–15. The non-viral 
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CFTR-encoding plasmid–liposome complex pGM169/GL67A has been one of the most promising therapeuti-
cal approach used in clinical trial by Alton’s group. Beside some encouraging results, the trial only managed to 
modestly improve forced expiratory volume in 1 s (FEV1) after repeated administration along with no improve-
ment in patient’s quality of life16,17. Recently, in vitro transcribed (IVT) chemically modified messenger RNA 
(cmRNA) came into focus, which has the potential to combine striking advantages in a single-stranded mole-
cule18,19. Chemically modified mRNA has been tested for repeated administration, without developing immune 
responses or losing efficacy, presenting cmRNAhCFTR complexed with biodegradable chitosan-coated PLGA nan-
oparticles (NPs) as a promising therapeutic for the treatment of CF patients19–21. Versatile delivery options of 
mRNA ensure the unique possibility to utilize NP-cmRNAhCFTR in early infants as well as adults, independent of 
the underlying CFTR mutation. To the best of our knowledge, we provide the first in vivo studies delivering cmR-
NAhCFTR to the lungs of CFTR deficient mice (Cftr−/−) by intravenous (i.v.) and intratracheal (i.t.) administration, 
complexed with NPs. We provide a proof of concept of NP- cmRNAhCFTR mediated, ELISA quantified, hCFTR 
expression in the lungs of Cftr−/− mice, leading to significantly reduced chloride secretion and, more importantly, 
restored criticial lung function parameters, including the most important parameter to evaluate mortality and 
morbidity of CF patients, the forced expiratory volume (FEV) in 1s or 0.1s in small animals, respectively22–24.
Materials and Methods
mRNA production. hCFTR was PCR amplified from pcDNA3.hCFTR with primers adding NheI (Fwd: 
5′-TTAGCTAGATGCAGAGGTCGCCTC-3′) and KpnI (Rev: 5′-GCGGGTACCTATCTTGCATCTCTTCT -3′) 
restriction sites to each end. The PCR product was cloned into a poly(A)-120 containing pVAX (pVAX.A120, 
www.lifetechnologies.com) by sticky-end ligation using the mentioned restriction sites. pVAX.A120 containing 
hCFTR is referred as pDNAhCFTR throughout this study. For control experiments, DsRed reporter protein was 
sub-cloned into pVAX.A120 vector from its original vector pDsRed (www.clontech.com). For in vitro transcrip-
tion (IVT), the plasmids were linearized downstream of the poly(A) tail with XhoI (www.neb.com). IVT reaction 
was carried out using MEGAscript T7 Transcription kit (www.ambion.com) with an anti-reverse CAP analog 
(ARCA) at the 5′ end (www.trilink.com). To produce chemically modified mRNA, the following chemically mod-
ified nucleosides were added to the IVT reaction in the indicated ratios: uridine-tri-phosphate (UTP) and cyti-
dine-tri-phosphate (CTP) were fully replaced by N1-Methylpseudo-UTP and 5-Methyl-CTP, abbreviated to 
cmRNA CFTRN1 /m5C
h
1 0 1 0Ψ . .
 and partly replaced by the incorporation of 25% 2-Thio-UTP and 25% 5-Methyl-CTP, respec-
tively, abbreviated to 
. .
cmRNA CFTRs2U /m5C
h
0 25 0 25
 (www.trilink.com). The cmRNAhCFTR and cmRNADsRed were purified 
using the MEGAclear kit (www.ambion.com) and analyzed for size and concentration using an RNA NanoChip 
6000 for Agilent 2100 Bioanalyzer (Supplement, Fig. S1) (ww.agilent.com).
Cell culture and Transfection. CFBE41o− and 16HBE14o- cells (from Gruenert’s lab) were incubated 
at 37 °C in a humidified atmosphere containing 5% CO2 until they reached 80–90% confluency. Cell lines were 
washed with cold, sterile PBS and detached by Trypsin-EDTA. Trypsinization was stopped by adding minimum 
essential medium (MEM; www.thermofisher.com) containing 10% fetal calf serum. Cells were collected and 
spun down at 500 × g for 5 minutes before resuspension in fresh MEM. One day before transfection, 250,000 
cells/well/1 ml were plated in 12-well plates and grown overnight in MEM without antibiotics. At confluence 
of 70–90%, cells were then transfected with 1000 ng (c)mRNAhCFTR or equivalent (in nmol) pDNAhCFTR using 
Lipofectamine 2000 (www.invitrogen.com) following the manufacturer’s instructions and after changing the 
media to the reduced serum media, Opti-MEM (www.thermofisher.com). After 5 hours, the complexes were 
removed by replacement with fresh culture medium. Cells were kept for 24 h and 72 h before further analyses.
Flow cytometry analyses. All flow cytometry analyses were performed using a BD LSR Fortessa X-20 
SORP (www.bdbioscience.com). For detection of hCFTR protein in 16HBE14o- and CFBE41o− cell lines, 
cells were transfected as described above and subsequently prepared for intracellular staining using a Fixation/
Permeabilization Solution Kit as directed in the manufacturer’s instruction (www.bdbioscience.com). As primary 
antibody mouse anti-human hCFTR clone 596 (1:500, kindly provided by the cystic fibrosis foundation thera-
peutics Inc.) has been used. As secondary antibody served Alexa Fluor 488 goat anti-mouse IgG (1:1,000, www.
lifetechnologies.com). At least 20,000 gated cells per tube were counted. Data were analyzed with FlowJo software, 
version 10.
Western blot analysis. Protein isolated from cell lines was separated on Bolt NuPAGE 4–12% Bis-Tris 
Plus gels and a Bolt Mini Gel Tank (all from www.lifetechnologies.com). Immunoblotting for hCFTR was per-
formed by standard procedures according to the manufacturer’s instructions using the XCell II Mini-Cell and 
blot modules (www.lifetechnologies.com). After blocking for 1 h in 5% dry milk at room temperature, primary 
antibody against hCFTR clone 596 (1:500, kindly provided by the cystic fibrosis foundation therapeutics Inc.) or 
anti-GAPDH (1:1000) (www.scbt.com) was incubated overnight, horseradish peroxidase–conjugated secondary 
antibodies (anti-mouse from www.dianova.com) were incubated for 1 h at room temperature. All blots were 
processed by using ECL Prime Western Blot Detection Reagents for 30 min exposure time (www.gelifesciences.
com). Semiquantitative analysis was performed using the ImageJ software and overexposure has been avoided as 
per as digital image and integrity policies.
Immunofluorescence. CFBE41o− and 16HBE14o- were plated on a cell culture insert (0.75 × 106 cells per 
insert) containing a PET membrane (0.4 µm pore size) (www.corning.com) to provide an air-liquid interface. 
Cells were transfected 12 h after plating with 5000 ng cmRNAhCFTR or equivalent (in nmol) pDNAhCFTR using 
Lipofectamine 2000 (www.invitrogen.com) according to manufacturer’s instructions. Membranes were cut out 
from the insert 24 h after transfection, fixed with 4% PFA, blocked with 0.1% BSA and Fc blocker. Blocking was 
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followed by overnight incubation with hCFTR clone 596 (1:250, kindly provided by the cystic fibrosis founda-
tion therapeutics Inc.). As secondary antibody served Alexa Fluor 594 goat anti-mouse IgG (1:250, www.abcam.
com, (ab150116)). Membranes were mounted on a coverslip and images were acquired by Zeiss Confocal Laser 
Scanning Microscope (CLSM) 710 NLO with Zen software.
YFP-based functional assay. CFTR activity following transient transfection of (c)mRNAhCFTR in A549 
and CFBE41o− cells was determined using the halide-sensitive yellow fluorescent protein YFP-H148Q/I152L25. 
CFTR deficient A549 or CFBE14o- cells stably expressing the YFP were plated in 96-well microplates (50,000 
cells/well) in 100 µl of antibiotic-free culture medium and, after 6 h, transfected (in case of CFBE14o- reverse 
transfected) with either plasmids carrying the coding sequence for CFTR or different (c)mRNAhCFTR. For each 
well, 0.25 µg of mRNA or plasmid DNA and 0.25 µl of Lipofectamine 2000 were pre-mixed in 10 µl of Opti-MEM 
(www.invitrogen.com) to generate transfection complexes that were then added to the cells. After 24 hours, the 
complexes were removed by replacement with fresh culture medium. The CFTR functional assay was carried out 
24, 48 or 72 h after transfection. For this purpose, the cells were washed with PBS and incubated for 20–30 min 
with 60 µl PBS containing forskolin (20 µM). After incubation, cells were transferred to a microplate reader 
(FluoStar Galaxy; www.bmg.labtech.com) for CFTR activity determination. The plate reader was equipped with 
high-quality excitation (HQ500/20X: 500 ± 10 nm) and emission (HQ535/30M: 535 ± 15 nm) filters for yellow 
fluorescent protein (www.chroma.com). Each assay consisted of a continuous 14-s fluorescence reading (5 points 
per second) with 2 s before and 12 s after injection of 165 µl of a modified PBS containing 137 mM NaI instead of 
NaCl, resulting in a final 100 mM NaI concentration in the well). To determine iodide (I−) influx rate, the final 
11 s of the data for each well were fitted with an exponential function to extrapolate initial slope. After back-
ground subtraction, cell fluorescence recordings were normalized for the initial average value measured before 
addition of I−. Maximum slopes were converted to rates of variation of intracellular I− concentration (in mM/s) 
using the equation: d[I−]/dt = KI[d(F/F0)]/dt, where KI is the affinity constant of YFP for I
−, and F/F0 is the ratio 
of the cell fluorescence at a given time vs. initial fluorescence25.
Whole blood assay. Ethical approval for using whole blood from healthy donor was obtained from Ethics 
Commission University Clinic of Tuebingen, Germany (349/2013BO2) and experiments were conducted in 
accordance with relevant guidelines and regulations. Informed consent form (following WHO guideline) was 
signed by each volunteer (healthy donor) and kept safely by principal investigator for privacy requirement. Blood 
samples from three healthy donors were collected in EDTA collection tubes (www.sarstedt.com). For each treat-
ment group, 2 ml of EDTA-blood was transferred into 12-well plates and treated accordingly. R848 (Resiquimod, 
www.sigmaaldrich.com) was added at a concentration of 1 mg/ml to the respective blood positive controls. cmR-
NAhCFTR and pDNAhCFTR (7 picomol each) were complexed to NPs at a ratio of 1:10. The samples were kept at 
37 °C incubator maintaining 5% CO2. At 6 h and 24 h, 1 ml of whole blood was transferred into microtubes con-
taining serum gel (www.sarstedt.com) and spun down at 10,000 × g for 5 min to obtain serum. Sera were stored 
at −20 °C for further cytokine measurement analyses. Serum was used to conduct IFN-α, TNF-α and IL-8 ELISA 
at manufacturer’s instruction (www.thermofisher.com).
Animal experiments. All animal experiments were approved by Regierungspräsidium Tübingen, 
Baden-Württemberg and carried out according to the guidelines of the German Law for the Protection of Animals 
(File Number: 35/9185.81-2/K3/16). Cftr−/− mice (CFTRtm1Unc) were purchased from Jackson Laboratory (www.
jax.org) at the age of 6 to 8 weeks and were maintained under standardized specific pathogen-free conditions on 
a 12 h light-dark cycle. Food, water as well as nesting material were provided ad libitum. Prior to i.t. spray appli-
cations, mice were anesthetized intraperitoneally (i.p.) with a mixture of medetomidine (0.5 mg/kg), midazolam 
(5 mg/kg) and fentanyl (50 µg/kg). Cftr−/− mice received 40 µg or 80 µg of cmRNAhCFTR or an equivalent amount 
(calculated using nmols) pDNAhCFTR complexed with chitosan-coated PLGA nanoparticles [Chitosan (83% 
deacetylated (Protasan UP CL 113) coated PLGA (poly-D,L-lactide-co-glycolide 75:25 (Resomer RG 752 H)) 
nanoparticles; short: NPs] (Full details of nanoparticles are provided in Supplement Table T1 and Fig. S5) by 
intratracheal (i.t.) spraying (n = 4), and intravenous (i.v.) injection (n = 4–7) into the tail vein. Mock-treated 
control Cftr−/− mice received 40 µg or 80 µg cmRNADsRed complexed to NPs (n = 5) by i.v. or i.t administration, 
respectively, or just 200 µl NPs by both i.v. and i.t. delivery. An antidote with a mixture of naloxone (1.2 mg/kg), 
flumazenil (0.5 mg/kg) and atipamezol (2.5 mg/kg) was used against anesthetizing reagents. For both interven-
tions, NP-cmRNA and NP-pDNA complexes were administered in a total volume of 200 µl, twice at an interval of 
3 days (day 0 and day 3). After 6 days, mice were sacrificed for endpoint analyses. A detailed description of the i.t. 
procedures are explained in previously published study26.
Pulmonary mechanics. Lung function for each group was evaluated using a FlexiVent® equipped with 
FX1 module and NPFE extension and was operated by the flexiWare v7.2 software (www.scireq.com). Prior to 
tracheostomy, mice were anesthetized intraperitoneally as described above. After anesthesia, a 0.5 cm incision 
was performed in rostral to caudal direction. A flap of skin was retracted, the connective tissue was dissected, 
and the trachea was exposed. The trachea was then cannulated between the second and third cartilage ring with 
a blunt-end stub adapter. The mouse was connected to the FlexiVent® system and quasi-sinusoidally ventilated27 
with a tidal volume of 10 ml/kg. A breathing frequency of 150 breaths per min was maintained with an inspiratory 
to expiratory ratio of 2:3.
Airway resistance (Rn), which is dominated by the resistance of the large conducting airways was considered 
in this study when the coefficient of determination of the model fit was ≥0.9. Compliance (Cst) was calculated 
straight from deflating arm of the pressure volume (PV) loops and ramp style pressure-driven maneuver (PVr-P). 
For obtaining FEV0.1 data a NPFE maneuver was performed which results in FV loops and FE-related parameters. 
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The mice lung was inflated by a pressure of +30 cmH2O over 1.2 s and rapidly deflated to a negative pressure of 
−55 cmH2O to generate an imposed negative expiratory pressure gradient.
Salivary assay. Prior to tracheostomy, anesthetized mice were injected with 50 µl of 1 mM acetylcholine 
(ACh) in the cheek to stimulate the production of saliva. The fluid was collected via glass capillaries and a chloride 
assay was performed using the Chloride (Cl−) Assay Kit according to the manufacturer’s protocol (www.sigmaal-
drich.com). Briefly, saliva was diluted at a ratio of 1:100 with water in a total volume of 50 µl and subsequently 
150 µl chloride reagent was added. After 15 min incubation at room temperature in the dark, absorbance was 
measured at 620 nm using an Ensight Multimode plate reader (www.perkinelmer.com).
Enzyme-linked immunosorbent assays (ELISAs). To detect protein levels of hCFTR after i.t. or i.v. 
injection of differently modified cmRNAhCFTR in Cftr−/− mice (CFTRtm1Unc), the lungs were isolated at day 6 
(experimental endpoint), homogenized and lysed in 600 µl RIPA-buffer and 5 µl protease inhibitor cocktail with 
tubes of the Precellys Ceramic Kit 1.4/2.8 mm at 6,500 rpm for 10 s for a total of three cycles, each interrupted by 
a 15 s break in a Precellys Evolution Homogenizer for protein isolation (all from www.peqlab.com). Subsequently, 
supernatants were kept on ice and additionally homogenized 10 times with a 20G needle and incubated for 
20 min (www.bdbioscience.com). Lysates were spun down for 20 min at 13,000 × g and 4 °C. The supernatant 
was collected and stored at −20 °C for further use. Prior to hCFTR ELISA detection, protein concentration was 
measured using the Pierce BCA protein assay kit (www.thermofisher.com). For each sample, an equal amount 
of 15 µg whole protein lysate was used. A human CFTR ELISA kit (www.elabscience.com) was used for hCFTR 
detection according to manufacturer’s instructions.
Real-time RT-PCR. After i.t. or i.v. injection of cmRNAhCFTR the lungs were isolated at day 6 (experimen-
tal endpoint), homogenized and lysed with tubes of the Precellys Ceramic Kit 1.4/2.8 mm at 5,000 rpm for 20 s 
in a Precellys Evolution Homogenizer for subsequent RNA-isolation (all from www.peqlab.com). Reverse tran-
scription of 200 ng RNA was carried out using an iScript cDNA synthesis kit (www.bio-rad.com) and 1:20 dilu-
tion of the cDNA product had been used for further experiment. Detection of mRNAhCFTR was performed by 
SYBR-Green based quantitative Real-time PCR in 15 µl reactions on a ViiA7 (www.lifetechnologies.com). In all 
involved procedures, we strictly followed the MIQE protocols for RealTime experiments28. Pre- and post-reaction 
rooms were strictly separated. Reactions were incubated for 10 min at 95 °C, followed by 40 cycles of 15 s at 95 °C 
and 2 min at 50 °C (annealing and extension), followed by standard melting curve analysis. The following primer 
pairs were used:
hCFTR fwd 5′-GAGATGCTCCTGTCTCCTGG-3′, rev 5′-CCTCTCCCTGCTCAGAATCT-3′; 18S rRNA fwd 
5′-GGGAGCCTGAGAAACGGC-3′, rev 5′-GACTTGCCCTCCAATGGATCC-3′. Differences in mRNA expres-
sion between groups were analyzed by pair-wise fixed reallocation randomization tests with REST 2009 software 
after collection of the data from Viia7.
Immune response in vivo. To assess immune responses to (c)mRNAhCFTR and pDNAhCFTR, C57BL/6 
(Jackson Laboratory (www.jax.org)) mice (n = 4 per group) were treated as described for Cftr−/− mice. As posi-
tive controls a group of mice received two administrations of E. coli mRNA-NPs (20 µg) i.v. or i.t. C57BL/6 mice 
received two injections of 20 µg cmRNAhCFTR complexed to NPs i.v. or i.t. After 6 h, 24 h, and 72 h of second 
injection mice were sacrificed and blood was collected. For cytokine measurement, blood from mice was used 
to obtain serum using a serum separator (www.sarstedt.com) and tested for IFN-α and TNF-α production as 
directed in the manufacturer’s instructions (www.thermofisher.com).
Statistics. All analyses were performed using the Kruskal-Wallis test with GraphPad Prism Version 6 (www.
graphpad.com). Most of the data are represented as mean ± SD; box plot data are represented as a mean ± mini-
mum to maximum values. P ≤ 0.05 was considered statistically significant.
Results
(c)mRNAhCFTR and hCFTR protein quantification in vitro. To evaluate the influence of chemical nucle-
oside modification, we first conducted a set of in vitro analyses to characterize the expression and functionality of 
hCFTR protein. First, we compared the expression profile of plasmid-encoded hCFTR (pDNAhCFTR), unmodified 
hCFTR mRNA (mRNAhCFTR) and two well-defined nucleoside modifications (cmRNA CFTRs2U /m5C
h
0 25 0 25. .
 and 
cmRNA CFTRN1 /m5C
h
1 0 1 0Ψ . .
) which have been described to exert state-of-the-art stability/expression in vitro or lung-spe-
cific cell contexts in vivo21,29–31. Flow cytometry analyses 24 h after transfection of human cystic fibrosis bronchial 
epithelial (CFBE41o−) cells with pDNAhCFTR, mRNAhCFTR, 
. .
cmRNA CFTRs2U /m5C
h
0 25 0 25
 and cmRNA CFTRN1 /m5C
h
1 0 1 0Ψ . .
, showed 
hCFTR positive cells (marked as black dots) ranging from 15.8% (pDNAhCFTR) to 49.6% ( Ψ . .cmRNA
CFTR
N1 /m5C
h
1 0 1 0
) 
(P ≤ 0.01; Fig. 1A, lower panel). At 24 h, hCFTR positive cells and hCFTR median fluorescence intensities (MFIs, 
marked as columns) of (c)mRNAhCFTR were significantly higher compared to pDNAhCFTR (P ≤ 0.05; Fig. 1A, lower 
panel). At 24 h the total hCFTR expression, defined as median fluorescent intensity (MFI) multiplied by the trans-
fection efficiency, of Ψ . .cmRNA
CFTR
N1 /m5C
h
1 0 1 0
 was significantly higher compared to pDNAhCFTR and mRNAhCFTR 
(P ≤ 0.01; Fig. 1A, upper panel). In contrast, after 72 h (c)mRNAhCFTR expressed significantly lower compared to 
pDNAhCFTR transfected cells, reflected in the percentage of positive cells, MFI and in total hCFTR expression 
(P ≤ 0.05; Fig. 1B).
To confirm and substantiate those findings, we performed Western blot analyses of protein lysates taken from 
transfected CFBE41o- cells at 24 h and 72 h post treatment (Fig. 1C). As a positive control served protein lysate 
from untransfected 16HBE14o- cells, and GAPDH was used to normalize band intensities. At 24 h pDNAhCFTR 
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transfected CFBE41o- cells showed an average of 22.8% of the protein expression compared to hCFTR observed 
in 16HBE14o- cells, which increased 4.1-fold to 94.0% at 72 h (P ≤ 0.05; Fig. 1C). This drastic increase of hCFTR 
expression after pDNA transfection goes well in line with the observations in flow cytometry. As well as the quick 
Figure 1. (c)mRNAhCFTR and pDNAhCFTR mediated expression of hCFTR in vitro (A) Total expression of 
hCFTR (calculated by multiplying positive cells (dots) and MFI (bars)) 24 h after transfection with 1 µg (c)
mRNAhCFTR and equivalent nmols of pDNAhCFTR detected by flow cytometry. (B) Total expression of hCFTR 
72 h after transfection with 1 µg (c)mRNAhCFTR and equivalent nmols of pDNAhCFTR detected by flow cytometry. 
(C) Western Blots, semi-quantifying human CFTR in transfected CFBE41o- cells, normalized to GAPDH and 
put relative to CFTR levels in 16HBE14o- cells. Blot section cropped from different blots are delineated with 
clear dividing lines (black) and full blot of same exposure time (30 mins) are depicted in Supplement Fig. S4. 
All bar graph data are depicted as means ± SDs while box plots data are depicted as the means ± minimum to 
maximum values. *P ≤ 0.05 versus unmodified mRNAhCFTR; §P ≤ 0.05 and §§P ≤ 0.01 vs. pDNAhCFTR.
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onset of hCFTR expression after (c)mRNAhCFTR transfection at 24 h (P ≤ 0.05; Fig. 1C). However, relative to the 
24 h time-point, hCFTR expression after 72 h either remained nearly static (mRNAhCFTR resulted in 33.8% and 
34.7% expression at 24 h and 72 h, respectively), decreased (
. .
cmRNA
CFTR
s2U /m5C
h
0 25 0 25
 resulted in 45% and dropped to 
29.3% hCFTR expression at 24 h and 72 h, respectively) or increased (
Ψ
. .
cmRNA
CFTR
N1 /m5C
h
1 0 1 0
, 46.4% at 24 h and raised 
to 63.3% at 72 h). Ultimately, the expression of hCFTR mRNA in vitro was strongly dependent on its chemical 
modification, with Ψ . .cmRNA
CFTR
N1 /m5C
h
1 0 1 0
 resulting in the most robust hCFTR expression among all (c)mRNA trans-
fections (All the blots are separately provided in Supplement Fig. S4).
All in vitro results are also underlined by the conducted immunofluorescence imaging. All tested samples 
show a higher amount of hCFTR positive cells compared to the negative control (CFBE41o- cells; Fig. 2A). 
Additionally, transfection with unmodified mRNAhCFTR produced a lower amount of hCFTR positive cells com-
pared to both pDNAhCFTR and cmRNAhCFTR with the highest amount of hCFTR positive cells in the samples 
transfected with cmRNA CFTRN1 /m5C
h
1 0 1 0Ψ . .
 (Fig. 2A). Looking at the fluorescence image itself transfection of pDNAhCFTR 
shows a quite dispersed appearance of hCFTR within the cells compared to cmRNAhCFTR transfection seeming to 
have a higher abundance of hCFTR towards the cell membrane (Fig.  2A, left panel). In general, the 
Figure 2. (c)mRNAhCFTR and pDNAhCFTR mediated expression of hCFTR by immunofluorescence and 
functional hCFTR in vitro and immunogenicity in human whole blood. (A) Detection of hCFTR protein by 
immunofluorescence (after 24 h), percent of hCFTR expression in pDNAhCFTR or (c)mRNAhCFTR transfected 
CFBE41o- cells compare to untransfected CFBE41o- and 16HBE14o- cells. Image J has been used for 
calculating means ± SDs of hCFTR positive cells; (B) Quenching efficacy of pDNAhCFTR or (c)mRNAhCFTR 
transfected CFBE41o- and CFTR null A549 cells relative to un-transfected controls was measured at 24 h, 48 h 
and 72 h post-transfection. *P ≤ 0.05 versus un-transfected controls; (C) 2 ml whole blood, each from three 
different healthy human donors, were incubated with either R848 (1 mg/ml) or 7 pmol pDNAhCFTR or 7 pmol (c)
mRNAhCFTR (providing the same total number of nucleic acid molecules) and NPs at a 1:10 ratio; after 6 h and 
24 h the immune response was determined by ELISA in the sera; The blue area represents the variance of the 
negative controls which are biological replicates. n.d., not detectable and red dotted lines mark the detection 
limit as specified in the respective ELISA kit. All bar graph data are depicted as means ± SDs while box plots 
data are depicted as the means ± minimum to maximum values. *and §P ≤ 0.05 (§§P ≤ 0.01) versus control at 6 h 
and 24 h, respectively.
www.nature.com/scientificreports/
7SCIENTIFIC REPORTS |         (2018) 8:16776  | DOI:10.1038/s41598-018-34960-0
Immunofluorescence imaging confirms that transfection with pDNAhCFTR as well as (c)mRNAhCFTR leads to 
increased levels of hCFTR protein within the transfected cells.
hCFTR (c)mRNA functionality test in vitro. For functional analysis of the (c)mRNAhCFTR -encoded 
CFTR channel, we performed a YFP-based functional assay using CFTR null A549 cells or ∆F508 CFBE41o- cells 
which stably express halide-sensitive YFP-H148Q/I152L30. Quenching of the YFP signal induced by hCFTR 
channel-mediated I− influx is reciprocally proportional to hCFTR channel function25,32. Figure 2B shows the 
quenching efficacy after transfection of 250 ng (c)mRNAhCFTR, for three different time points, normalized to 
mock-transfected cells. In pDNAhCFTR transfected cells, the quenching efficacy was significantly higher after 48 h 
and stayed high even after 72 h (P ≤ 0.05), while mRNAhCFTR as well as modified cmRNAhCFTR transfected cells 
revealed a single peak quenching at 48 h (P ≤ 0.05), which was undetectable at 72 h in A549 cells. In CFBE41o- 
cells mRNAhCFTR could not provide any detectable quenching but Ψ . .cmRNA
CFTR
N1 /m5C
h
1 0 1 0
 produced significant 
quenching at all the time points (P ≤ 0.05) and cmRNA CFTRs2U /m5C
h
0 25 0 25. .
 showed very significant quenching at 48 h 
(P ≤ 0.001), which is in line with expression patterns seen in Fig. 1A,B.
(c)mRNAhCFTR immunogenicity ex vivo by an adapted human whole blood assay. Due to lack 
of a reliable method to detect immune responses that therapeutic mRNAs may trigger in a living organism, we 
focused on an innovative approach to using whole blood from humans. Blood was collected from three healthy 
donors and used fresh to conduct whole blood assays. Interestingly, the negative control groups (blood only and 
NP only) did not raise IFN-α values above the detection limit (Fig. 2C, red dotted lines), while TNF-α and IL-8 
were already measurable in human blood untreated or treated only with NPs. That is the reason why we adapted 
the graphical presentation, using a blue colored area that represents the variance of the negative controls, which 
are biological replicates. The positive control (R848) lead to a strong and significant production of IFN-α (6 h 
and 24 h, respectively; P ≤ 0.05), IL-8 (6 h and 24 h, respectively; P ≤ 0.01) and TNF-α (6 h and 24 h, respectively; 
P ≤ 0.05) (Fig. 2C). All cmRNAhCFTR showed a very similar result in cytokine expression as observed for negative 
controls: the IFN-α levels did not reach the detection limit of the ELISA; IL-8 and TNF-α responses were not 
statistically significant at 6 h and 24 h, respectively (Fig. 2C). Unmodified mRNAhCFTR resulted in a significant 
increase of IFN-α at 6 h and 24 (P ≤ 0.05), only significant increase in IL-8 at 24 hours (P ≤ 0.05) and the TNF-α 
levels were in line with the negative control. While pDNAhCFTR triggered high TNF-α responses at 6 h (P ≤ 0.05), 
significant and detectable IFN-α and IL-8 responses after 6 h and 24 h (P ≤ 0.05). Due to both, significantly lower 
expression of mRNAhCFTR in vitro (Fig. 1) and unwanted higher immune responses of mRNAhCFTR, we focused on 
cmRNAhCFTR and pDNAhCFTR in the following therapeutic studies.
Therapeutic effect of cmRNAhCFTR in vivo in mice after i.t. and i.v. application. All in vivo experi-
ments were performed with nanoparticles if not stated otherwise. Therapeutic potential of cmRNAhCFTR was 
investigated in a mouse model of Cystic Fibrosis. Cftr−/− and Cftr+/+ mice have been used in several experimental 
settings that are explained and color-coded in Fig. 3A. To assess the impact of cmRNAhCFTR on lung function, we 
evaluated clinically relevant parameters using the FlexiVent® lung function measurement system. We observed 
significant differences between Mock controls, Cftr−/− and healthy wild-type mice for all parameters measured 
(P ≤ 0.05; Figs 3 and 4B, P ≤ 0.01; Figs 3 and 4C and P ≤ 0.001 Figs 3 and 4D). I.v. administration of 
cmRNA CFTRs2U /m5C
h
0 25 0 25. .
 significantly increased the compliance from 0.02 ± 0.01 ml/cmH2O (Cftr
−/− mice) to 
0.03 ± 0.01 ml/cmH2O (P ≤ 0.05), reaching equivalent values to those measured in Cftr
+/+ mice (Fig. 3B). In con-
trast, the i.v. application of 40 µg 
Ψ
. .
cmRNA
CFTR
N1 /m5C
h
1 0 1 0
 or pDNAhCFTR did not alter compliance significantly. 
Applying 40 µg of cmRNA CFTRs2U /m5C
h
0 25 0 25. .
 or 
Ψ
. .
cmRNA
CFTR
N1 /m5C
h
1 0 1 0
 i.v. significantly lowered the resistance (P ≤ 0.01 and 
P ≤ 0.05 respectively, Fig. 3C) but pDNAhCFTR did not alter the resistance at a significant level. FEV0.1 (human 
equivalent of FEV1) of Cftr
+/+ mice defined as projecting 100% forced expiratory volume is pointedly different 
compared to the FEV0.1 value of Cftr
−/− mice of only 66% of the wild-type (P ≤ 0.001). I.v. injection of 40 µg 
cmRNA
CFTR
s2U /m5C
h
0 25 0 25. .
 significantly improved the FEV0.1 by 23 percentage points (P ≤ 0.01) and i.v. injection of 40 µg 
cmRNA
CFTR
N1 /m5C
h
1 0 1 0Ψ . .
 provided a significant FEV0.1 improvement of 14 percentage points compared to FEV0.1 value 
of untreated Cftr−/− mice (P ≤ 0.05; Fig. 3D). However, i.v. administration of pDNAhCFTR showed no significant 
improvement of FEV0.1. I.v. injected mock cmRNA
DsRED or nanoparticles alone encouragingly aligned with 
untreated groups in all determined lung function parameters. Taken together, these results demonstrate signifi-
cant lung function improvement in all relevant lung function parameters of Cftr−/− mice intravenously (i.v.) 
treated with cmRNAhCFTR.
In the i.t. treated groups, a substantial improvement in compliance and resistance could be detected when the 
cmRNA CFTRs2U /m5C
h
0 25 0 25. .
 dose was increased to 80 µg (0.04 ± 0.01 ml/cmH2O and 0.86 ± 0.18 cmH2O.s/ml respec-
tively; P ≤ 0.05; Fig. 4B,C). However, 80 µg of cmRNA CFTRN1 /m5C
h
1 0 1 0Ψ . .
 i.t. lowered the resistance but did not improve 
the compliance as effectively as 
. .
cmRNA CFTRs2U /m5C
h
0 25 0 25
 (P ≤ 0.05; Fig. 4B,C). pDNAhCFTR (80 µg) i.t. treated mice also 
produced significant improvements of resistance and compliance (P ≤ 0.05, Fig. 4B,C). In terms of FEV0.1, i.t. 
application of 80 µg 
. .
cmRNA CFTRs2U /m5C
h
0 25 0 25
 was improved by 19 percentage points and i.t. application of 80 µg 
cmRNA CFTRN1 /m5C
h
1 0 1 0Ψ . .
 improved the FEV0.1 by 12 percentage points with respect to untreated Cftr
−/− mice (P ≤ 0.05, 
Fig. 4D). I.t. administration of pDNAhCFTR showed no significant improvement of FEV0.1. Taken together, these 
results demonstrate significant lung function improvement in all relevant lung function parameters of Cftr−/− 
mice treated intratracheally with cmRNAhCFTR.
A well-established functional test, measuring the mouse saliva chloride concentration33 was conducted to 
complement the functional results observed using FlexiVent. The saliva chloride concentration detected in 
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Cftr−/− mice (4084 ± 236.8 ng/µl) was significantly higher compared to Cftr+/+ mice (748.8 ± 96.9 ng/µl, 
P ≤ 0.001; Fig. 5A,B). The treatment of 
. .
cmRNA CFTRs2U /m5C
h
0 25 0 25
 i.v. significantly lowered the chloride concentrations 
in the saliva of Cftr−/− mice by more than 52 percentage points (P ≤ 0.01; Fig. 5A) underlining the FlexiVent 
results. However, Ψ . .cmRNA
CFTR
N1 /m5C
h
1 0 1 0
 and pDNAhCFTR treated mice (i.v.) only provided about 20 percentage points 
reduction. The treatment with cmRNA CFTRs2U /m5C
h
0 25 0 25. .
 i.t. (80 µg) significantly lowered the chloride concentrations in 
the saliva of Cftr−/− mice by 36 percentage points (P ≤ 0.01; Fig. 5B). Ψ . .cmRNA
CFTR
N1 /m5C
h
1 0 1 0
 treated mice (i.t.) 
abridged the chloride concentration not significantly in saliva of Cftr−/− mice but pDNAhCFTR treated Cftr−/− pro-
vided a significant reduction (P ≤ 0.01; Fig. 4B) but not as proficiently as 
. .
cmRNA CFTRs2U /m5C
h
0 25 0 25
. The mock mRNA 
treated group and just nanoparticle treated group failed to decrease the chloride concentration.
cmRNAhCFTR and hCFTR protein quantification in lungs after application in vivo. All in vivo 
experiments were performed with nanoparticles if not stated otherwise. We tested for the localization of cmR-
NAhCFTR complexed with nanoparticle in the lungs after i.t. or i.v. application via RT-qPCR, quantified the hCFTR 
protein expression with hCFTR ELISA and then evaluated its immunogenicity depending on modification. In 
contrast to the in vitro data, when 40 µg cmRNA CFTRs2U /m5C
h
0 25 0 25. .
 was i.v. injected into the mice, this resulted in a 
higher accumulation of that mRNA in the lung as compared to 40 µg Ψ . .cmRNA
CFTR
N1 /m5C
h
1 0 1 0
 and pDNAhCFTR 
(P ≤ 0.01, Fig. 6C). More importantly, we wanted to analyze if there is a significant increase in hCFTR protein 
levels in the lungs of treated mice by hCFTR ELISA (Fig. 6B,E). These analyses confirmed that mice treated with 
40 µg 
. .
cmRNA CFTRs2U /m5C
h
0 25 0 25
 i.v. had a highly significant increase of hCFTR protein in the lungs of treated mice vs. 
control mice (P ≤ 0.01; Fig. 6B). Besides, we tested the effects of an increased amount (80 µg) of cmRNAs and 
pDNAhCFTR with i.t. instillation, cmRNA CFTRs2U /m5C
h
0 25 0 25. .
 and pDNAhCFTR showed a clear and significant increase of 
hCFTR protein compared to control mice (Fig. 6E) (P ≤ 0.01). All the mock controls used in hCFTR ELISA have 
proven to be not significantly different from the negative control.
cmRNAhCFTR immunogenicity in vivo in mice after i.v. application. All in vivo experiments were per-
formed with nanoparticles if not stated otherwise. First, we applied different compounds such as nanoparticles, 
E. coli extract total RNA (positive control), cmRNAhCFTR and pDNAhCFTR i.v. or i.t. to mice and monitored their 
immune reaction at three different time points. Applying 40 µg cmRNAhCFTR (with any modifications used) or 
Figure 3. In vivo lung function measurements in cmRNAhCFTR and pDNAhCFTR treated Cftr−/− mice by i.v. 
route. All mouse groups utilized in (B–D) are color-coded for their treatment schemes (A), including dosage 
and application routes. (B–D) Precision in vivo lung function measurements covering all relevant outcome 
parameters on in Cftr−/− mice treated twice via i.v. route and measured 72 hours after the 2nd instillment; 
n = 4–7 mice per group. The blue area represents the variance of the negative controls which are biological 
replicates. Data represent the means ± SD on compliance, resistance and Forced Expiratory Volume in 
0.1 seconds (FEV0.1). *P ≤ 0.05; **P ≤ 0.01 and ***P ≤ 0.001 versus untreated Cftr
−/− mice.
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pDNAhCFTR i.v. or i.t. did not lead to detectable responses of key cytokines IFN-α or TNF-α (detected by ELISA) 
at all three-time points (Fig. 7A)34,35. Nanoparticles alone (used in all in vivo experiments) showed no immune 
response over the detection limit. However, as expected the positive control (E. coli extract total RNA) i.v. and 
i.t. resulted in a significant increase of IFN-α and TNF-α at 6 h and a trend increase of IFN-α at 24 h, while an 
effect at 72 h was not detectable (Fig. 7A). No immune response had been observed apart from positive control in 
groups treated intratracheally (i.t) (Fig. 7B).
Figure 4. In vivo lung function measurements in cmRNAhCFTR and pDNAhCFTR treated Cftr−/− mice by i.t. 
route. All mouse groups utilized in (B–D) are color-coded for their treatment schemes (A), including dosage 
and application routes. (B–D) Precision in vivo lung function measurements covering all relevant outcome 
parameters on Cftr−/− mice treated twice via i.t route and measured 72 hours after the 2nd instillment; n = 4–7 
mice per group. The blue area represents the variance of the negative controls which are biological replicate. 
Data represent the means ± SD on compliance, resistance and Forced Expiratory Volume in 0.1 seconds 
(FEV0.1). *P ≤ 0.05; **P ≤ 0.01 and ***P ≤ 0.001 versus untreated Cftr
−/− mice.
Figure 5. In vivo saliva chloride concentration measurement of cmRNAhCFTR and pDNAhCFTR treated Cftr−/− 
mice by i.v./ i.t. route (A,B) Functional test of reconstituted CFTR channel and reduced chloride concentration 
after i.v. (A) or i.t. (B) treatment of Cftr−/− mice compared to untreated Cftr−/− (black), positive controls 
(violet), and percentages relative to the positive control; n = 4 mice per group; two mock controls were included 
(white); boxes represent the means ± minimum and maximum values. The blue area represents the variance of 
the negative controls which are biological replicates. *P ≤ 0.05; **P ≤ 0.01 versus untreated Cftr−/− mice.
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Figure 6. Expression of hCFTR protein in mouse lungs and delivery of cmRNAhCFTR and pDNAhCFTR in lungs. 
(A,D) All mouse groups, particles and particle combinations depicted in the study plan are color-coded for their 
treatment schemes, including dosage and application routes. (B,E) hCFTR ELISA, detecting specifically human 
CFTR, was performed on lung preparations at day 6 from Cftr−/− mice treated twice via i.v. (B) or i.t. (E) route 
and measured 72 hours after the 2nd instillment (endpoint); the same n = 4–7 mice per group were used. (C,F) 
Relative amounts of differently modified hCFTR mRNAs in the lungs applied i.v. or i.t., then determined by 
RT-quantitative PCR, compared to untreated Cftr−/− mice (*P ≤ 0.05); n = 4–7 mice per group. All bar graph 
data are depicted as means ± SDs while box plots data are depicted as the means ± minimum to maximum 
values. The blue area represents the variance of the negative controls which are biological replicates. *P ≤ 0.05; 
**P ≤ 0.01 and ***P ≤ 0.001 versus untreated Cftr−/− mice.
Figure 7. (c)mRNAhCFTR and pDNAhCFTR mediated immunogenicity in vivo Mice were i.v. or i.t. injected with 
a mix of (c)mRNA and NPs at a 1:10 ratio and ELISAs were performed post-i.v./i.t.-injection at three different 
time points. n.d., not detectable. The red dotted lines in (A,B) mark the detection limit as specified in the 
respective ELISA kit. All bar graph data are depicted as the means ± SD and box plots data are represented as 
the means ± minimum to maximum values.
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Discussion
Although much progress has been achieved since the discovery of the CFTR gene 25 years ago, there is still a sub-
stantial need to restore robust CFTR function in patients suffering from cystic fibrosis8. With the recent approvals 
of the small molecule agents ivacaftor and lumacaftor, science has paved a possible way to overcome the hurdles 
caused by the disease-conferring gene. Those treatments can be more or less effectively applied to patients bearing 
CFTR mutations delF508 (Lumacaftor-ivacaftor/Orkambi) and G551D (ivacaftor)36–39. However, lung function, 
as one of the main outcome parameters probably having the most significant influence on life quality of CF 
patients, is rarely tested in preclinical models. In fact, actual effects of (modern) existing drugs on lung function, 
with forced expiratory volume in one second (FEV1) as a key parameter, are quite low
40. Here, by using cmR-
NAhCFTR, we are presenting a proof of concept for a viable and potent therapeutic alternative. We have vigorously 
tested mRNA therapy with focus on in vivo lung function normalization while avoiding any possible, unwanted 
immune responses for a possibility of repeated dosing. The unique formulation utilized can be used both topically 
(intratracheally) and systemically (via i.v. injection), having in both cases a profound effect on normalizing the 
lung function parameters, including compliance, resistance and FEV0.1 of treated Cftr
−/− mice to values obtained 
from Cftr+/+ mice.
In vitro, using cmRNAhCFTR, CFTR protein expression in CFBE41o− cells was increased up to 5.5-fold com-
pared to mRNAhCFTR, which is consistent with previous studies obtained by us and others18,31,41. Incorporation 
of naturally occurring chemically modified nucleosides has been shown to suppress inhibitory effects on trans-
lation by avoiding detection by pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs) TLR3, 
TLR7, and TLR834,35. Those receptors play a crucial role in the detection, processing, and degradation of mRNA. 
Interestingly, depending on the mRNA modification, kinetics of hCFTR expression varies upon the different 
nucleosides used. In fact, after 72 h we only observe an increased quenching of Yellow fluorescent protein (YFP) 
in YFP assay in CFTR null A549 and CFBE41o− cells by pDNAhCFTR which would corroborate our findings 
from our flow cytometry and western blot analyses in CFBE41o− cells. In contrast there is a significant increase 
in I− influx by functional hCFTR channels and quenching of YFP at 48 h post transfection by cmRNAhCFTR. 
Consequently, we assume that upon different cell lines, kinetics by which the hCFTR protein is expressed varies. 
Earlier studies support our notion that differently modified mRNAs can have an impact on the translational effect 
between distinct cell lines31,35.
To better mimic in vivo human conditions, we performed an ex vivo whole blood assay (WBA) which offers 
a more complex environment to test for immune responses. This assay has already been used in a number of 
preclinical settings, and Coch and colleagues could demonstrate that it has the potential to reflect broad aspects 
of the in vivo cytokine release caused by oligonucleotides42. Indeed, we could show that the small molecule 
Resiquimod (serving as a positive control by activating TLR7 and TLR8) lead to a substantial release of IFN-α, 
TNF-α and IL-8. pDNAhCFTR, as well as unmodified mRNAhCFTR, also showed elevated cytokine levels probably 
due to the activation of innate immune receptors34,35. In contrast, incorporation of modified nucleosides into 
hCFTR mRNA (cmRNAhCFTR) abolished such responses, with no detectable amounts of IFN-α. This is in concert 
with previously published data, demonstrating cmRNA’s limited immune responses, mainly by evading detection 
from receptors such as TLRs, RIG-1, MDA-5 or PKR34,41. Interestingly, even though TNF-α or IL-8 could be 
detected, it rather shows donor-dependency than effects deriving from NPs and/or cmRNAhCFTR with cytokine 
levels being all within the variance of negative controls. Although it mirrors only the blood compartment and 
does not reflect the more complex in vivo situation, the WBA can give a prediction of how cytokines are released 
in the human system in response to systemically applied (c)mRNA prior to clinical testing.
To determine the clinical potential of CFTR-encoded cmRNA we compared not only different modifications 
in vivo but also two different routes of administration. I.t. application has been chosen for this study on the base of 
our previous findings of applying cmRNA i.t. in a surfactant protein-B deficient mouse model leading to signifi-
cantly prolonged survival26. Given the fact that in patients suffering from CF one of the key barriers is the airway 
mucus layer in which inhaled particles are more likely to get trapped and removed, we sought to apply cmRNAh-
CFTR/pDNAhCFTR complexed to NPs by i.v. injection as an alternative administration route. Systemic delivery via 
lipid-modified polymeric nanoparticles have been already shown to target the lungs efficiently43.
To support our notion of improved CFTR activity, we performed extensive lung function measurements using 
state-of-the-art technology to provide detailed in vivo information on different lung function parameters. There 
are doubts about Cftr−/− mice as a proper model for cystic fibrosis as it does not reflect the typical lung phenotype 
seen in CF patients44. However, the reason behind that seems to be in how deeply lungs or other affected organs 
had been investigated. A layer of material can be observed with characteristics of an acid mucopolysaccharide on 
the bronchiolar surface and is also evident in alveoli by using scanning electron microscopy in Cftr−/− mice, 
which is not evident in Cftr+/+ mice45. It has also been reported Cftr−/− mice shows similar effect of CF patients 
like, age-dependent pulmonary inflammation, death of respiratory epithelial cells and high vulnerability to severe 
Pseudomonas aeruginosa infection46. Recent studies could demonstrate reduced airway compliance and increased 
resistance in comparison to wild-type mice47,48. Indeed, we observed significantly higher and lower levels regard-
ing resistance and compliance, respectively, in Cftr−/− controls and mock-treated Cftr−/− mice compared to 
homozygous wild-type mice (Cftr+/+) mice and demonstrated that treatment with cmRNAhCFTR-NPs improved 
compliance and resistance significantly equal to those seen in healthy Cftr+/+ mice. FEV1 percentage (for mouse 
or small animal FEV0.1) is related to survival in CF and a most important physiological parameter for CF patients. 
A previous study demonstrated that patients with a %FEV1 of <30 compared to healthy individuals had a 50% 
chance of mortality within 2 years and hence are regularly examined in clinical setup49. A strong variance amid 
Cftr−/− controls and mock-treated Cftr−/− mice compared to homozygous wild-type mice (Cftr+/+) mice has been 
perceived in the case of FEV0.1. Our study provides a significant improvement of FEV0.1 due to treatment with 
NP-cmRNAhCFTR. Interestingly, NP-pDNAhCFTR when administered via i.t. route improved parameters of lung 
function measurements including FEV0.1, but not as significant as cmRNA
hCFTR. We also observed i.v. or i.t. 
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administration of 
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cmRNA CFTRs2U /m5C
h
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 to positively compensate most of lung function parameters. Overall, we 
could demonstrate that certain protocols, applying cmRNAhCFTR either i.v. or i.t. efficiently restored lung function 
values equal to those of wild-type. Suggesting a more even distribution through arteries and the bronchial circu-
lation by i.v. injection, this route and formulation could lead to a very potent therapy especially for newborns and 
young infants. By providing functional CFTR early in life, the lungs could be protected from irreversible damage. 
Nevertheless, when applied intratracheally, which mimics deep inhalation of a spray or powder formulation (pri-
mary application route in adults), an adjustment in dose and/or formulation (e.g. cmRNA CFTRs2U /m5C
h
0 25 0 25. .
 increased 
to 80 µg) might easily abrogate any negative effect of the Cftr−/− genetic background on lung function.
Eventually, we determined the impact of cmRNAhCFTR and pDNAhCFTR on another relevant physiological out-
come such as the saliva chloride concentration to evaluate therapeutic effect and complement the lung function 
results. Sweat chloride concentration has become an accepted method as a diagnostic readout to assess treatment 
effects of CF patients50. As an analog, chloride concentration of β-adrenergic stimulated salivary glands of Cftr−/− 
mice can be investigated as it complies with findings in CF patients33. In this study, we could show a substantial 
difference in salivary Cl− content of cmRNAhCFTR and pDNAhCFTR treated mice – both, i.v. and i.t. – compared to 
their untreated counterpart. With end point-analysis, a significant decrease in Cl− to nearly 50% was observed, 
indicating a restoration of CFTR in the duct compartment of salivary glands and thus leading to an improved 
Cl− absorption. Previous studies estimated that a restoration of CFTR activity to 50% could lead to sweat chloride 
levels to near normal levels in CF patients. Given that, it is possible that cmRNAhCFTR treatment has the potential 
to improve CFTR activity to levels that are at least similar to those in patients with a mild CF phenotype51.
In this study, by applying cmRNAhCFTR consecutively, both modifications were successfully delivered to the 
lungs with the i.v. route being more efficient at doses of 40 µg (2 mg/kg body weight) per treatment. Intriguingly, 
in contrast to the results obtained in vitro, 
. .
cmRNA CFTRs2U /m5C
h
0 25 0 25
 showed a significantly higher CFTR protein 
expression with higher accumulation of hCFTR mRNA in lung cells. Assuming differences of cmRNA-encoded 
transgene expression between distinct cell lines, it is plausible to consider such differences between in vitro versus 
in vivo applications, which is by far more complex. In this respect, the higher amount of cmRNA CFTRs2U /m5C
h
0 25 0 25. .
 
found in lung cells after i.v. injection, might be due to the fact that its nucleoside composition is more favorable to 
evade PRRs, thus being less degraded. However, regardless of cmRNA kinetics we also observed differences in the 
delivery route of cmRNAhCFTR/pDNAhCFTR -NPs. Our data suggest i.v. injection to be more efficient in delivering 
such complexes to the lung than topical administration. Tests of cmRNAhCFTR -NP’s capacity of mucus penetra-
tion are in planning phase including detection of cmRNAhCFTR and CFTR protein (glycosylated) in a Cftr-deficient 
mouse model especially at the apical side of the bronchial epithelium. The upper airways are lined with mucus 
and mucociliary movements clear foreign particles immediately. In addition, the main barriers in the deeper areas 
are the alveolar lining, scavenger transporters and alveolar macrophages52,53. We, therefore, concluded that the 
original dosing by which cmRNA-NPs were delivered i.t. was not as efficient as using the i.v. route. Indeed, 
increasing the amount by doubling the dose (to 80 µg) for each treatment showed a hCFTR expression close to 
levels seen using the i.v. route.
To exclude immune reactions caused by either NPs or the cmRNAhCFTR itself, we conducted extensive immune 
assay tests in vivo. Except for the positive control (E. coli total mRNA), we could not detect any immunostimu-
latory effect in vivo that could arise from NPs or the cmRNAhCFTR. These results confirm our previous studies in 
which we showed that NPs, as well as modified mRNA, could be administered safely to the lungs without any 
substantial increase in cytokines, or inflammatory-related cells such as macrophages or neutrophils26. Systemic 
delivery has also been reported to have no impact on proinflammatory cytokine secretion29.
Taken together, this study is the first proof of concept of efficient application of NP-cmRNAhCFTR in vivo to 
restore lung function in a Cftr-deficient mouse model. Importantly, we could neither detect immune responses 
in vivo nor in a more defined setting ex vivo. Applying cmRNAhCFTR to Cftr−/− mice could efficiently restore lung 
function close to levels of healthy control mice. In addition, our study compared - apart from two well-known 
mRNA modifications and pDNAhCFTR - also two different delivery routes, demonstrating that systemic admin-
istration of cmRNA targets lung cells more efficiently at lower dosages. This study provides a proof of concept 
for alternative treatment of patients suffering from CF. cmRNAhCFTR transcript supplementation may be broadly 
applicable for most CFTR mutations, not only in adults but already in the postnatal state, thereby protecting the 
lungs from exacerbations from the very beginning of life.
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Gene correction of HBB mutations in CD34+
hematopoietic stem cells using Cas9 mRNA
and ssODN donors
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Abstract
Background: β-Thalassemia is an inherited hematological disorder caused by mutations in the human hemoglobin
beta (HBB) gene that reduce or abrogate β-globin expression. Although lentiviral-mediated expression of β-globin
and autologous transplantation is a promising therapeutic approach, the risk of insertional mutagenesis or low
transgene expression is apparent. However, targeted gene correction of HBB mutations with programmable
nucleases such as CRISPR/Cas9, TALENs, and ZFNs with non-viral repair templates ensures a higher safety profile
and endogenous expression control.
Methods: We have compared three different gene-editing tools (CRISPR/Cas9, TALENs, and ZFNs) for their targeting
efficiency of the HBB gene locus. As a proof of concept, we studied the personalized gene-correction therapy for a
common β-thalassemia splicing variant HBBIVS1–110 using Cas9 mRNA and several optimally designed single-
stranded oligonucleotide (ssODN) donors in K562 and CD34+ hematopoietic stem cells (HSCs).
Results: Our results exhibited that indel frequency of CRISPR/Cas9 was superior to TALENs and ZFNs (P < 0.0001).
Our designed sgRNA targeting the site of HBBIVS1–110 mutation showed indels in both K562 cells (up to 77%) and
CD34+ hematopoietic stem cells—HSCs (up to 87%). The absolute quantification by next-generation sequencing
showed that up to 8% site-specific insertion of the NheI tag was achieved using Cas9 mRNA and a chemically
modified ssODN in CD34+ HSCs.
Conclusion: Our approach provides guidance on non-viral gene correction in CD34+ HSCs using Cas9 mRNA and
chemically modified ssODN. However, further optimization is needed to increase the homology directed repair
(HDR) to attain a real clinical benefit for β-thalassemia.
Keywords: HBB, Beta-thalassemia, Gene correction, CRISPR/Cas9, IVS1–110, Cas9 mRNA
Background
β-Thalassemia (OMIM: 613985) is an inherited
hematological disorder caused by mutations of the hu-
man hemoglobin beta (HBB) gene, leading to deficient
β-globin expression and severe anemia [1]. The current
treatment options include allogeneic bone marrow
transplantation and hematopoietic stem cell (HSC)
transplantation but are limited to histo-compatible
donors. However, gene therapy based on autologous trans-
plantation of a lentiviral-transferred HBB gene to HSCs
resulted in remarkable clinical benefit [2, 3]. Though the
safety and efficacy of lentiviral-based gene therapy is
positive in a treated patient, the transactivation of the
proto-oncogene HMGA2 and more than 3500 unique inte-
gration sites in tested mouse model forewarns the possibil-
ity of insertional mutagenesis [2, 4]. Earlier retroviral gene
therapy studies on other inherited diseases reported the
treatment-related leukemogenesis [5–7], and lentiviral
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therapy resulted in T cell lymphoma in a mouse model of
X-SCID due to random integration into oncogenes [8].
Therefore, the ideal gene therapy with viral vectors must
ensure targeted integration of a therapeutic HBB transgene
in the endogenous locus. Otherwise, personalized gene-cor-
rection therapy with programmable nucleases and non-vi-
ral repair templates such as single-stranded
oligonucleotides (ssODNs) must be employed as it is
less likely to randomly integrate into the genome and
result in a safe and precise gene editing [9]. Though
several studies targeted HBB gene with ZFNs,
TALENs, and CRISPR/Cas9, no study has ever com-
pared all the three gene-editing platforms simultan-
eously. Therefore, in the present study, we compared
these three approaches for their target efficiency in
parallel. Here, we tested the gene correction efficiency
of strategically designed ssODNs as repair templates
to target HBB gene. This is an important measure
while editing the highly proliferating stem cell popula-
tion to avoid clonal selection and thereby triggering
oncogenesis.
Correspondence/findings
First, we designed ZFNs, TALENs, and CRISPR/sgRNA
for targeting the promoter region of the HBB gene
(Additional file 1: Figure S1). The HBB gene-targeting effi-
cacy of designed ZFNs, TALENs, or CRISPR/Cas9 was de-
termined by T7 endonuclease-I (T7EI) assay in HEK293
cells. Interestingly, CRISPR/Cas9 exhibited higher indels
for all three different concentrations (0.5 μg, 1.0 μg, and
1.5 μg) compared to ZFNs and TALENs (Fig. 1a;
Additional file 1: Figure S1). Similar results were observed
earlier for the HBBIVS2–654 mutation where gene-targeting
efficiency of CRISPR/Cas9 was superior to TALENs [10].
Fig. 1 Comparison of three different gene-editing tools at HBB promoter and targeting HBBIVS1–110 locus. a HEK-293 cells were transfected with
500, 1000, and 1500 ng of expression plasmid of either ZFNs, TALENs, or CRISPR/Cas9 targeting the promoter of the β-globin gene locus. The
indel rate was measured by T7 endonuclease-I (T7EI) assay. Results represent mean values for each concentration, and significant difference was
observed among the tools used (P < 0.0001). b Design of HBBIVS1–110 sgRNA and ssODN donor templates. K562 cells electroporated with pX330.sg
HBB
IVS1–110 plasmid measured for indel rate and HDR. The experiment results from T7EI assay and RFLP assay (c, d) plotted as a bar graph against
utilized ssODNs. c The results of T7EI assay analyzed by 1.5% agarose gel electrophoresis. d The results of RFLP assay measured in Bioanalyzer
using DNA1000 kit (N = 3)
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Therefore, we focused on CRISPR/Cas9 to examine the
gene correction efficiency of non-viral repair templates.
Several studies have targeted the HBB gene using
CRISPR/Cas9 system in HSCs, induced pluripotent stem
cells, and human embryos [11–16]. Most of these studies
were either focused on HBB gene addition or targeting
sickle cell disease mutation. To the best of our knowledge,
this is the first study that attempted to target a common
β-thalassemia splicing variant HBBIVS1–110 (rs35004220),
which leads to an alternative splice site and reduced
β-globin expression with a non-viral strategy [17].
To target the HBBIVS1–110 locus, we designed a sgRNA
and several ssODNs (Fig. 1b; Additional file 1: Figure S1)
with varying lengths of homology arms, symmetrical dif-
ference, and chemical modifications and complimentary
to the strand targeted or not targeted by the guide-RNA
[18]. To evaluate the ability of CRISPR/Cas9 to correct
the HBBIVS1–110 mutation by an exogenous DNA se-
quence, we introduced an NheI-tag (restriction site) into
the ssODNs that can be stably integrated upon successful
homology-directed repair (HDR) (Fig. 1b). We electropo-
rated pX330.sg HBBIVS1–110 plasmid and ssODN donors
harboring NheI-tag using a Neon system into K562 cells
and evaluated the frequency of indels by T7EI assay and
HDR-driven NheI integration by restriction fragment
length polymorphism (RFLP) assay (Figs. 1c/d). Mean
indel frequencies for the targeted loci were 44 ± 18%. We
next determined whether any of the rationally designed
ssODNs could stimulate gene targeting by HDR and
found that most of the tested ssODNs resulted in similar
HDR frequencies with the median of 20% (range 5–31%).
To assess our non-viral correction strategy with bone
marrow-derived CD34+ HSCs, we co-delivered pX330.sg
HBBIVS1–110 plasmid and several ssODNs. Unlike our re-
sults with K562 cells, the indel frequencies in HSCs were
relatively low with a median of 30% (range 0–56%) and
only one ssODN (5TS) exhibited 3% HDR rate in TIDE
analysis (Fig. 2a; Additional file 1: Figure S3.A). We next
sought to determine HDR rate for 5TS-ssODN by a
semi-quantitative single-colony sequencing and found
that 2% (3/172) of clones showed NheI insertions
(Fig. 2b). We observed that pDNA resulted in lower
transfection rate and higher cell death in HSCs (data not
shown). Due to the low indel rate achieved by
pDNA-encoded Cas9, we aimed to increase the efficiency
and viability by using mRNA-encoded Cas9 as others and
ourselves earlier reported the superiority of mRNA over
pDNA [19–21]. In addition, transiently expressed Cas9
mRNA resulted in reduced off-targets compared to
long-term Cas9 expression systems [22]. Therefore, we deliv-
ered Cas9 mRNA and chemically modified sgRNA with four
different ssODNs (chemically modified, 2 PAM-depleted,
5TS) using a 4D-Nucleofector. Genomic analysis with the
T7EI assay resulted in high indels ranging from 65% (mod.
ssODN) to 87% (11 NTS), and the RFLP assay showed up to
11% integration ofNheI tag at theHBBIVS1–110 locus (Fig. 2c).
Our results clearly imply the superiority of Cas9 mRNA over
pDNA (Additional file 1: Figure S3.B). We noticed significant
enrichment of 6-bp insertion (range 2–9%) by NheI integra-
tion at the target locus for tested ssODNs (Fig. 2d;
Additional file 1: Figure S4).
However, the absolute quantification of site-specific
insertion events of the NheI tag at the HBBIVS1–110
locus by next-Generation sequencing showed 8% cor-
rection for modified ssODN (Fig. 2e; Additional file 1:
Figure S5). All the analyses spotted improved gene cor-
rection for chemically modified ssODN in HSCs as re-
ported earlier [23]. No detectable off-target cleavage
was found in six of the in silico predicted off-targets
(Additional file 2: Table S4; Additional file 1: Figure S6)
for the sgRNA-targeted HBBIVS1–110 locus. We found
that CRISPR/Cas9 greatly facilitates targeted genome
modification compared to TALENs and ZFNs, and
introduction of new DNA sequences in HSCs using
Cas9 mRNA and ssODN is feasible without viral vec-
tors. However, correction of 8% in HSCs at ex vivo set-
ting is sub-optimal. Therefore, further improvement on
HDR efficacy and selection of corrected cells is needed
to attain a meaningful gene correction of HBB muta-
tions to treat β-thalassemia and other related genetic
diseases.
Online methods
Design of gene-editing tools
The targeting efficacy at the promoter of the HBB gene
locus (200 bp upstream of the transcription start site) be-
tween three different gene-editing tools (CRSIPR/Cas9,
TALENs, and ZFN) was evaluated (Additional file 1: Figure
S1). The ZFN constructs targeting the promoter were or-
dered from Sigma-Aldrich (http://www.sigmaaldrich.com).
The full amino acid sequences of the ZFN pair are shown
in Additional file 2: Data S1. The targeting TALEN pair was
designed with the help of the online tool ZiFiT Targeter
Version 4.2 (http://zifit.partners.org) and assembled by fast
ligation-based automatable solid-phase high-throughput
(FLASH). Plasmids encoding TALE repeats harboring dif-
ferent repeat variable di-residues (RVDs) with their FLASH
IDs are summarized in Additional file 2: Table S1. The
sgRNAs for promoter (5′-AGCCAGTGCCAGAAGAGCC
A-3′) and HBBIVS1–110 (5-GGGTGGGAAAATAGACCAA
T-3′) were designed using CRISPR design tool. The re-
spective oligo pairs encoding the 20-nt guide sequences are
annealed and ligated into a pX330 vector consisting of a
SpCas9 expression cassette and a U6 promoter driving
the expression of chimeric sgRNA. The chemically
modified sgRNA for HBBIVS1–110 mutation was synthe-
sized by incorporating 2-O-methyl 3′phosphorothioate
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(MS) modification at three terminal nucleotides at both
the 5′ and 3′ ends.
Cell culture and transfection
HEK-293 cells were cultured in DMEM (https://
www.thermofisher.com) supplemented with 10% FBS
and 1% penicillin/streptomycin at 37 °C with 5% CO2. In
HEK-293 cells, pDNA-encoded gene-editing tools
(CRSIPR/Cas9, TALENs, and ZFN) were transfected
using Lipofectamin 3000 at three different concentra-
tions of 0.5, 1, and 1.5 μg. K562 cells were cultured in
RPMI 1640 (https://www.thermofisher.com) supple-
mented with 10% FBS and 1% penicillin/streptomycin at
37 °C with 5% CO2. In K562 cells, 200 ng of
pX330-Chimeric vector targeting HBBIVS1–110 loci was
co-electroporated with 10 pmol of different ssODN
Fig. 2 Gene correction of HBBIVS1–110 in CD34+ HSCs using CRISPR/Cas9 and ssODNs. a CD34+ HSCs co-nucleofected with pX330.sg HBBIVS1–110
plasmid and 5TS ssODN. Indel frequency was measured by TIDE analysis and 3% of 6 bp insertions were spotted. b Single-colony sequencing
analysis samples showed successful gene insertion of NheI restriction-site tag to the HBB gene by HDR in pX330.sg HBBIVS1–110/5TS ssODN-treated
sample. c Indel and HDR rate of CD34+ HSCs co-nucleofected with specified ssODN and Cas9 mRNA measured by T7 assay and RFLP assay in
Bioanalyzer using DNA1000 kit. d TIDE analysis exhibited the significant enrichment of 6 bp insertions up to 8%. e The absolute quantification by
next-generation analysis displayed the significant enrichment of 6 bp insertions up to 8% (N = 1)
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using Neon Transfection System (https://www.thermo-
fisher.com). Bone marrow-derived CD34+ HSCs from
healthy donors were cultured in StemSpan™ serum-free
medium II (SFEMII) containing StemSpan™ Cytokine
Cocktail 110 (https://www.stemcell.com). 1 × 105 CD34+
HSCs were electroporated with 1.2 μg pX330 vector tar-
geting HBBIVS1–110 mutation and 100 pmol of specified
ssODN repair template using Lonza© 4D-Nucleofector™
(Program: EO 100). The similar amount of p.Max eGFP
pDNA (1.2 μg) was electroporated as a transfection con-
trol. For Cas9 mRNA experiments, 1 × 105 CD34+ HSCs
were co-electroporated with 5 μg chemically modified
sgRNA, 10 μg Ca9 mRNA vector, and 100 pmol of
specified ssODN repair template using Lonza©
4D-Nucleofector™ (Program: EO 100).
Repair templates
The ssODNs were synthesized by Metabion, Germany
(www.metabion.com). The ssODNs were designed with an
insertion site harboring an NheI recognition site (GCTA
GC). The ssODNs were complimentary to either the
strand targeted or not targeted by the gRNA, asymmetric
or symmetric to the NheI tag. The chemically modified
ssODN for HBBIVS1–110 mutation was synthesized by in-
corporating 2-O-methyl 3′phosphorothioate (MS) modifi-
cation at three terminal nucleotides at both the 5′ and 3′
ends with 72 bp homology arms. The complete details can
be found in Additional file 2: Table S2.
T7 endonuclease assay and RFLP assay
Five days post transfection, genomic DNA was isolated using
Merchery-Nagel NucleoSpin Tissue Kit following the manu-
facturer’s instructions. The promoter region was amplified
using the primer pair Prom-For_5′-GTAGACCACCAGCA
GCCTAA-3′ and Prom-Rev_5′ TGGAGACGCAGGAA
GAGATC-3′, and the region covering HBBIVS1–110 mutation
was amplified using the primer pair IVS1–110-For_
5′-GGGTTTGAAGTCCAACTCCTAA-3′ and 3′UTR-
For_5′-AGAAAACATCAAGCGTCCCATA-3′. The target
regions were amplified using the AmpliTag® Gold 360 Mas-
terMix (https://www.thermofisher.com). The cycling param-
eters for both amplicons were as follows: initial denaturation
at 95 °C for 10 min, followed by 40 cycles of denaturation at
95 °C for 30 s, annealing at 55 °C for 30 s, and elongation at
72 °C for 1 min. PCR products were purified by etha-
nol precipitation, and 1 μg of PCR product was used
for T7 endonuclease assay. Likewise, 1 μg of PCR
product was used for the RFLP assay where ampli-
cons bearing the NheI tag upon successful gene cor-
rection will result in a specific cleavage after the
treatment with the NheI restriction enzyme. The
readout of the T7 endonuclease assay and the RFLP
assay were determined on a 1.5% agarose gel and on
a Bioanalyzer chip using DNA1000 kit. The band
intensities were quantified using ImageJ embedded in
Fiji software (www.fiji.sc).
TIDE analysis and single-colony and next-generation
sequencing
For analyzing allele modification frequencies with non-en-
zymatic assays, we used TIDE (Tracking of Indels by De-
composition) analysis by Sanger-sequencing the purified
PCR products used for T7 assay and examined with the on-
line TIDE software (http://tide.nki.nl.) with the respective
control sample. To precisely measure the events of
site-specific insertion of NheI tag at HBBIVS1–110 loci in
CD34+ HSPCs, we performed two different approaches: (i)
Sanger-based single-colony sequencing and (ii) next-gener-
ation sequencing. For single-colony sequencing, the
HBBIVS1–110 region was PCR amplified from 5TS ssODN
gene-corrected CD34+ HSCs and cloned into pJET1.2 vector
using CloneJET PCR Cloning kit (https://www.thermo-
fisher.com) and transformed into Top10 competent cells
using standard cloning techniques. Closely, 192 (two 96-well
plates) single colonies were processed for Sanger sequencing
with pJET1.2 forward sequencing primer (5′-CGACTCACT
ATAGGGAGAGCGGC-3′) and analyzed for the presence
for NheI recognition site (GCTAGC) using Geneious-R6
software. Three of 192 clones resulted in NheI insertion
(1.5%). In case of next-generation sequencing (NGS), new
primers were designed with the amplicon length of 150 bp
to be sequenced with the Illumina platform (Forward
5′-AGAAACTGGGCATGTGGAGA-3′; Reverse 5′-CCAT
AACAGCATCAGGAGTGG-3′). Further, barcode-tagged
PCR primers were used to multiplex samples (Add-
itional file 2: Table S3), and are adapter ligated, size selected,
and bridge amplified and proceeded with amplicon sequen-
cing in HiSeq 4000 system (http://www.illumina.com). The
standard R-Package was used for NGS analysis where the se-
quencing reads were pre-filtered for low-quality reads and
mapped to the reference sequence using a BWA tool. Fur-
ther, the number of indel-carrying sequence reads was calcu-
lated using SAM tools. The distribution plot was generated
by calculating the size of the indels in sequence and calculat-
ing the median percentage for each indel class.
In vitro transcription (IVT) of Cas9 mRNA
The open reading frame of SpCas9 was PCR amplified from
the pX330 vector and sub-cloned into the pVAX.120 vector
consisting of a T7 promoter and 120 bp length of a poly-A
tail using standard molecular biology techniques. The IVT
reaction was performed in linearized plasmid using T7 RNA
polymerase in MEGAscript T7 kit (https://www.thermo-
fisher.com). All mRNAs were produced with an anti-reverse
CAP analog (ARCA; [m7G(5′)G]) at the 5′ end (https://
www.trilinkbiotech.com/). The IVT-mRNAs were made with
following chemical modifications in the indicated ratios:
100% Pseudo-UTP and 25% s2-thio-UTP/5-methyl-CTP
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(https://www.trilinkbiotech.com/). All IVT mRNAs were
purified using the MEGAclear kit (https://www.thermo-
fisher.com) and quantified with nano-photometer and bioa-
nalyzed for quality using the RNA6000 kit in Agilent 2100
Bioanalyzer (https://www.agilent.com).
Statistics
Kruskal-Wallis or Wilcoxon-Mann-Whitney rank-sum
tests were applied wherever appropriate to analyze the
differences in indel induction among the gene-editing
technologies and comparison between encoded pDNA
Cas9 and Cas9 mRNA using Graphpad Prism v.6.0d
(https://www.graphpad.com).
Additional files
Additional file 1: Figure S1. Strategy for targeting the promoter and
IVS1–110 mutation of the HBB gene. A) The promoter region of HBB gene
targeted with three different gene-editing tools, HBBIVS1–110 targeted with
CRISPR/Cas9. B) The design of three different gene-editing tools at
sequence level. Figure S2 Comparison of three different gene-editing
tools at HBB promoter. The complete raw data of Fig. 1a. Figure S3 Gene
correction of HBBIVS1–110 in CD34+ HSCs using pX330.sg HBBIVS1–110 and
ssODNs. A) CD34+ HSCs nucleofected with pX330.sg HBBIVS1–110 plasmid
and ssODNs and measured for indel rate by T7 assay and HDR by TIDE
analysis. Only 5TS resulted 3% HDR rate in TIDE analysis (as in Fig. 2a). B)
Gene-editing capacity of pDNA-encoded Cas9 and mRNA-encoded Cas9
were compared, and superiority of Cas9 mRNA was observed (P < 0.0001).
Figure S4 TIDE analysis-gene correction of HBBIVS1–110 in CD34+ HSCs
using Cas9 mRNA and ssODNs. TIDE analyses of four different ssODNs
resulted in varying levels of 6 bp insertions that rely with the ssODN
design. Modified ssODN resulted up to 8% HDR rate. Figure S5 NGS
analysis-gene correction of HBBIVS1–110 in CD34+ HSCs using Cas9 mRNA
and ssODNs. The absolute quantification of NheI insertion by NGS
analyses for four different ssODNs showed distinct rate of 6 bp insertions
and correlate with ssODN design. Modified ssODN resulted up to 8%
HDR rate. Figure S6 Off-target analysis for the in silico predicted sites.
The indel rate was measured by T7 endonuclease-I (T7EI) assay for six
different off-target sites predicted through in silico (Additional file 2:
Table S4) in K562 cells. We preselected top three hits in intronic and
three hits in an exonic region. (PDF 2219 kb)
Additional file 2 Data S1 The complete amino acid sequences of the
HBB targeting ZFNs. Table S1 TALE FLASH IDs and RVDs targeting the
promoter of HBB gene. Table S2 Details of ssODNs (sequence, symmetry,
and length of homology arms). Table S3 Barcode and sample details of
next-generation sequencing. Table S4 Details of off-target position,
primer details, and indel frequency. (PDF 601 kb)
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The Cas9/guide RNA (Cas9/gRNA) system is commonly used
for genome editing. mRNA expressing Cas9 can induce innate
immune responses, reducing Cas9 expression. First-generation
Cas9mRNAs were modified with pseudouridine and 5-methyl-
cytosine to reduce innate immune responses. We combined
four approaches to produce more active, less immunogenic
second-generation Cas9 mRNAs. First, we developed a novel
co-transcriptional capping method yielding natural Cap 1. Sec-
ond, we screened modified nucleotides in Cas9mRNA to iden-
tify novel modifications that increase Cas9 activity. Third, we
depleted the mRNA of uridines to improve mRNA activity.
Lastly, we tested high-performance liquid chromatography
(HPLC) purification to remove double-stranded RNAs. The ac-
tivity of these mRNAs was tested in cell lines and primary hu-
man CD34+ cells. Cytokines were measured in whole blood and
mice. These approaches yielded more active and less immuno-
genic mRNA. Uridine depletion (UD) most impacted insertion
or deletion (indel) activity. Specifically, 5-methoxyuridine UD
induced indel frequencies as high as 88% (average ± SD =
79% ± 11%) and elicited minimal immune responses without
needing HPLC purification. Our work suggests that uridine-
depleted Cas9 mRNA modified with 5-methoxyuridine
(without HPLC purification) or pseudouridine may be optimal
for the broad use of Cas9 both in vitro and in vivo.
INTRODUCTION
The Cas9/guide RNA (Cas9/gRNA) system, which is derived from the
type II bacterial CRISPR adaptive immune system, is a powerful tool
for manipulating genomes.1–4 The Cas9/gRNA system consists of an
RNA-guided nuclease (Cas9) and a single short gRNA. Upon delivery
of these components to the nucleus of a cell, the guide strand directs
the Cas9 protein to a specific chromosomal location, and Cas9/gRNA
generates site-specific DNA double-strand breaks (DSBs), which are
repaired by endogenous cellular mechanisms. Twomajor genome-ed-
iting events arise from the Cas9/RNA-induced DSBs: (1) a specific site
can be mutated via mutagenic non-homologous end joining (NHEJ)
by creating insertions or deletions (indels) at the site of the break, or
(2) an exogenously introduced donor template can mediate a precise
genomic sequence change via homologous recombination.5
Various methods have been described for delivery of the Cas9 protein
into the nucleus. These include expression of Cas9 protein from a
plasmid6 or viral vectors,7 transfection of recombinant Cas9 protein
complexed to a gRNA (ribonucleoprotein or ribonucleoprotein
[RNP] complex),6,8,9 or expression from a transfected Cas9
mRNA.6 Expression of Cas9 protein from a plasmid or viral vector
may be problematic because it risks integration of the promoter
and/or Cas9 gene cassette at the double-stranded break site, a feature
of all double-stranded DNA vectors, or random integration of the
DNA vector into the genome.10 By way of contrast, Cas9 protein
and mRNA do not pose the risk of Cas9 gene integration, and they
also induce limited off-target effects due to transient expression.5,11,12
Although nanoparticle delivery of Cas9 protein has been reported, the
most common approach to deliver transgenes into cells in vivo in-
volves the use of mRNAs complexed with nanoparticles. This makes
Cas9mRNA an attractive tool for genome editing in hard-to-transfect
cells or tissues.
An ideal Cas9mRNA should mimic a fully processed mRNA and not
activate innate immune pathways. Activation of these receptors in-
duces inflammation, leads to translational inhibition, and causes
mRNA degradation.13–16 Our goal was to design and produce
mRNAs that do not activate, or minimally activate, these RNA-
sensing pathways. Exogenous mRNA can activate innate immunity
pathways when various pattern recognition receptors (PRRs), present
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in both endosomes and the cytosol, recognize pathogen-associated
molecular patterns (PAMPs) associated with exogenous RNA (viral
or transfected RNA). Specifically, Toll-like receptors (TLRs) 7 and
8, which recognize single-stranded RNA (ssRNA),17,18 and TLR3,
which recognizes double-stranded RNA (dsRNA),19must be avoided,
since the activation of TLRs leads to inflammation and the inhibition
of translation.17–20 In addition, cytosolic PRRs to be avoided by Cas9
mRNA include retinoic acid-inducible gene I (RIG-I), melanoma dif-
ferentiation-associated protein 5 (MDA5), protein kinase R (PKR),
and the interferon (IFN)-induced tetratricopeptide repeat (IFIT) pro-
teins. RIG-I recognizes 50 triphosphate (50ppp)21,22 or diphosphate,23
panhandle structures of viral genomic RNA (reviewed in Weber and
Weber24), and uridine-rich sequences.25–28 MDA5 is activated by
binding very long dsRNA,13,29while PKR recognizes dsRNA stretches
of at least 33 nt.30 Lastly, IFITs sense aberrant cap structures.31 There-
fore, Cas9 mRNA must avoid both endosomal TLRs and cytosolic
PRRs to achieve maximal translation and protein activity. In this
study, we tested the ability of cap structure modifications, chemical
modifications, sequence engineering (uridine depletion), and high-
performance liquid chromatography (HPLC) purification to reduce
immune activity and increase Cas9 mRNA activity.
RESULTS
Eukaryotic Cap Structures
Eukaryotic RNAs are capped with a 7-methylguanosine (m7G) con-
nected by a 50-to-50 triphosphate bridge to the first nucleotide. This
structure is referred to as Cap 0. Cap 0 is important for the recruit-
ment of translational initiation factors, and it prevents degradation
of the mRNA. In higher eukaryotes, the 20 ribose position of the first
cap-proximal nucleotide is methylated to form a Cap 1 structure
(m7GpppN20Om N), and, in 50% of transcripts, the second cap-
proximal nucleotide is 20 O-methylated to form Cap 2
(m7GpppN20OmN20Om) (Figure 1A).
32
While the presence of Cap 1 and Cap 2 in eukaryotic RNAs has been
known since the 1980s, the function of these modifications has re-
mained largely unknown. Cytoplasmic viruses frequently possess
mechanisms to acquire a Cap 1 structure (reviewed in Decroly
et al.33 and Hyde et al.34). Many of these viruses are attenuated
when their methyltransferases are inactivated, suggesting that cap
structure may play an important role in self versus non-self-recogni-
tion. Cap 1 methylation has been shown to modulate binding or acti-
vation of innate immune sensors. For example, the binding affinity of
IFIT-1 for Cap 1 and Cap 2 is much weaker than for 50 triphosphate or
Cap 0 RNAs, and IFIT-1 binding to non-20-Omethylated RNAs com-
petes with the translational initiation factor EIF4E to prevent transla-
tion.35,36 Cap 0 and 50-triphosphate bind RIG-I with similar affinities,
while Cap 1 modification abrogates RIG-I signaling.37 Similarly, Cap
1 prevents detection by MDA5.38
Frequently, synthetic mRNAs are co-transcriptionally capped by
including a cap analog in excess in the transcription reaction. The
current state of the art is co-transcriptional capping with anti-reverse
cap analog (ARCA), which is a capped dimer with the chemical struc-
ture shown in Figure 1B. ARCA results in a Cap 0mRNA. ARCA pos-
sesses a 30-O-methyl group on the sugar adjacent to the m7G, which
Figure 1. Eukaryotic Cap Structures and Cap Analogs
(A) Eukaryotic cap structure. Presence of 20-O-methyl groups at R1 and R2 determine if a cap structure is Cap 0, Cap 1, and Cap 2 as indicated. (B) Structure of anti-reverse
cap analog used in standard co-transcriptional capping. (C) Structure of CleanCap AG Cap1 Trimer. (D) Proposed mechanism of CleanCap co-transcriptional initiation in
which the AmG dimer portion of CleanCap docks onto the +1 and +2 template nucleotides. Initiation occurs when CleanCap couples to an NTP occupying the +3 position.
www.moleculartherapy.org
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prevents it from incorporating in the incorrect orientation, although
this is not a naturally found Cap 0 modification. In general, T7 tran-
scripts initiate at the +1-transcript position with guanosine triphos-
phate (GTP) incorporated opposite a +1-template cytosine. The
ARCA cap analog is provided at a 4:1 excess over GTP in the tran-
scription reaction such that, when competing with GTP, ARCA in-
corporates at the +1-transcript position 70% of the time leaving a
Cap 0 structure (Figure 1A). Therefore, 30% of the time ARCA
transcription initiates with GTP to yield an mRNA with a 50 triphos-
phate. Our previously published work utilized an ARCA Cap 0 Cas9
mRNA that was fully substituted with pseudouridine (J) and
5-methylcytidine (5meC).6
Recently, we developed a co-transcriptional capping method called
CleanCap that utilizes an initiating capped trimer instead of
ARCA. Co-transcriptional capping with our CleanCap Cap1 AG
trimer yields a naturally occurring Cap1 structure. In this study,
we tested the ability of our newly developed CleanCap Cap1 AG
trimer to improve Cas9 mRNA activity or reduce its immunoge-
nicity. We utilized T7 RNA polymerase to generate in vitro-tran-
scribed mRNAs. The structure of a CleanCap Cap 1 AG trimer is
shown in Figure 1C. With the CleanCap Cap 1 AG trimer, the +1
and +2 template nucleotides are thymidine and cytosine, respec-
tively (Figure 1D). Our hypothesis is that the CleanCap Cap 1
AG trimer initiates by occupying the +1 and +2 transcript positions
and elongation occurs when the CleanCap trimer couples to the
nucleoside triphosphate (NTP) occupying the +3 position. We
also tested an anti-reverse CleanCap trimers with a 30-O-methyl
group on the sugar of the m7G (30 O-methyl CleanCap AG) to pre-
vent incorporation in the opposite orientation, but we found this to
be unnecessary both in terms of yielding Cap1 structures and for in-
del formation (data not shown). A more extensive discussion of
the CleanCap method will be presented elsewhere. To determine
if we could improve on our previously published ARCA Cap
0 J/5meC mRNA, we used CleanCap to generate a series of Cap
1 mRNAs that contained either wild-type (WT) bases or completely
substituted with one or two modified bases (Table 1).
Chemical Modification of mRNA
Although over 100 post-transcriptional modifications are found in
RNA,39 only a subset are found in mRNAs. These mRNA modifica-
tions include N6-methyladenosine (m6A), inosine, N1-methyladeno-
sine (m1A), J, 5meC, and 5-hydroxymethylcytosine (5hmC).40–42
Such chemical modifications have been shown to reduce innate im-
mune responses and improve mRNA activity.43–45
Karikó et al.43–45 demonstrated that substitution with modified ba-
ses reduced innate immune responses to transfected mRNAs. Based
on this work, many first-generation mRNAs were modified with
5meC and J.46 They showed that chemical modification of
mRNA limited TLR signaling,43 decreased activation of 20-50-oligoa-
denylate synthetase,45 and decreased binding to PKR.44 Durbin
et al.47 showed that RNAs modified with m6A bind RIG-I with
reduced affinity, while J, N1-methylpseudouridine (N1-me-J),
and 5meC RNAs bind RIG-I with high affinity yet fail to activate
RIG-I signaling. Work by Peisley et al.48 also reported reduced
RIG-I filament formation triggered by J, 2-thiouridine (2sU),
or m6A RNAs.
Table 1. List of In Vitro-Transcribed Modified Cas9 Cap 1 mRNAs Made with CleanCap
Abbreviation Full Name Uridine Depleted Cap Form Screen
WT UD wild-type bases yes Cap 1 full
5moU UD 5-methoxy uridine yes Cap 1 full
J UD pseudouridine yes Cap 1 full
WT wild-type bases no Cap 1 full
5moU 5-methoxy uridine no Cap 1 full
J pseudouridine no Cap 1 full
5meC/J 5-methyl cytidine/pseudouridine no Cap 1 full
5meU 5-methyl uridine no Cap 1 full
N1-me-J N1-methyl pseudouridine no Cap 1 full
5meC 5-methyl cytidine no Cap 1 full
5hmC 5-hydroxymethyl cytidine no Cap 1 full
N1-et-J N1-ethyl pseudouridine no Cap 1 initial
me1-J /5meC N1-methyl pseudouridine/5-methyl cytidine no Cap 1 initial
5moC 5-methoxy cytidine no Cap 1 initial
5camU 5-carboxy methyl ester uridine no Cap 1 initial
10% 5meC/2sU 5-methyl cytidine/2-thio uridine no Cap 1 initial
25% 5meC/2sU 5-methyl cytidine/2-thio uridine no Cap 1 initial
ARCA 5meC/J 5-methyl cytidine/pseudouridine no Cap 0 initial
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In addition to reducing innate immune responses, Karikó et al.49,50
also showed that full substitution of mRNA withJ increased activity
in vivo. Pardi et al.51 showed that N1-me-J mRNAs were efficiently
expressed in mice when delivered by a variety of routes. Andries
et al.52 also reported that N1-me-J mRNAs gave higher expression
relative to J-substituted mRNAs in mice.
Previously, we used partial substitution of mRNAs with 2sU and
5meC to express surfactant protein B (SP-B) to rescue SP-B-defective
mice53 and to reduce asthma by expression of Foxp3.54 We have also
used 2sU/5meC-modified mRNAs encoding zinc-finger nucleases
and transcription activator-like effector nucleases (TALENs) in
mouse lung, and we were able to demonstrate gene correction in vivo
at the SP-B locus.55 In this study, we screened modifications such
as J, 5meC, N1-me-J, 2sU, and others (Table 1) to identify modi-
fications that improved Cas9 activity.
Sequence Engineering
In addition to chemical modifications, studies have reported
that sequence-engineered unmodified mRNAs may be superior
to J-modified RNAs in vivo.56,57 Sequence engineering of mRNA
utilizes the degeneracy of the genetic code to substitute specific nucle-
otides of an mRNA sequence or optimize codon utilization without
altering the resulting amino acid composition. Several groups have re-
ported that codon optimization could increase the activity of trans-
fected mRNAs. Karikó et al.50 saw an increase in erythropoietin
(Epo) expression in human dendritic cells upon codon optimization
of both unmodified andJ-modified mRNA. Thess et al.56 sequence-
engineered luciferase and Epo mRNAs by using only the most guano-
sine/cytosine (GC)-rich codons. They found that, while J substitu-
tion improved the activity of non-sequence-engineered luciferase,
J modification decreased the expression of a sequence-engineered
luciferase mRNA relative to an unmodified mRNA in HeLa cells. In
mice, they found that sequence-engineered Epo performed better
than non-sequence-engineered Epo mRNA and that J modification
of the optimized sequence decreased activity.
While designing our study, we found that, in the context of the lucif-
erase open reading frame (ORF), depletion of uridines in the tran-
script using synonymous codons increased the luciferase activity for
unmodified,J, and 5-methoxyuridine (5moU)-modified RNAs (Fig-
ure S1). Based on these preliminary results and on reports by other
groups that sequence engineering could improve mRNA activity,56,57
we uridine-depleted the Cas9 ORF and synthesized 3 additional Cas9
mRNAs containing WT bases, J, or 5moU (Table 1). We selected
these modifications for uridine depletion because work with other
reporter mRNAs had shown improved activities with these modifica-
tions upon uridine depletion (data not shown). We compared the
activity and immune response of these uridine depletion (UD) vari-
ants to the previously published ARCA Cap 0 J/5meC mRNA.
HPLC
dsRNA is produced as an undesired side product during in vitro tran-
scription with T7 RNA polymerase.58,59 This dsRNA could activate
innate immune sensors, including TLRs, PKR, or MDA5. Karikó
et al.60 reported that purification of mRNAs by HPLC reduced the
levels of dsRNA impurities as assessed by a slot blot analysis with a
dsRNA-specific antibody. They found that HPLC-purified J-modi-
fied mRNAs had significantly higher activity in vivo than mRNAs
that had not been HPLC purified.60 In this study, we adapted this
method to HPLC purify a portion of each mRNA listed in Table 1
in order to test if HPLC purification of Cas9 mRNA would reduce
innate immune stimulation or increase indel activity.
Thus, we performed an unbiased investigation of ability of these
different methods to increase Cas9 mRNA activity with minimal im-
mune activation. We found the highest frequency of genome editing
with uridine-depleted 5moU, and these transcripts showed minimal
in vitro and in vivo activation of the innate immune response without
the need for HPLC purification.
Uridine Depletion Improved Cas9 Activity by Indel Formation
Assay
We conducted an initial indel formation screen of the mRNAs listed
in Table 1 in primary CD34+ hematopoietic stem and progenitor cells
(HSPCs) mobilized from peripheral blood. We used primary human
cells for these assays as they are more sensitive to the immunostimu-
latory activity of delivered nucleic acids than cancer cell lines. Cells
were co-transfected with 3 mg Cas9mRNA and 2 mg MS-single-guide
RNA targeting the interleukin-2 receptor subunit gamma (IL2RG)
locus. As a control, we also included Cas9 RNP using 6 mg Cas9 pro-
tein with 3.2 mg guide strand, as we have previously described.6 Indels
were quantitated using TIDE analysis.61 Based on this initial screen,
we narrowed our list to 11 candidate mRNAs (each with and without
HPLC purification; Table 1, lead candidates). We tested the lead can-
didates on CD34+ cells from five different donors.
The uridine-depleted mRNAs (WT UD, WT UD HPLC, 5moU UD,
5moUUDHPLC,JUD, andJUDHPLC) yielded the highest indel
rates (77%–87%) (Figure 2). This was a major improvement over
our first-generation Cap 0 5meC/J mRNA, which gave 61% indel.
Indel frequencies with the Cas9 RNP complexed to guide were
67%. WT UD and 5moU UD HPLC showed a statistically significant
improvement in indel frequency relative to their non-uridine-
depleted counterparts (p < 0.0001). Among the non-uridine-depleted
sequences, WT HPLC,J, andJ HPLC gave 66%–69% indel forma-
tion. The chemical modifications in combination with UD did not
improve Cas9 mRNA activity. Even among the non-UD samples,
the chemical modifications did not outperform WT HPLC-purified
samples. Chemical modifications among non-UD samples were still
relevant from the perspective of immune response, as discussed
below.
To our surprise, in most cases, HPLC purification did not increase
indel formation significantly. One notable exception was WT, where
HPLC purification improved activity from 40% to 68% (p = 0.028).
To assess the level of dsRNA contamination and depletion of
dsRNA during HPLC, we adapted a previously described dsRNA
www.moleculartherapy.org
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immunoblot with a dsRNA-specific antibody.60 Based on this quali-
tative assay, we estimate that HPLC purification reduced dsRNA
levels by 50%–80%, while uridine depletion reduced dsRNA levels
by approximately 30% (Figure S2). While Karikó et al.60 interpreted
a decrease in blot signal to reflect removal of dsRNA, another alterna-
tive is that heating and denaturation of the mRNA during HPLC
unfolded long double-stranded intramolecular structures within the
purifiedmRNA, resulting in a decrease in slot blot signal.These exper-
iments suggest that uridine depletion of Cas9mRNA can significantly
improve CRISPR gene editing and may then obviate the need for
HPLC purification in CD34+ cells.
Lastly, we tested the influence of the CleanCap, ARCA, and anti-
reverse CleanCap cap structures on the performance of the 5moU
UD mRNA. Notably, there was no significant difference in the indel
activity between the 5moU UD ARCA CleanCap and 30 O-methyl
CleanCap Cas9 mRNA (Figure S3).
IFN Responses in Differentiated THP-1 Cells Transfected with
Unmodified and Modified mRNAs
We next tried to narrow down mRNA variants with improved ac-
tivity that also induced low innate immune responses in the ex vivo
setting. We used an IFN reporter cell line to assess IFN stimulation
upon transfection of the various mRNAs into THP-1 Dual cells.
THP-1 Dual cells are human monocyte stable transfectants, which,
upon IFN stimulation, express a secreted coelenterazine luciferase
(Lucia) driven by the ISG54 (IFN-stimulated gene) minimal pro-
moter and five IFN response elements. The majority of modified
mRNAs did not induce significant IFN responses above the nega-
tive control with or without HPLC purification (Figure 3). Notably,
J-modified mRNAs induced elevated IFN responses both with
and without UD. Apart from J-modified mRNA, WT UD and
5meU that had not been HPLC purified gave significantly elevated
IFN signaling relative to the negative control. In each case, HPLC
purification reduced IFN signaling to background levels. To our
surprise, non-HPLC-purified WT Cas9 did not induce significant
IFN signaling. Among the UD variants, 5moU UD did not
exhibit significant IFN response even without HPLC purification,
and, thus, it appears to be an attractive choice for editing
applications.
IL-12, TNF-a, and IL-6 Measurements in Whole Blood
In addition to ex vivo editing of isolated cells, the Cas9/gRNA sys-
tem can be applied in whole organisms. The activation of the innate
immune response in vivo has been a major barrier to gene therapy
vectors, even inducing a patient death.62 We next sought to assess
immune responses in the more complex environment of whole hu-
man blood and identify mRNA variants that induced lower immune
responses in whole blood. Whole blood obtained from healthy do-
nors was transfected with mRNAs that were complexed with
TransIT delivery reagent. At 6 and 24 hr, serum was isolated and
interleukin (IL)-12 (Figure 4A), tumor necrosis factor alpha
(TNF-a) (Figure 4B), and IL-6 (Figure 4C) were measured by
ELISA.
Most Cas9 mRNA variants did not induce IL-12 secretion. Among
the UD samples, levels of IL-12 were significantly elevated relative
to blood-only controls for WT UD, but not the other variants, at 6
and 24 hr. For the non-UD variants, levels of IL-12 were significantly
elevated relative to 6-hr blood-only control for 5meC at 24 hr. While
some other groups were slightly elevated, they did not reach statistical
significance.
Many Cas9 mRNA variants induced TNF-a secretion. Among the
UD samples, TNF-a levels reached significance at 24 hr only for
WT UD and WT UD purified by HPLC. Among the non-UD sam-
ples, TNF-a levels were significantly elevated at 6 and 24 hr regardless
of HPLC purification for WT, 5moU, N1-me-J, 5meC, 5meC/J,
and 5hmC. But HPLC purification abolished TNF-a induction only
for 5meC/J. Interestingly, 5moU UD did not increase TNF-a even
though the non-UD 5moU increased TNF-a.
Most Cas9 mRNA variants that induced TNF-a secretion also
induced IL-6 secretion (except WT UD). For uridine-depleted se-
quences, IL-6 levels reached significance only for WT UD purified
by HPLC at 24 hr. Among the non-UD samples, IL-6 levels were
significantly elevated at 6 and 24 hr regardless of HPLC purification
for WT, N1-me-J, 5meC, and 5hmC. 5meU increased IL-6 at 6
and 24 hr without HPLC purification but only increased IL-6 after
24 hr when purified by HPLC. For 5meC/J, IL-6 levels were signif-
icantly elevated at 24 hr, but HPLC purification abolished IL-6 induc-
tion. IFN-a was also tested, but it was not measurably induced by any
of the tested mRNAs (data not shown).
Figure 2. Indel Formation in CD34+ HSPCs Nucleofected with Modified
Cas9 mRNAs
CD34+ HSPCs were nucleofected with 3 mg of the indicated Cas9mRNA and 2 mg
IL2RGlocus MS-sgRNA. 6 mg Cas9 RNP complexed to 3.2 mg IL2RGlocus MS-
sgRNA was nucleofected for comparison. ARCA 5meC/J is our previously pub-
lishedCas9mRNA6 and was also included for comparison. Cells were isolated after
4 days, and indel formation was assessed by TIDE analysis. Bars represent mean ±
SEM of at least 5 independent transfections. White and gray bars indicate RNeasy
and HPLC-purified mRNAs, respectively. sgRNA complexed to Cas9 RNP was
included as a control. ***p < 0.0005 and *p < 0.05.
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IL-12, TNF-a, and IL-6 Measurements in Mice
To measure immune responses in mice in vivo, Cas9 mRNAs were
encapsulated in chitosan-coated poly-D,L-lactide-co-glycolide
(PLGA) nanoparticles and injected into the tail vein of mice
(n = 3). At 6 or 24 hr, mice were sacrificed and serum IL-12 (Fig-
ure 5A), TNF-a (Figure 5B), and IL-6 (Figure 5C) were measured
by ELISA. None of the UD samples showed elevated serum IL-12,
TNF-a, or IL-6. Only WT non-HPLC-purified IL-12 and IL-6 levels
were significantly elevated relative to 6-hr blood-only control at
6 hr. Similarly, at 6 hr, TNF-a levels were elevated relative to con-
trol for both WT and WT HPLC, while no other significant changes
were observed.
DISCUSSION
Improvement in Cas9 mRNA Activity by UD
In our current study, we applied four design principles to improve
the activity of our previously published ARCA Cap 0 J/5meC Cas9
mRNA.6 These included exploring sequence engineering, screening
different modified bases, examining the influence of HPLC purifica-
tion, and using a Cap 1 structure. Among these strategies, a combi-
nation of UD with 5moU modification was able to achieve indel
rates as high as 87% in primary CD34+ HSPCs while avoiding
immune responses even in the absence of HPLC purification
(Figure 2).
UD was most effective in increasing Cas9 mRNA activity, but
further chemical modification was necessary to reduce immunoge-
nicity. However, this increase in indels by UD variants only reached
statistical significance for WT UD and 5moU UD HPLC relative
to their non-uridine-depleted counterparts (p < 0.05). We also
tested the off-target activity of 5 moU UD against ARCA
5meC/J at a previously reported off-target site (chromosome
[chr]1: 167730172–167730194).6 The off-target indel activity was
close to the limit of detection, and it was not significantly different
between 5 moU UD (8% ± 1%) and ARCA 5meC/J (5% ± 2%).
Uridine depletion may improve indel levels by increasing protein
expression, reducing immune responses, or a combination of the
two effects. In our studies with luciferase (Figure S1), uridine deple-
tion increased protein expression, but the percent increase was
significantly different between 5moU and J. Consistent with our
results, studies have reported that codon optimization can influence
both expression and mRNA stability.63 More specifically, GC-en-
riched (adenosine/uridine [A/U]-depleted) genes have been re-
ported to exhibit higher steady-state mRNA levels when expressed
using plasmids.64 The study further seemed to suggest that UD
did not affect mRNA degradation rates, and it speculated that
some mRNA-processing pathway(s) may influence mRNA levels.64
It is also possible that uridine depletion could reduce recognition
by TLRs. Interestingly, it has been reported that TLR7 recognizes
uridine stretches.20 Tanji et al.65 also reported that uridine contain-
ing single-stranded RNA degradation products could be sensed by
TLR8. Further studies with a variety of primary sequences may be
necessary to understand the mechanism by which the combination
of mRNA sequence and chemical modifications influences protein
translation in different cell types.
Immunogenicity of UD and non-UD Cas9 mRNA Variants
To test immune responses, we employed two complementary assays,
a whole-blood assay and an in vivo mouse model. The whole-blood
assay appears to be the most sensitive assay for monitoring these re-
sponses. The difference between the whole-blood and in vivo results
may reflect difficulties in measuring systemic cytokines in mice in
response to local delivery to a subset of cells. In these assays, uridine
depletion also decreased most, but not all, immune responses elicited
by WT, 5moU, and J. Specifically, UD reduced TNF-a and IL-6 for
5moU (Figures 4B and 4C). For WT Cas9 mRNA, UD significantly
reduced IL-6 levels in whole-blood assay (Figure 4C) and reduced
TNF- a, IL-6, and IL-12 in the mouse assay (Figure 5). However,
UD was insufficient to reduce IFN responses completely for J and
increased IFN for WT (Figure 3).
Themechanism by which uridine depletion affects immune responses
is unclear. It is possible that sequence engineering could influence
binding to PRRs and thereby minimize the translational inhibitory ef-
fects that are activated through PRRs. It seems possible that PRRs de-
signed to recognize aberrant RNAs might focus on uridine residues,
as this is a major difference between DNA and RNA. For example,
it was reported that triplets of sequential uridines could activate
TLR-7 and cause dendritic cells to release IFN-a.20 Likewise, RIG-I
is reported to recognize uridine-rich sequences.25–28 Further research
will be required to define the precise mechanism by which uridine
depletion improves the activity of some Cas9mRNA variants despite
immune activation.
In the context of nucleofection of CD34+ HSPCs, we show that
Cas9 WT UD can have similar indel formation rates as J and
Figure 3. IFN Response Generated by THP-1 Dual Cells Transfected with
Modified Cas9 mRNAs
THP-1 dual cells were transfected in sextuplicate with 100 ng of the indicated
mRNAs complexed with 1 mL transfection reagent mRNA-In. At 24 hr, Lucia
expression in the media was assayed as a measure of IFN activity. Bars represent
mean ± SEM of three independent assays comprising a total of 18 replicates.
*p < 0.05.
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5moU-modified RNAs (Figure 2). Thus, at least in CD34+ cells, uri-
dine depletion may be sufficient and chemical modification may not
be necessary. By way of contrast, reducing immune responses may
be still important for in vivo applications, since the route of delivery
may be an important determinant of efficacy and innate immune
induction.66 Since electroporation likely bypasses the endosomal
compartment (where RNA-sensing TLRs reside), it remains to be
determined if the same results would be observed with lipid or poly-
mer transfection. A significant body of research supports the idea
that chemical modification of mRNA can improve its activity by
reducing innate immune stimulation in several instances.49–55,60
Indeed, chemical modification of mRNA has been reported to
decrease binding to or activation of TLRs,43 20-50-oligoadenylate
synthetase,45 PKR,44 and RIG-I.47,48 Chemical modifications are
known to change the structure, base pairing, and codon/anti-codon
pairing of mRNAs (reviewed in Harcourt et al.67), and they may
thus make them poor substrates for PRRs. In contrast to the above
reports, several groups have reported that sequence-engineered
mRNAs may not require chemical modification. Thess et al.56 found
Figure 4. Amounts of IL-12, TNF-a, and IL-6 inWhole
Human Blood Transfected with Modified Cas9
mRNAs
To assess immune responses to transfected mRNAs,
whole blood from healthy human volunteers (n = 3) was
transfected with 10 mg mRNA complexed with 10 mL
TransIT (https://www.mirusbio.com/). After 6 or 24 hr of
incubation, sera were isolated and (A) IL-12, (B) TNF-a, or
(C) IL-6 was measured by ELISA. Bars represent mean ±
SEM. *p < 0.05 relative to 6-hr blood-only control.
that, while chemical modification improved the
activity of some sequences, when they used
mostly GC-rich codons, WT mRNAs had the
highest activity. Kaufmann et al.57 found that
when they formulated mRNAs in lipid nano-
particles and delivered them intravenously to
mice, WT and J mRNAs had similar activities
and immune responses. Thus, the need for
chemical modification may depend on the
individual mRNA sequence as well as the
route of administration. Since UD did not
completely inhibit immune responses, we also
explored the combination of UD with chemical
modification.
In our studies, most chemical modifications
reduced IFN responses except for J and 5
meU. This suggests that the chemical modifica-
tion present in many of the Cas9 mRNAs tested
may mask dsRNA recognition. It is also possible
that these modifications are not recognized by
the relevant PRRs. The observation that J did
not reduce IFN stimulation was somewhat surprising based on the
literature.49 Unfortunately, all chemically modified variants, except
J, still induced TNF-a and IL-6 in the absence of UD (Figures 4
and 5). Therefore, we tested the ability of HPLC to reduce the remain-
ing immune responses.
Influence of HPLC Purification on Reducing Immunogenicity of
Cas9 mRNA Variants
HPLC was successful in reducing IFN responses when a combination
of chemical modification and UD did not reduce IFN (WT UD, J
UD,J, and 5meU) (Figure 3). Surprisingly, this reduction in immune
response by HPLC purification only resulted in significant improve-
ment in indel frequencies for non-uridine-depleted WT (Figure 2).
This may reflect that the natural substrate for dsRNA-sensing PRRs
is WT RNA. The reduction of IFN response after HPLC purification
is consistent with literature (Karikó et al.60), especially forJ.60 How-
ever, we also noticed that several chemical modifications (for 5moU
UD, 5moU, 5meC/J, N1-meJ, 5meC, and 5hmC) showed no
IFN response even without HPLC purification. Indeed, on further
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comparison with Karikó et al.,60 we noticed that the influence of
chemical modification on IFN and TNF responses was protein depen-
dent in their study. Thus, our data are broadly consistent with Karikó
et al.60 that HPLC purification reduces IFN responses if they are
present.
In contrast to IFN responses, HPLC was unsuccessful in reducing
TNF-a and IL-6 secretion induced by all variants except 5meC/J,
as measured by the whole-blood assay. This result is inconsistent
with Karikó et al.60 Unlike Karikó et al.,60 our results show that we
were only able to deplete, but not completely rid, our mRNAs of
dsRNA using HPLC purification (Figure S2). Thus, it is also possible
that the remaining dsRNA in the HPLC-purified samples is sufficient
to trigger immune responses that are equivalent to the non-HPLC-
purified RNAs, rendering HPLC purification insufficient to provide
a benefit within the context of CD34+ HSPCs. These results suggest
that a further reduction in dsRNA may be necessary to reduce
IL-12, IL-6, and TNF- a and increase indels.
Figure 5. Amounts of IL-12, TNF-a, and IL-6 in the
Sera of Mice after Intravenous Infusion of Modified
Cas9 mRNAs
To assess immune responses in vivo, 20 mg Cas9 mRNA
encapsulated in chitosan-coated PLGA nanoparticles
was injected intravenously (n = 3) into the tail vein of mice.
After 6 or 24 hr of incubation, sera were isolated and (A)
IL-12, (B) TNF-a, or (C) IL-6 was measured by ELISA.
Blood treated with R-848 serves as a positive control.
Bars represent mean ± SEM. *p < 0.05 relative to 6-hr
blood-only control.
Influence of Capping Strategy Cas9 mRNA
Activity and Immunogenicity
Lastly, the capping strategy did not seem to
impact indel formation (Figure S2). We had hy-
pothesized that the presence of Cap 1 in our
mRNAs may also decrease binding to PRRs
and reduce the need for HPLC purification. It
has been reported that MDA5 does not recog-
nize Cap 1 mRNAs efficiently.38 It remains to
be tested if other dsRNA sensors such as
RIG-I have decreased sensitivities to Cap 1
mRNA. We only compared the Cap 0 and
Cap 1 modifications for the 5moU UD variant
mRNAs, and we did not observe any difference
in indel levels (Figure S3). However, there was a
small but statistically significant increase in
IL-12 production, but not TNF-a or IL-6,
in the whole-blood assay in response to Cap
0 ARCA relative to the Cap 1 CleanCap analogs
(Figure S4). There was no difference in cyto-
kine production in the less sensitive mouse
model system for the Cap 0 or Cap 1 mRNAs
(Figure S5). It is possible a Cap 1 structure
would have provided more benefit for 5moU-modified mRNA in
the absence of UD.
Conclusions
In summary, we have used a variety of approaches in combination to
identify several improved Cas9mRNAs. Among these strategies, uri-
dine depletion resulted in the greatest increase in indel levels (Table 2),
but WT UD samples still elicited innate immune responses. J UD
showed high indel levels and reduced both IL-6 and TNF-a, but
not IFN. IFN induction by J UD was resolved by using HPLC. By
way of contrast, 5moU modification of WT UD Cas9 mRNA main-
tained indel frequencies and reduced all immune responses, even
without HPLC purification. Given that no benefit was seen upon
HPLC purification, HPLC would not be recommended for this modi-
fication, because of the additional cost and the significant loss of yield
upon HPLC purification. Taken together, 5moU UD would be the
preferred candidate for Cas9 mRNA given that it does not require
HPLC purification (Table 2). Future studies may be necessary to
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investigate the influence of sequence engineering and chemical modi-
fication on the in vivo activity of 5moU Cas9 mRNA.
MATERIALS AND METHODS
Transcription Templates and Sequence Optimization
The Cas9 ORF with C-terminal nucleoplasmin nuclear localization
signal (NLS) and hemagglutinin epitope tag was provided by Feng
Zhang. It was cloned into the mRNA expression vector pmRNA,
which contains a T7 RNA polymerase promoter, an unstructured
synthetic 50 UTR, a multiple cloning site, and a 30 UTR that was
derived from the mouse a-globin 30 gene. An N-terminal SV40
NLS was added to generate the vector pmRNA_NLS_Cas9_NLS. A
transcription template was generated by PCR using mRNA for-
ward primer 50-TCGAGCTCGGTACCTAATACGACTCAC-30 and
mRNA reverse primer T(20OMe)T(20OMe)(T)118CTTCCTACTCAG
GCTTTATTCAAAGACCA-30. The poly A tail was encoded in the
template, and the resulting PCR product encoded a 120-nt poly A
tail.The uridine-depleted plasmid pmRNA_UD_NLS_Cas9_NLS
was created by codon optimization of theCas9mRNAORF contained
within pmRNA_NLS_Cas9_NLS plasmid. UD of the Cas9 mRNA
sequence was performed with the “optimize codons” tool in Geneious
version R8.1.8 (https://www.geneious.com).68 A new sequence in
Geneious was created for the Cas9 ORF; this sequence was selected,
and under the tab “annotate and predict,” the “optimize codons”
function was chosen. Parameters were chosen as follows: source of ge-
netic code, standard; target organism, Homo sapiens; target genetic
code, standard; threshold to be rare = 1; and avoid restriction sites,
No. Base content for our standard Cas9 ORF was as follows: 28.6%
A, 27.8% C, 28.1% G, 15.5% U, and 55.8% GC. Base content for
our uridine-depleted Cas9 ORF was as follows: 25.3% A, 30.6% C,
31.5% G, 12.6% U, and 62.1% GC.
In Vitro Transcription of Modified mRNAs
Chemically modified, co-transcriptionally capped Cap 1 Cas9 and
firefly luciferase (FLuc) mRNAs were synthesized by T7 RNA poly-
merase in vitro transcription. All enzymes were purchased from
New England Biolabs (Ipswich, MA). Transcriptions were done in
1 transcription buffer (40 mM Tris, 10 mM dithiothreitol, 2 mM
spermidine, 0.002% Triton X-100, and 27 mM magnesium acetate)
using final concentrations of 8 U/mL T7 RNA polymerase
(M0251L); 0.002 U/mL inorganic pyrophosphatase (M2403L);
1 U/mL murine RNase inhibitor (M0314L); 0.025 mg/mL standard or
uridine-depleted transcription template; 5 mM CleanCap Cap 1 AG
trimer; and 5 mM each of ATP, cytidine triphosphate (CTP) (or
CTP analog), GTP, and uridine triphosphate (UTP) (or UTP analog),
as indicated in Table 1. Transcription reactions were incubated at
37C for 2 hr and treated with final 0.4 U/mL DNase I (M0303L) in
1 DNase I buffer for 15 min at 37C. We initially made anti-reverse
CleanCap trimers with a 30-O-methyl group on the sugar of the m7G
to prevent incorporation in the opposite orientation, but we found
this to be unnecessary, as the 30-O-methyl version functioned equiv-
alently to CleanCap with a 30 OH. mRNAs were purified by RNeasy
Maxi (QIAGEN, 75162), phosphatase treated for 1 hr with final
0.25 U/mg Antarctic phosphatase (M0289L) in 1 Antarctic phos-
phatase buffer, and then re-purified by RNeasy. A portion of each
mRNA was purified by HPLC as described by Kariko et al.,60 except
that mRNA was recovered from HPLC fractions by RNeasy purifica-
tion. Purification was carried out on a PRP-H1 column (Hamilton
Company) at 65C using a gradient of 100 mM triethylammonium
acetate/acetonitrile. Transcription quality was measured by bio-
analyzer analysis (Agilent 2100 Bioanalyzer). mRNA concentrations
were measured by UV spectroscopy and corrected for predicted
extinction coefficient.
dsRNA Slot Blot
Detection of dsRNA was performed by slot blot based on previously
established methods60 adapted for use with a 48-well slot blot vacuum
manifold (GE Whatman, Pittsburgh, PA, 10447941) and SNAP i.d.
2.0 Protein Detection System (EMD Millipore, Burlington, MA,
SNAP2MIDI). In brief, RNA samples (1,000 or 200 ng) were blotted
on a super-charged nytran membrane (GE Amersham, Pittsburgh,
PA, 10416230) pre-wetted in 1 TBST (50 mM Tris-HCL,
138 mM NaCl, 27 mM KCl, and 0.05% Tween-20 [pH 7.5]) by
applying vacuum. The membrane was then transferred to a SNAP
i.d. apparatus and blocked with 30 mL 0.5% w/v nonfat dried milk
in 1 TBST for 1 min prior to the application of vacuum. Blocking
buffer was incubated over the membrane for 1 min before the vacuum
was applied. The membrane was probed with 15 mL 1:1,500 dsRNA-
specific monoclonal antibody (mAb) J2 (English & Scientific Consul-
ting, Hungary) in 0.5% milk for 20 min and washed 4 times with
30 mL 1 TBST. The membrane was incubated for 20 min with
15 mL 1:1,500 horseradish peroxidase (HRP)-conjugated donkey
anti-mouse immunoglobulin G (IgG) (Jackson ImmunoResearch,
West Grove, PA, 715-035-150) in 0.5% milk and washed 4 times
with 1 TBST. The membrane was developed in the dark
with 30 mL enhanced chemiluminescence (ECL) western blotting
Table 2. Summary of Assay Results for Uridine-Depleted Sequences
WT UD WT UD HPLC 5moU UD 5moU UD HPLC J UD J UD HPLC
High indel + + + + + +
Lack of IFN in THP-1 Dual cells – + + + – +
Lack of IL-12 in whole blood – + + + + +
Lack of TNF-a in whole blood – – + + + +
Lack of IL-12 in vivo + + + + + +
Lack of TNF-a in vivo + + + + + +
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detection reagent (GE Amersham, RPN2134) for 5 min before being
imaged on G:BOX Chemi XRQ (Syngene, Frederick, MD) chemilu-
minescent imaging system with accompanying GeneSys (version
[v.]1.5.6) software. Raw light units (RLUs) were measured and back-
ground corrected using densitometry software (GeneSys). For com-
parison of HPLC samples, RLU signals per mRNA were normalized
to matched non-HPLC and reported as a percentage. Similarly, for
comparison of UD samples, RLU signals per mRNA were normalized
to non-UD and reported as a percentage. Percent reduction in dsRNA
signal resulting from HPLC purification or UD was calculated using
the following formula:
% reduction= 100

HPLC intensity
nonHPLC intensity

 100
% reduction= 100

uridine depleted intensity
WT intensity

 100:
We calculated this for the 200- and 1,000-ng inputs and averaged
these two values.
THP-1 and THP-1 Dual Cell Culture
THP-1 cells (ATCC, TIB-202) and THP-1 Dual cells (InvivoGen, San
Diego, CA, thpd-nfis) were grown in RPMI-1640 medium (ATCC,
30-2001) supplemented with 10% fetal bovine serum (Gibco, Grand
Island, NY, 10437-028), 1 mM sodium pyruvate (Gibco, 11360-
070), 1 MEM non-essential amino acids (Gibco, 11140-050),
100 U/mL penicillin and 100 mg/mL streptomycin (Gibco, 15140-
122), and 100 mg/mL Normocin (InvivoGen, ant-nr-1) at 37C in
an atmosphere of 5% CO2. THP-1 Dual cells were grown in the pres-
ence of 100 mg/mL zeocin (InvivoGen, ant-zn-1) and 10 mg/mL blas-
ticidin (InvivoGen, ant-bl-1) every other passage to maintain positive
selection of reporters.
Luciferase Assay in Cultured THP-1 Cells
In preparation for THP-1 cell transfections, 2 105 cells per well were
seeded in a 24-well plate format (Corning Costar, Tewksberry, MA,
3527) and allowed to differentiate in culture for 72 hr using
200 nM phorbol ester 12-O-Tetradecanoylphorbol-13-Acetate (Cell
Signaling Technology, Danvers, MA, 4174). Cells were then trans-
fected with 100 ng in vitro-transcribed, non-HPLC, and HPLC-puri-
fied unmodified or modified FLuc mRNAs complexed with 1 mL
transfection reagent mRNA-In (MTI-GlobalStem, Gaithersburg,
MA, 73741) and Opti-MEM (Gibco, 11058-021) in a total volume
of 50 mL. Complexed mRNAs were briefly vortexed and incubated
for 10 min at room temperature, then added drop-wise to each
well. Modified FLuc mRNAs were transfected in sextuplicate. 24 hr
post-transfection, media were aspirated from each transfected well,
and adhered monolayers were lysed with the ONE-Glo Luciferase
Assay System (Promega, Madison, WI, E6120) to assay for FLuc
activity. Lysates were incubated in the dark for 10 min at room tem-
perature with gentle rocking, then transferred to a white 96-well
microtiter plate (Greiner Bio-One, Monroe, NC, 655073). Luciferase
activity was measured using a GloMax Multi+ Detection System
luminometer (Promega, E8032) with a 0.5-s integration per well.
IFN Response Assay in Cultured THP-1 Cells
THP-1 Dual cells were seeded, differentiated, and transfected as above
except that cells were transfected with 100 ng in vitro-transcribed,
non-HPLC, and HPLC-purified unmodified or modified Cas9
mRNAs. Modified Cas9 mRNAs were transfected in sextuplicate,
and supernatants from each transfected well were assayed for Lucia
activity 24 hr post-transfection. To assay Lucia activity as a measure
of an IFN response, 50 mL media were mixed with 150 mL QUANTI-
Luc coelenterazine luciferase substrate (InvivoGen, rep-qlc) in a white
96-well microplate (Greiner Bio-One, 655073), and luminescence was
measured using a GloMax Multi+ Detection System luminometer
(Promega, E8032) with a 10-s integration per well.
CD34+ HSPC Tissue Culture
CD34+ HSPCs derived from mobilized peripheral blood donated by
male donors were purchased from AllCells (Alemeda, CA). Cells
were thawed according to themanufacturer’s instructions and cultured
at a density of 250,000/mL in a 24-well plate. CD34+ HSPCs were
cultured in StemSpan SFEM II (STEMCELL Technologies, Vancouver,
Canada) supplemented with stem cell factor (100 ng/mL), thrombo-
poietin (100 ng/mL), Flt3-Ligand (100 ng/mL), IL-6 (100 ng/mL),
StemRegenin1 (0.75 mM), and UM171 (STEMCELL Technologies,
35 nM). Cells were cultured at 37C, 5% CO2, and 5% O2.
Nucleofection of CD34+ HSPCs
Nucleofection was performed 48 hr after cells were thawed. Cell
viability was confirmed to be >80% using trypan blue before nucleo-
fection. Cells were resuspended in 1 M buffer (5 mM KCl,
15 mM MgCl2, 120 mM Na2HPO4/NaH2PO4 [pH7.2], and 50 mM
Manitol) at a density of 5 million cells/mL. As a control, we also
included Cas9 RNP at a Cas9:sgRNAmolar ratio of 1:2.5 as previously
described by Hendel et al.6 Briefly, 6 mg Cas9 protein was incubated
with 3.2 mg IL2RG locus MS-sgRNA6 (ACAACTTCGGTAG
TAATGGT.) for 15 min prior to nucleofection. 3 mg Cas9 mRNA
and 2 mg MS-sgRNA were used for nucleofections.6,69 Cas9 mRNA
and RNP were then mixed with 100,000 CD34+ cells (20 mL of cell
suspension) and transferred to a 16-well nucleofection strip (Lonza,
MD, USA). Each treatment was performed in duplicate. Cells were
nucleofected using DZ100 program in the Lonza 4D nucleofector.
Cells were suspended in 200 mL CD34+ media after nucleofection.
Measurement of Indels
Genomic DNA was obtained using QuickExtract DNA Extraction
Solution (Epicenter, Madison, WI). The mixture was vortexed and
incubated at 65C for 6 min followed by 100C for 10 min, a slight
deviation from the manufacturer’s recommendations for more
optimal downstream applications. The target sequence in the
IL2RG locus was amplified using PCR and sequenced. Indels were
measured using TIDE software as previously described.61 Briefly,
the software uses quantitative sequence trace data from control cells
and cells edited using Cas9 RNP or mRNA. The software decomposes
the edited sequence trace into individual components using multi-
variate non-negative linear modeling, and it uses the control sequence
as a template to model indels.
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The following primers were used for PCR amplification of the IL2RG
site: forward, 50-TCACACAGCACATATTTGCCACACCCT-30 and
reverse, 50-TGCCCACATGATTGTAATGGCCAGTGG-30.
Whole-Blood Assay
Blood samples from three different healthy donors was taken and
collected in EDTA collection tubes (Sarstedt, Germany). For each
treatment group, 2 mL EDTA-blood was transferred into 12-well
plates and treated accordingly. 10 mL 1 mg/mL (un-)modified
mRNAs were complexed to 10 mL TransIT (Mirus Bio, Madison,
WI). For a positive control group, blood was treated with the
TLR 7 and 8 agonist R-848 (Resiquimod, Sigma-Aldrich, St. Louis,
MO). Samples were incubated for 6 or 24 hr at 37C in a humidified
atmosphere containing 5% CO2. At each time point, 1 mL whole
blood was transferred into columns for serum separation (Sarstedt,
41.1378.005) and spun down at 10,000  g for 5 min to obtain
serum. Sera were stored at 20C until further cytokine measure-
ment analyses.
Animal Experiments
All animal experiments were approved by the local ethics committee
and carried out according to the guidelines of the German Law for the
Protection of Animals. BALB/cJ mice were purchased from Jackson
Laboratory (Bar Harbor, ME) at an age of 6–8 weeks and were main-
tained under standardized specific-pathogen-free conditions on a
12-hr light-dark cycle. Nesting material was provided and food and
water were provided ad libitum. Prior to injections, mice were
anesthetized intraperitoneally with a mixture of medetomidine
(0.5 mg/kg), midazolam (5 mg/kg), and fentanyl (50 mg/kg). BALB/cJ
mice received 20 mg Cas9 mRNA encapsulated in chitosan-coated
PLGA nanoparticles (Chitosan, 83% deacetylated [Protasan UP CL
113] coated PLGA 75:25 [Resomer RG 752H] nanoparticles [NPs])
by intravenous injection (n = 3) into the tail vein. For both interven-
tions, mRNA-NPs were administered in a total volume of 200 mL. To
assess immune responses after 6 and 24 hr, mice were sacrificed and
blood was collected to obtain serum.
Cytokine Measurement
Blood from mice and human donors was used to obtain serum and
tested for IL-12, IL-6, and TNF-a (human and mice, respectively)
production by ELISA, as directed in the manufacturer’s instructions
(BD Biosciences, San Jose, CA).
Statistics
Data were analyzed using Prism 6 Software (GraphPad, San Diego,
CA) using a 95% confidence interval. For indel measurements, data
were analyzed by one-way ANOVA with a Tukey’s multiple compar-
isons test. For IFN, mouse cytokine, and whole-blood cytokine mea-
surements, an ANOVAwith a Dunnet’s test for multiple comparisons
was used.
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Protein supplementation therapy using in vitro-transcribed
(IVT) mRNA for genetic diseases contains huge potential as a
new class of therapy. From the early ages of synthetic mRNA
discovery, a great number of studies showed the versatile use
of IVT mRNA as a novel approach to supplement faulty or ab-
sent protein and also as a vaccine. Many modifications have
been made to produce high expressions of mRNA causing
less immunogenicity and more stability. Recent advancements
in the in vivo lung delivery of mRNA complexed with various
carriers encouraged the whole mRNA community to tackle
various genetic lung diseases. This review gives a comprehen-
sive overview of cells associated with various lung diseases
and recent advancements in mRNA-based protein replacement
therapy. This review also covers a brief summary of develop-
ments in mRNA modifications and nanocarriers toward clin-
ical translation.
RNA, a fundamental molecule in the eukaryotic and prokaryotic cells
and viruses, came recently into focus for therapeutic approaches:1–3
tRNAs for nonsense mutation correction, RNA aptamers for binding
to a specific target molecule, and RNAi and long noncoding RNAs
(lncRNAs) for gene regulation.4–8 mRNA gives rise to a new therapy
for diseases associated with functional protein loss by supplementing
the protein with a transcript encoding. The first study of in vitro-tran-
scribed (IVT) mRNA in the late 1980s showed that this mRNA can be
directly translated into a functional form immediately after transfec-
tion in vitro and in vivo.9,10 This was shortly followed by a therapeutic
application of mRNA in a temporary reversal of diabetes insipidus,
unraveling its therapeutic potential.11
Therapeutic applications of mRNA are advantageous due to its
unique properties. Cytoplasm being mRNA’s functional site requires
no transportation across the nuclear membrane. Furthermore, due to
the transient nature and biodegradability of mRNA, permanent
adverse effects can potentially be avoided.12 This includes preventing
the permanent manipulation of the genome, making mRNA a prev-
alent molecule for protein supplementation therapy.13–15 Several
aspects of mRNA have to be addressed in order to achieve therapeutic
benefits: potential immunogenicity mediated by innate immune
system reactions (pattern recognition receptor),16–19 degradation of
single-stranded mRNA by nucleases, and its negative charge that
inhibits the passive crossing of the cell membrane. Concerning these
obstacles, solutions such as chemical modifications of nucleosides to
reduce immunogenicity and usage of nanocarriers to facilitate
crossing the cell membrane are emerging. The recent advancements
in the field of nanocarriers suggest the possibility to customize parti-
cles for target organs.20,21
Based on our research interest in lungs, this review focuses on protein
replacement therapy of lung disease, especially monogenetic diseases,
such as cystic fibrosis (CF) and surfactant protein B (SP-B) deficiency,
as well as multifactorial diseases, such as chronic obstructive pulmo-
nary disease (COPD) and asthma. To achieve targeted therapy
options, lung structure and methods to reach specific lung cell popu-
lations are critical. Therefore, this review gives an overview of lung
cell populations and diseases associated with them. Furthermore, a
comprehensive summary of mRNA transcript improvements by
chemical modification of nucleosides or capping and nanocarriers
to target lung cell populations is also featured.
Lung Architecture and Disease Pathology
The lung has a very unique architecture to enable efficient transfer of
oxygen and carbon dioxide required for oxidative metabolism.
Inhaled gases travel through the airway tubes via trachea bronchi
and bronchioles to the alveoli enriched with blood vessels, the
primary site of gas exchange. Inflation and deflation of the lung is a
prerequisite for gas exchange at the alveoli. This process requires mul-
tiple components like the extracellular matrix, smooth muscle cells,
and cartilage for support and flexible collagen and the elastin fiber
network for flexibility during inflation and deflation. Precisely regu-
lated surface fluids, electrolytes, and mechanical activity of secretory
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and ciliated cells determine the mucociliary clearance, whereas on the
other hand the epithelium maintains the barrier function.
The airway epithelium (tracheal and bronchiolar) consists of goblet
cells, brush or tuft cells, ciliated cells, basal cells, neuroendocrine or
neuroepithelial bodies, club cells, lineage-negative epithelial progeni-
tor (LNEP) cells, and the newly identified ionocytes.22,23 The ducts of
submucosal glands consist of goblet cells, serous cells, andmyoepithe-
lial cells. The alveolar epithelium consists primarily of alveolar type I
(ATI) cells (95%), macrophages, and alveolar type II (ATII) cells,
with close association to capillary endothelial cells of pulmonary
microcirculation.24 The terminal airway ducts and alveoli are
supported by fibroblasts and myofibroblasts producing extensive
elastin-collagen networks, which help with inflation and defla-
tion.25–27 Other important cell populations include stem cells and
immune cells, which help in region-specific regeneration and protec-
tion against pathogens, respectively. Abnormalities of lungmechanics
are observed in various diseases, including CF,28,29 asthma,30,31 idio-
pathic pulmonary fibrosis (IPF),32,33 COPD,34,35 and bronchiolitis
obliterans.34,36 These conditions are detrimental in nature and involve
multiple factors, such as increased resistance of lung tissue due to
fibrosis of the lung; collapsing tubes or thickening of airway walls
due to mucus overproduction; and the loss of ciliary function, result-
ing in airflow obstruction, mucus plugging, chronic infection, and
inflammatory damages. In that process, multiple cell populations un-
dergo remodeling, directly contributing to clinical symptoms.
Broncho-Epithelial Cells and Associated Diseases
Goblet cells, present in the broncho-epithelia and submucosal glands,
produce mucins (MUC5B andMUC5AC), and they are differentiated
from basal and club cells upon various stimuli (toxic substances,
pathogens, particles, and neural and innate immune signals). Goblet
cells are not only helping to establish the innate immune system but
also key players in pulmonary diseases, as described before.37 These
cells produce cytokines and chemokines that recruit and educate
innate immune cells, including dendritic cells (DCs), innate lymphoid
cells, and eosinophils. This contributes to the CD4+ T helper cell 2
(Th2)-mediated immune response typical of asthma.38,39 Hyper-
production of mucus and goblet cell metaplasia are characteristics
of Th2-mediated and non-mediated inflammation (pathogen medi-
ated), which leads to complications in CF, COPD, and IPF.40,41 The
fluids for hydration are regulated by serous cells that line the acinar
region of submucosal glands and are important for the pathology
of CF. The mucins are precisely balanced by fluid, and electrolyte
transport enables rapid secretion and dispersal of mucus onto the
airway surfaces and the movement of the mucus gel up the airway
by ciliary activity. In CF, the secretion of chloride and bicarbonate
is impaired, disrupting mucociliary clearance due to mutations in
CF transmembrane conductance regulator gene (CFTR), which leads
to recurrent airway infections, sinusitis, bronchiectasis, and pulmo-
nary tissue remodeling.42
Brush cells, containing distinctive apical microvilli, are found in mul-
tiple organs, e.g., pancreas, intestine, nose, and trachea. Brush cells are
known to play an important role in activating the innate immune sys-
tem in the intestine43 and nose (Tas2R receptors),44 however, a
similar phenomenon in airway trachea requires testing. Recent
studies in the trachea have indicated their role as chemosensory for
immune surveillance and as respiratory regulators.45 These might
be responsible in transducing signals regulating wheezing and cough-
ing during episodes of asthma. However, further studies are required
to understand their role.46
Ciliated cells are characterized by their multiple apical, motile cilia
composed of structural proteins and motor proteins (dynein)47–49
that regulate the coordinated bidirectional beating critical for particle
and pathogen clearance.50,51 Ciliated cells respond to both physical52
and chemical53 stimulation. Mucociliary clearance can be affected by
ciliary dysfunction, impaired fluid secretion, disruption of epithelial
cell lining, or lack of cough. This impairment can initiate an inflamma-
tory response, damaging the airway epithelium. Disruption in ciliated
cell function results in recurrent and persistent infections, morbidity,
and mortality in chronic pulmonary disorders.54 In COPD, direct
evidence has been provided of suppressed ciliary beating in nasal
epithelium55 with normal mucus production. Cigarette smoking
has been shown to have a detrimental effect on the number and size
of cilia in vitro,56 whereas in vivo a slight increase in ciliary beating
initially followed by significant loss of cilia over prolonged time was
observed.57 Primary ciliary dyskinesia (PCD) resulting from ciliary
dysfunction is caused by recessive mutations in one of multiple
genes involved at different points in cilium structure, assembly, and
function, which include DNAI,58 DNAH(5,59 1160), ARMC4,61
TXNDC3,62 HEATR2,63 HYDIN,64 CDC (39,65 40,66 65,67 103,68
114,69 15170), DNAAF(1,71 2,72 373), RHSP(4A, 9),74 DYX1C1,75
LRRC6,76 ZMYND10,77 CCNO,78 and recently identifiedMCIDAS.79
Club cells are columnar, secretory cells that express high levels of
cytochrome P450-detoxifying enzyme CYP2F, surfactant proteins
(SP-A, SP-B, and SP-D), and innate immune proteins, including de-
fensins, lactoferrin, and secretaglobins (SCGB1A1 and SCGB3A1).80
Upon stimulus or injury, these differentiate into alveolar cells,81,82
goblet cells,38,83,84 or ciliated cells.85 However, in humans, these are
only localized in terminal bronchioles, and they may play a role in
the maintenance of distal bronchioles.86 Club cells being progenitor
cells also plays an important role in the repair mechanism of the
airway epithelium, and, therefore, they are connected to damage re-
sponses in CF, COPD, and IPF.80 Club cells also metabolize chemical
toxins (e.g., naphthalene) to toxic compounds that selectively kill club
cell subsets. SP-A and SP-D (C-type lectins) are responsible for host
defense, enhancing the clearance of various microbial pathogens,
whereas the secretory lipids and proteins (SP-B and SP-C) help in
minimizing surface tension and collapsing forces caused by inhaled
gases when in direct contact with alveolar structures, protecting
peripheral saccules from atelectasis during ventilator cycles.87
Neuroendocrine cells represent less than 1% of the airway epithe-
lium,88 and they are found either isolated or in clusters known as neu-
roepithelial bodies located at precise airway branch points.89 The
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localization aids in their role as airway (environmental) sensors
(acidosis, hypoxia, and hypercarbia),90,91 and clustering is required
for the appropriate innate immune responses.92 The response to a
stimulus is via the release of stored amines (serotonin) and peptides
(calcitonin gene-related peptide [CGRP]).92Hyperplasia is associated
with a wide range of congenital and infantile lung disorders. Though
the underlying cause is unknown, NKX2-1 mutation has been associ-
ated with neuroendocrine hyperplasia of infancy (NEHI).93
Ionocytes (Foxi1+) are the rare cell type of the airway epithelium
recently characterized, in both mice and humans, by two independent
research groups.22,23 These reside at multiple levels of the airway tree,
and they are needed to maintain airway surface physiology, including
mucus viscosity.23 Foxi1 is already known to regulate V-ATPase,
which is important for transport and fluid pH in other cell types in
skin.94,95 Knockout in a mouse model reduced Cftr and Ascl3 expres-
sion, indicating the role of Foxi1 in CFTR regulation.23 Montoro
et al.23 also performed pulse-sequence tracing that indicated the basal
cell lineage, with an increased expression of CFTR.
Basal cells are progenitor cells96–98 that are regulated by NOTCH
signaling to give rise to ciliated cells (NOTCH), goblet cells
(NOTCH+), and club cells (NOTCH2+).99–102Due to their basal prox-
imity, these cells interact with the columnar epithelium; underlying
mesenchymal cells; basal membrane; neurons; and also lymphocytes,
inflammatory cells, and DCs.103 A loss in tight regulation of basal cell
differentiation can result in inappropriate cell fate determination,
leading to pathological airway remodeling. This includes epithelial
hypoplasia (proliferation failure), basal cell hyperplasia (excessive
proliferation with no differentiation), goblet cell metaplasia or hyper-
plasia instead of ciliated cell generation, and squamous metaplasia
(suprabasal cells) instead of luminal cells. Pathological airway remod-
eling occurs frequently in association with CF, COPD, and chronic
asthma.103 Araya et al.104 in their study showed that hyper-prolifer-
ating basal cells secrete cytokines (interleukin-1b [IL-1b]) that pro-
mote airway wall fibrosis via transforming growth factor b (TGF-b)
signaling in COPD.
Alveolar Cells and Associated Diseases
Alveolar type I cells (ATI) are squamous cells lining the alveolar
compartment involved in gas exchange. These are terminally differ-
entiated cells (lifespan120 days) that form a barrier to sense micro-
bial products and generate inflammatory responses.105,106 These cells
undergo excessive physical and chemical stresses due to their higher
exposure, and they require constant regulated repair.107,108Adefect in
repair directly and indirectly contributes toward injurious manifesta-
tions of the lung, leading to diseases like acute respiratory distress
syndrome (ARDS) and IPF.109,110 ATII (progenitor of ATI cells)
are cuboidal cells and cover about 7% of the total alveolar surface.
These produce surfactant lipids (phosphatidylcholine) and surfactant
proteins (SP-A to -D). Congenital SP-B deficiency leads to death87,111
soon after birth; however, targeted disruption of SP-C,112 SP-A,113
and SP-D114,115 gene loci does not show detrimental effects. In cases
with acute respiratory distress syndrome, a decrease in the expression
of SP-B is also observed.116,117
Stem Cells of the Airways
To maintain the constant dynamic function of the lung, it is very
crucial that the respiratory epithelium is equipped with fast and
extensive regenerative ability following injury. Airway basal cells
and ATII cells have been known for their role in repair of the
airway epithelium. Recently, studies have identified distinct niches
throughout the lung that can mediate graded and region-specific
responses.118,119 Myoepithelial cells (MECs) and bronchoalveolar
stem cells (BASCs) are a couple of the established stem cells in lungs.
It was well established that the innervated MECs encircle the submu-
cosal glands and mediate mucus secretion in response to neural
inputs, which can activate massive secretory responses after stimula-
tion by irritants and toxins (also reviewed in Boers et al.86 and Yei
et al.120).37,42,121 However, recent work by Lynch et al.122 and Tata
et al.123 have explained the potency of MECs in generating seven
cell types of surface airway epithelium and the submucosal gland
following airway injury. These can be activated via Sox9 or Lef-1 tran-
scriptional signaling, and they can be exploited for regenerative med-
icine. BASCs have been identified as stem cells that co-express both
club cell and ATII cell markers.124 BASCs sorted by flow cytometry
and cultured in vitro showed differentiation, self-renewability, and
response to injury.124–126 Lineage-tracing studies have revealed the
BASC’s ability to give rise to alveolar epithelial cells in vivo127,128
and its contribution to homeostasis and repair, along with club and
ATII cells.127–130
RespiratoryDiseases Targeted byProtein Replacement Therapy
SP-B Deficiency
SP-B deficiency is a rare genetic disease leading to neonatal lethality,
including interstitial lung disease (ILD) and ARDS.131–135 SP-B is
crucial for breathing transition of neonates at birth, and it helps in
reducing surface tension of the alveolus. Dipalmitoylphosphatidyl-
choline (DPPC) is the principal surface tension-reducing component
that combines with hydrophobic SP-B or SP-C peptides to form stable
surfactant film.136 Surfactant supports rapid adsorption and insertion
of phospholipids, reduction in surface tension upon compression,
and rapid re-spreading during expansion. Changes in surfactant
lead to alveolocapillary leakage, alveolar instability, compromised
gas exchange, and respiratory failure. Both SP-B and SP-C peptides
are processed from their pro-peptide forms to their functional
form. Absence of proSP-C processing leads to the accumulation of
misprocessed SP-C, consisting of the mature peptide with an N-ter-
minal extension (relative molecular weight [Mr]6,000), and to a sig-
nificant decrease in mature SP-C peptide in alveolar surfactant.
ProSP-C processing is also closely related to SP-B expression.87,111,137
The combinatorial effect exacerbates lung function at birth, and
in vivo studies showed respiratory failure in selective loss of SP-B in
adult.138
Natural surfactant replacement, such as Survanta beractant (modified
bovine surfactant 8 mg SP-B/mL) by Abbott Laboratories, Curosurf
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(porcine surfactant 80 mg/mL) by Chiesi, and Infasurf (calf surfac-
tant), are a few of the FDA-approved preventive medications for
infants with ARDS or premature babies at the risk of developing
RDS. Accompanied by physical measures, corticosteroids, or immu-
nosuppressants and repeated lung lavage, surfactant replacements
have shown improvement in the disease condition until lung trans-
plantation.139–144 The potential risks with animal-derived protein
include immunological reactions and transmission of animal-derived
diseases, justifying the need for standardized human-like alterna-
tives.145–147 One alternative involves synthetic mimics that have
shown superior surfactant properties.144,148
Since SP-B deficiency is a monogenetic disorder, it acts as a perfect
model for gene therapy. Both DNA- (virus120 and plasmid149) and
mRNA-150 based gene supplementation have been tested in a condi-
tional SP-B-knockout mouse model, which indicated improvements
in lung function and SP-B expression and a significant increase in
survival. Kormann et al.150 showed for the first time that intratracheal
(i.t.) instillation of modified SP-BmRNA to the lung can restore up to
71% of the wild-type SP-B expression, and the treated conditional
SP-B-knockout mouse model survived until the predetermined end
of the study of 28 days. Presently, the Rudolph team from Ethris holds
a patent for pulmonary delivery of mRNA with polyethylenimine
(PEI) (US patent application 20150126589), and their teaming up
with AstraZeneca and MedImmune could bring the therapy closer
to the reach of patients.151
Asthma
Asthma is a multifactorial disease and can be characterized by airway
obstruction, chest tightness, wheezing, cough, and breathlessness, fol-
lowed by recurrent pneumonia or bronchitis. The initiating event in
asthmatic airway diseases revolves around interactions between DCs
and T cells. DC and T cell interactions favor the generation of Th2,
leading to eosinophilia, mucus hypersecretion, and chronic airway
inflammation.152,153 The overactive Th2 response induces the pro-
duction of cytokines and chemokines, followed by a cascade of
immune-activating events, leading to changes in airway smooth mus-
cle contractility,154 a characteristic of asthma. Studies by Hellings
et al.155 andWilson et al.156 showed that Th17 cells orchestrate airway
inflammation by enhancing neutrophil recruitment to the lung. The
Th2-mediated immune response can be contained via Th1-type cyto-
kines (by Th1 cells), IL-10, and TGF-b (by T regulatory cells [Tregs]),
but the roles of IL-17 and IL-22 (by Th17 cells) are debated.155,157,158
Both circulatory and airway fluids of asthmatic patients indicate
increased IL-17 levels155 and decreased airway Tregs,159 indicating
an imbalance in Th2 regulation.
Corticosteroid treatment is found to suppress the Th2 immune
response via increased Foxp3+ Tregs in asthmatic patients.160 Similar
results were found with exposure to microbes161,162 influencing Treg
expression, modulation of IL-6,163 prostanoids,164 and tumor necrosis
factor (TNF) pathway enhancement.165Mays et al.166 has successfully
demonstrated the protective role of Foxp3 by delivering chemically
modified Foxp3 mRNA into the lung of an asthma mouse model.
Site-specific instillation of chemically modified Foxp3 mRNA can
modulate both Th2 and Th17 responses in an IL-10-dependent
manner.166 Local administration of Foxp3 mRNA can influence the
balance among Treg, Th2, and Th17 responses, and it can reduce
side effects in terms of the anti-tumoral and anti-infective167,168 ef-
fects of Tregs in comparison to systemic delivery.165 Kormann
et al.169 produced a unique insight into Toll-like receptors (TLRs),
as polymorphisms in TLRs 1, 6, and 10 have shown protective effects
on atopic asthma in humans by forming heterodimers with TLR2.
A subsequent study by Zeyer et al.170 demonstrated that Tlr1/2 and
Tlr2/6 mRNA instillation in the lungs of a house dust mite-induced
mouse model of asthma reduced airway resistance by 40%.
CF
CF, caused by mutations in the CFTR gene, is the most common life-
limiting autosomal-recessive disease in the Caucasian population,
and it affects more than 80,000 people worldwide. Around 2,000
mutations have been identified and are categorized into 6 classes,
ranging in severity from no production of functional protein to
decreased synthesis, stability, or function of CFTR protein. CFTR
protein acts as a small conductance ATP and cyclic AMP (cAMP)-
dependent chloride channel, found at the apical side of epithelial
cell lining of most exocrine glands. In the lung epithelium (ionocytes
and ciliated and goblet cells), CFTR ensures the secretion of chloride
ions, resulting in more hydration and regulated mucus clearance in
the airway. A lack of functional CFTR leads to decreased chloride
secretion and increased sodium absorption, resulting in dry and rigid
mucus production by goblet cells.171 An increase in inflammatory
response is also observed, possibly due to the breakdown of elastin
fibers by neutrophil elastase and reduced IL-10.172 The defective
mucus clearance enables further pathogen (Pseudomonas aeruginosa
and Staphylococcus aureus) colonization, repetitive inflammatory
responses that result in irreparable lung damage, and ultimately
cardiac arrest. Defects of the CFTR channel lead to a failure in LPS
recognition, endocytosis of pathogens, and changes in airway fluid
composition. This inactivates beta defensins, causing detrimental
effects on the primary defense in the lung.
A readthrough agent for CFTR class I mutation (Ataluren, PTC
Therapeutics) showed potential benefits in vivo by increasing CFTR
production and function;173 however, it failed phase III clinical trial
due to a lack of efficacy.174 Channel modulators categorized into
potentiators, correctors, and amplifiers have been used for CF treat-
ment. Potentiators (ivacaftor, Kalydeco) can help in gating and con-
duction mutations by increasing the open probability of the CFTR
channels. Correctors (tezacaftor and lumacaftor) improve CFTR traf-
ficking by facilitating the formation of correct 3D protein structure.
Combinations of potentiator and corrector (Orkambi and Symdeko,
Vertex Pharmaceuticals) are commercially available only for patients
with F508del mutation, expanding the modulators also for applica-
tion on class II mutations.175,176 A triple combination of two correc-
tors (VX-659, tezacaftor) and one potentiator (ivacaftor) has also
shown greater potency in pre-clinical trials. PTI-428 (Proteostasis
Therapeutics), an amplifier to increase the amount of CFTR protein,
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is in phase II trial. Eluforsen (QR-010) can bind to defective CFTR
RNA, and it has shown increased CFTR function by nasal potential
difference test in compound heterozygous or homozygous F508del
CF patients.177
Protein replacement therapy with DNA, protein, or mRNA holds a
great potential as a universal therapy for curing the underlying
defect of CF. Initial attempts of in vivo protein transfer via phospho-
lipid liposomes into the apical membrane of nasal epithelia of
CFTR-knockout mice showed limited membrane incorporation by
electron microscopy but improvement of nasal potential difference
(NPD) measurement.178 Similarly, DNA-based vectors (viral and
plasmid) were tested by Alton’s group (pGM169/GL67A), reaching
phase II clinical trials with modest improvement in FEV1 after
repeated administration but no improvement in patient’s quality
of life.179,180 Haque et al.20 have observed a significant improvement
in CFTR protein translation, expression, and function in vitro
(CFBE41o- and 16HBE14o-) and in vivo (CFTR-knockout mice)
by administering chemically modified human CFTR (hCFTR)
mRNAs complexed with chitosan-coated poly(lactic-co-glycolic
acid) (PLGA) nanoparticles. The study also showed a substantial
improvement in FEV0.1 up to 89% of the level of a healthy control
group. Airway compliance and resistance are also significantly
improved by the treatment with chemically modified hCFTR
mRNAs. A significant decrease in chloride concentration (around
50%) was also observed, indicating a restoration of CFTR in the
duct compartment of submucosal glands and thus leading to
improved chloride absorption.20 A separate study from Robinson
et al.181 confirmed nasal application of chemically modified CFTR
mRNA can recover up to 55% of the net chloride efflux character-
istic of healthy mice. Bangel-Ruland et al.182 demonstrate restoration
of cAMP-induced CFTR current following transfection of CFBE41o-
cells with wild-type CFTR-mRNA similar to the values seen in
16HBE14o- control cells. Translate Bio is also working on CFTR-
encoding mRNA (MRT5005) and has entered phase I/II clinical trial
(Table 1). All these studies prove the potential of mRNA as a prom-
ising therapeutic in CF patients, irrespective of their CFTR mutation
status.
COPD and COPD-like Symptoms in a1-Antitrypsin Deficiency
COPD is a progressive and largely irreversible smoking-related dis-
ease characterized by small airway obstruction, emphysema, and
chronic bronchitis. It is mainly attributed to long-term exposure to
tobacco, toxic gases, and particles, activating both innate and adaptive
immune responses. The innate immune defense includes tight
junctions, TLRs of epithelial barrier, macrophages, and alveolar fluid
Table 1. Current Clinical Trials Involving mRNA Delivery
Name Disease Genetic/Protein Target Administration Route Administration Vehicle ClinicalTrials.gov Identifier Phase
Lipo-MERIT melanoma tumor-associated antigens intravenous infusion mRNA-Lipoplex NCT02410733 1
TNBC-MERIT
triple-negative
breast cancer
tumor-associated antigens intravenous infusion mRNA-Lipoplex NCT02316457 1
IVAC mutanome
/warehouse
triple-negative
breast cancer
patient-specific antigens intra-nodal naked NCT02035956 1
mRNA-1851 influenza A Hemagglutinin 7 (H7) protein intramascular injection not disclosed Not disclosed 1
mRNA 1440 influenza A Hemagglutinin 7 (H7) protein intramuscular injection not disclosed not disclosed 1
CV7201 rabies rabies virus glycoprotein intramuscular injection naked NCT02241135 1
CV8102 HIV, rabies, RSV RNA-based adjuvant intramuscular injection naked NCT02238756 1
mRNA MRK-1777 not disclosed vaccine intradermal not disclosed not disclosed 1
mRNA AZD-8601
cardiovascular
diseases
VEGF-A intramuscular injection naked NCT02935712 1
mRNA-1325 Zika viral antigenic protein intramuscular injection lipid nanoparticle NCT03014089 1/2
CV9103 prostate cancer tumor-Specific antigen
autologous dendritic
cell therapy
naked NCT01197625 NCT00831467 1/2
MRT5005 cystic fibrosis CFTR
nebulization to the
respiratory tract
lipid nanoparticle NCT03375047 1/2
AGS-004 HIV vaccine
autologous dendritic
cell therapy
naked NCT01069809, NCT02707900 1/2
AGS-003-LNG
non-small-cell
lung cancer
tumor-specific antigen
autologous dendritic
cell therapy
naked NCT02662634 2
iHIVARNA-01 HIV HIV-target antigen intranodal route naked NCT02888756 2
AGS-003 renal cell carcinoma tumor-specific antigen
autologous dendritic
cell therapy
naked
NCT01482949 NCT00678119
NCT01582672
2/3
Modified from Kaczmarek et al.321
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(secreted by ATII cells of lung). A second line of defense includes
exudation of plasma and circulating effector cells into damaged tissue,
regulated by IL-1, IL-8, and TNF-a. The infiltration of both bronchial
and alveolar tissue with macrophages, B and T lymphocytes, and
eosinophils has been associated with emphysematous destruction.
Both the responses are linked to tissue repair and remodeling that in-
crease mucus content of airway lumen and metaplasia of mucous and
squamous cells. This leads to a thickened wall and narrowed lumen of
conducting airways. Second, emphysema limits air flow by reducing
elastic recoil pressure for exhaling air during forced expiration.183
a1-antitrypsin deficiency (AATD) can cause COPD-associated symp-
toms like emphysematous destruction alongwith innate inflammation
in lung due to an imbalance in protease and antiprotease homeosta-
sis.184 In lungs, AAT has the major physiological function of protect-
ing the healthy but fragile alveolar tissue from proteolytic damage
of neutrophil elastases.185 The AATD is largely associated with
mutations within SERPINA1, resulting in abnormal protein folding,
intracellular retention, and consequently low serum levels.186Howev-
er, multiple other factors also contribute to disease severity, and much
research is being done to obtain a comprehensive picture for enabling
better diagnosis.187–196 Danozol was found to significantly improve
AAT circulating levels197 without eliciting side effects. Another
approach is to inhibit polymerization of AAT by small molecules,198
peptides,199 autophagy-enhancing drugs200,201 (ClinicalTrials.gov:
NCT01379469 Tregretol phase II clinical trial, rapamycin202), and
RNA silencing ofmutant AAT in liver hepatocytes.203–205 Intravenous
(i.v.) augmentation of plasma-derived AAT (Bayer Biologicals, ZLB
Behring, Baxter Healthcare)206,207 is an established method to raise
circulating levels of AAT in blood and bronchoalveolar lavage fluid
(BALF), slowing the progression of lung destruction.208
Various routes of administration and vectors have been tested for
gene delivery of AAT in various animal models (rat, mouse, and
dog), with varying expression efficiency in terms of time and localiza-
tion (reviewed in detail209). However, only AAVrh.10hAAT (Adve-
rum Biotechnologies, ClinicalTrials.gov: NCT02168686) has entered
the phase I/II clinical trial to assess the safety and therapeutic level
expression ofM1-type AAT in the serum and alveolar epithelial lining
fluid.210 Connolly et al.21 have shown successful expression of AAT
with liposome-encapsulated SerpinA1 mRNA in vitro and in vivo
after transfection. In an independent study, Michel et al.211 observed
significant expression of AAT in vitro and ex vivo along with a signif-
icant reduction in elastase activity.
Steps toward Pharmacologically Auspicious mRNA
In recent years substantial efforts have been made for engineering
mRNAwith diverse pharmacokinetic properties (Figure 1). Modifica-
tions of structural elements such as 50 Cap, 50 and 30 UTRs, poly(A)
tail, and the coding region were the main focus.14,212–215
Figure 1. mRNA IVT, Modifications, and Function and Timeline
Overview of milestones in protein supplementation therapy, in vitro transcription, and mRNA modification. White boxes, important milestones for the development of
mRNA therapy;250 blue boxes, evolution of different cap structures;215,220,322 red, green, and gray boxes, 50 UTR, 30 UTR, and poly(A) tail, respectively, the addition
of regulatory elements in the modification of mRNA;14,312,313 yellow boxes, nucleoside modifications and sequence optimizations in the development for mRNA
therapy.215,230,238,240,314,317
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50-Capping for Stability and Immune Evasion
50-capping is vital for the robust translation of mRNA as the natural
7-methylguanosine (m7G/Cap0), and it is connected by a 50-to-50
triphosphate bridge to the first nucleotide. Translation is initiated
by binding to eukaryotic translation initiation factors (eIF4E and
eIF4G), and mRNA deterioration is controlled by binding with
Dcp1, Dcp2, and DcpS (mRNA-decaying enzymes).57,216–218 In
in vitro transcription, m7G possesses the risk of constructing uncap-
ped or inactive IVT mRNA, as the m7G and GTP compete for
incorporation. m7GpppG cap was the first step to circumvent the
restriction of m7G, however, substantial proportions of m7GpppG
analog were incorporated in the reverse direction and thus yielded
substandard translational activity.9,219 Anti-reverse cap analog
(ARCA; m2
7,30-OGpppG) can counteract the reverse integration
and skip degeneration by Dcp2, and, thus, it results in superior
translational efficiency and extended half-life.13,150,220 Study on
viral capping systems reveals that the 20 ribose position of the
first cap-proximal nucleotide is 20O-methylated to form a Cap 1
structure (m7GpppN20Om N), and, in 50% of transcripts, the sec-
ond cap-proximal nucleotide is 20O-methylated to form a Cap 2
(m7GpppN20OmN20Om) structure.
221 Cap 1 20O-methylation has
been described to reduce recognition by pattern recognition recep-
tors (e.g., interferon [IFN]-induced protein with tetratricopeptide
repeats-1 and 5 [IFIT1 and IFIT5] and retinoic acid-inducible
gene I [RIG-I]) in comparison to Cap 0.222–224
Modification in UTRs
The poly(A) tail plays an important role in regulating the stability and
translational efficiency (half-life) of mRNA by preventing deadenyla-
tion by poly-specific nucleases.225 Integration of the poly(A) tail
during IVT mRNA synthesis can be conducted by encoding the
poly(A) stretch in the template or by a two-step enzymatic reaction
using recombinant poly(A) polymerase.226 The ideal length of the
poly(A) tail is between 120 and 150 nt, and the 30 end of the poly(A)
tail should not be concealed by additional bases.14,213 50 and 30 UTRs
also play a vital role in the stability and expression of IVT mRNA by
harboring several sequence elements. For example, mRNAs with
adenosine in 50 UTR can form a complex with Lsm1-7 at both the
50 and 30 ends and circularize the transcript to inhibit degradation
by exosome and Dcp1/2.227 Adenine uracil (AU)-rich elements in
the 30 UTR can destabilize the mRNA, and they might provide a
mechanism to limit the duration of protein production.228
Post-transcriptional Modifications
Post-transcriptional chemical modifications of RNA are not uncom-
mon, and over 100 modifications are listed by different studies.229 In
mRNA, only a small subset of these naturally occurring modifications
is reported to be essential for reducing innate immune response and
improvingmRNAexpression and stability.215,230,231N6-methyladeno-
sine (m6A) is one of the most frequent modifications in eukaryotic
mRNA. Insulin-like growth factor 2 (IGF2) mRNA-binding proteins
1, 2, and 3 (IGF2BP1/2/3) preferentially recognize m6A mRNA and
guard the modified mRNA against decay.232 Based on the studies of
Kormann andWarren et al.,233 thefirst generation ofmodifiedmRNAs
containing 5-methylcytidine (m5C) or pseudouridine (J-UTP) re-
duces innate immune responses and enhances translation. TLR3,
TLR7, TLR8, and RIG-I activations were significantly reduced when
mRNA contained modified nucleosides such as m5C, m6A, 5-methyl-
uridine (m5U), J-UTP, and 2-thiouridine (s2U).20,150,230,234 RNA-
dependent protein kinase (PKR) arbitrated the immune response,
and translation inhibition (by phosphorylating the alpha subunit
of translation initiation factor 2 [eIF-2a]) can be escaped using
J-UTP- or m5C-modified nucleosides.235 m5C is explicitly recog-
nized by the mRNA export adaptor ALYREF, and it increases
mRNA-binding affinity and associated mRNA export.236 Activation
of two important components of the innate immune response against
unmodifiedmRNA, the interferon-induced enzymes 20-50-oligoadeny-
late synthetase (OAS) and RNase L, can be limited by J-UTP.237
N1-methylpseudouridine (N1-mJ-UTP) is the most used chemical
modification in recent studies, and it showed remarkable expression
compared to J-UTP-substituted mRNA, even when delivered by
different routes in vivo.238 N1-mJ-UTP induces a tight binding to
RIG-I but failed to activate RIG-I signaling (Figure 2).234,239
Codon Optimization
Codon optimization of mRNA uses the degeneracy of the genetic
code to substitute specific nucleosides of a mRNA sequence without
altering the resulting amino acid composition. Several recent studies
have reported a high expression by codon optimization of unmodified
and J-UTP-modified mRNA through enriching guanosine and/or
cytosine (GC).231,240 Cas9 activity has been reported to produce
significantly higher insertion or deletion (indel) and to be less immu-
nogenic when uridine depletion has been used with 5-methoxyuri-
dine (5moU) modification compared to unmodified and J-UTP-
modified Cas9 mRNA.215 Pharmacologically favorable mRNA that
has undergone modification and sequence optimization still needs
to be transferred in lung using carriers, to circumvent the naturally
occurring barriers the lung possesses.
Reaching the Lung
In vivo delivery of mRNA therapeutics remains one of the biggest
hurdles for mRNA-based therapies in general. Apart from the
fragility of the mRNA molecules and the ubiquitous existence of
RNases, there are twomain obstacles in the delivery of mRNA in vivo:
targeting specific lung cell populations and crossing the cellular
membrane. For solving the latter part, nanocarriers as a delivery sys-
tem have gained increased attention. Therefore, this review focuses
on the benefits and obstacles in the use of mRNA-nanocarrier
complexes.
In terms of transport of mRNA to a specific tissue, the route of admin-
istration plays an important role when discussing the hurdles of
organ-specific mRNA therapy. Focusing on the lung, two main routes
of administration were investigated in the past: i.v. application of
mRNA or mRNA-complexes to reach the lung from the vascular
structures and i.t. delivery of mRNA therapeutics via dry powder
insufflation or high-pressure liquid suspensions using a micro-
sprayer.150,166,241–246
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Intravenous application of RNAs leads to a systemic distribution of
the therapeutic throughout the whole organism.247 This can be
beneficial for certain pulmonary diseases like CF affecting other
organs; on the contrary, only a small percentage of an active agent
reaches the desired location.239 A substantial amount of mRNA is
removed from the bloodstream, especially in the liver and spleen.248
This increases the amount of mRNA needed for reaching effective
dose levels in the lung.20 Another hurdle emerges in the lung itself.
The lung has a capillary system that consists of mostly small and
non-fenestrated capillaries.249 This is very efficient for gas exchange
at the alveoli, but it does not permit a free exchange of larger
molecules out of the blood into the tissue. This phenomenon affects
mRNA therapeutics by reaching cells in close proximity, while
cells farther away from capillaries are harder to reach by i.v. admin-
istration.250 In general, i.v. application of mRNA has the advantage
of circumventing some initial innate defense systems and lung
barriers while fighting with the problems of systemic application
of dispersed distribution and losing the targeted administration to-
ward the lung.
In contrast, i.t. administration of therapeutic substances gives the
advantage of local application of mRNA in the lung and airways.
Figure 2. Processing of IVT mRNA in a Cell
(A) In vitro-transcribed (IVT) mRNA from linearized DNA or PCR-amplified fragment is used to transfect the cell of interest. Step 1: mRNA protection from RNase degradation
and mRNA uptake are facilitated by various carriers. Step 2 of mRNA transport and release inside the cell is still unclear. Different capping modification can increase
translation in step 3 and also protect from degradation. In steps 3 and 4, the translated protein from delivered mRNA gets transferred to various parts of the cell system based
on post-translational modification. For an immunotherapeutic approach, the translated protein needs to get degraded by proteasome to antigen epitopes and delivered to
MHC (major histocompatibility complex) class I located in the endoplasmic reticulum. MHC class I mediates surface presentation of the presented epitope to CD8+ cytotoxic
T cells.320 The T cell further initiates the immune response by relocating the antigen and presenting in to MHC II. (B) IVTmRNA cause inflammatory responses and inhibition of
mRNA replication as triphosphorylated mRNA or double-stranded RNA (dsRNA) can be recognized by Toll-like receptors 3, 7, and 8 (endosomal innate immune receptors),
which can initiate inflammation associated with type 1 interferon (IFN), interleukin-6 and -12, and tumor necrosis factor (TNF).230 Cytoplasmic receptors, protein
kinase R (PKR), retinoic acid-inducible gene I protein (RIG-I), melanoma differentiation-associated protein (MDA5), and 20-50-oligoadenylate synthase (OAS) can detect
triphosphorylated mRNA or dsRNA and stalled translation through eIF2a, RNA degradation by ribonuclease L (RNase L), and inhibition of mRNA replication by IFN.323,324
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Moreover, the alveolar surface area is large and suitable for drug ab-
sorption, and the epithelial barrier is thin,242which could facilitate the
delivery of mRNA to lung cells. While endothelial cells and lung stem
cells are difficult to access, alveolar cells, epithelial cells, and macro-
phages can be targeted by i.t. administration.251A potential therapeu-
tic has to be appropriately formulated to be able to reach deep lung
surfaces. This includes a particle size of 4–7 mm in diameter252 for
targeting the tracheobronchial region and 1–3 mm for targeting the
alveolar region, when preparing a powder for insufflation or nebu-
lizing a liquid (Figure 3).253
To reach deep lung structures and alveoli, mRNA therapeutics still
has to pass the respiratory mucus. In a non-pathological condition,
the thickness of the mucus is between 2 and 5 mm in the bronchi
and 10 and 30 mm in the trachea,254 while in CF asthma and
COPD the mucus layer is reported to be much thicker.255 The gel-
on-brush model of Button et al.256 states that ciliary movement trans-
ports all material out of the lung at a rate of 3.6 mm/min,257 while a
layer of mucins and glycoproteins form a fine mesh preventing large
particles from reaching the periciliary layer and epithelial cells in the
lung.256 The mucus layer, lining epithelial cells from the nose to the
terminal bronchioles, also affects nanocarriers by sterical obstruction
or direct interaction from diffusion to the target cells.251 Different in-
dependent studies showed a correlation between nanocarrier size and
mobility in respiratory mucus. Sanders et al.258 and Dawson et al.259
reported that nanospheres at the size of 100 nm were able to pass
more or less freely through CF sputum compared to nanospheres
larger than 500 nm. Broughton-Head et al.260 detected that CF sputa
of three CF patients contained a mesh with a mean size of 300 ±
106 nm, 578 ± 191 nm, and 711 ± 328 nm, respectively, providing
evidence for the distinct transport parameters of different-sized nano-
spheres. Studies by Stern et al.,261 Kitson et al., 262 and Ferrari et al.263
suggested that not only the retention by the mesh structure in the
CF sputum but also the direct interaction with free DNA present
in CF sputum can reduce the gene transfer of 3ß-[N-(N’,N’-
dimethylaminoethane)-carbamoyl] (DC)-cholesterol (Chol)/1,2-dio-
leoyl-sn-glycero-3-phosphoethanolamine (DOPE)-based lipoplexes
up to 20-fold.
Respiratory mucus is not the only fluid presenting a barrier for the
nanocarrier delivery of mRNA. Also, the alveolar fluid is known to
inhibit cationic lipid nanocarriers, presumably by disintegration of
the lipoplexes by negatively charged lipids in the surfactant.251 In
contrast, PEI and dendrimer polyamidoamine (PAMAM)-based
gene delivery was observed to be resistant to the effects of pulmonary
surfactant in vitro and in vivo.264,265 Moreover, Exosurf (a synthetic
surfactant) has been reported to increase the efficiency of PAMAM-
pDNA complexes in vitro.265
Figure 3. Deposition of Nanoparticles for Delivery in the Lung after Intratracheal or Intravenous Administration
Left: intratracheal instillation requires a particle size of 1–3 mm to reach the alveoli efficiently; particles from 4 to 7 mm are mainly distributed to the upper airways and main
bronchioles, and particles smaller than 1 mm are exhaled again.252,318 Right: inhaled nanoparticles can enter bronchial as well as alveolar epithelium; nanoparticles can enter
lymph and blood circulation to be delivered to secondary organs.319 Intravenous injection can systemically deliver nanoparticles to a limited part of the alveolar epithelium due
to small and non-fenestrated endothelial cells in the capillaries in the lung.250
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To overcome the obstacles presented by both respiratory mucus
and pulmonary surfactant, various approaches have been tested.
Mucolytic agents, which degrade the biopolymer network built up
out of DNA, actin, and mucins, are a focus of many research
groups.258–260,263 Recombinant human DNase (rhDNase) liquifies
CF mucus by cleaving DNA chains in the biopolymer, and it has a
direct effect on the mobility of nanocarriers of CF sputum. It
increased the mobility of 270-nm nanospheres and 1,2-dioleoyl-3-
trimethylammonium-propane (DOTAP)/DOPE-based lipoplexes
2.5-fold and 1.4-fold, respectively.258,266 N-Acetylcysteine (NAC), a
clinically used mucolytic agent for asthma, COPD, and CF patients,
reduces the disulfate bonds between mucins and lowers the viscosity
and elasticity of respiratory mucus.267,268 NAC-mediated mucus
clearance of an ex vivo sheep trachea model increased gene transfer
via p-ethyl-dimyristoylphosphadityl choline (EDMPC)-Chol lipo-
plexes and PEI-based polyplexes 20-fold and 10-fold, respectively.
If the nasal epithelium of mice is treated with NAC 30 min before
the administration of EDMPC-Chol lipoplexes, the gene expression
can be increased up to 100-fold.263
An alternative strategy is to coat nanocarriers with biocompatible
hydrophilic but biologically inert polymers251 to shield the nanocar-
riers from respiratory fluids and surfactant. GL67 (genzyme lipid 67)/
DOPE lipoplexes can be coated with polyethylene glycol (PEG), and
they have been reported to circumvent the adverse effects of CF
mucus during gene transfection in vivo.269 Maisel et al.270 reported
that 10–40 kDa PEG-coated nanocarriers can diffuse through the
mucus as a mucoinert particle.
Nanotransporters to Target the Lung
The labile nature of mRNA and immunogenicity are the biggest hur-
dles of mRNA therapeutics. As discussed above, the immunogenicity
has been overcome by chemical modifications; however, the insta-
bility of mRNA under physiological conditions requires additional
action. Electroporation,271 gene gun,272 microinjection,273 and sono-
poration274 have been investigated for mRNA delivery; however,
these are restricted to ex vivomanipulation and ill suited for systemic
delivery. Therefore, suitable mRNA carriers should exhibit the
following functions: protection from RNase degradation, evasion of
direct renal clearance, avoidance of nonspecific interaction, facilita-
tion of mRNA stability, and sufficient mRNA loading and
release.275–277 The physiochemical properties, such as hydrodynamic
diameter, shape, size, surface charge, solubility, flexibility, stability,
formulation, and body composition with regard to route of adminis-
tration, decide the target binding bio-distribution as well as the clear-
ance of the nanocarriers. As many materials used to construct
nanoparticles are toxic or potentially toxic, biocompatibility and
biodegradability become key factors. Since our focus is delivering
mRNA therapeutics to the lung, we cover biomaterials such as lipids,
polymers, and combined formulations that are developed for delivery
to the lung.
Lipid-based nanoparticles (LNPs) or lipoplexes have gained popularity
since the beginning of drug and nucleic acid delivery.9,231,240,278,279
These have the significant advantages of easy synthesis, scalability,
low batch variability, and biocompatibility.280–282 Commercially avail-
able lipoplexes, such as RNAiMAX, Stemfect, and Megafectin, have
been successfully used in transfectingmRNA in vivo.279,283–285Cationic
lipids, such as 1,2-di-O-octadecenyl-3-trimethylammonium-propane
(DOTMA), DOTAP, and zwitterionic DOPE, have been used alone
or in combination, as these readily form complexes with mRNA.
Variants to reduce toxicity and immunogenicity associated with
cationic lipids and with improved efficacy have been developed. Addi-
tionally, the ratio of components substantially affects LNP efficacy.
These include ionizable lipidic systems that can reduce toxicity by pos-
sessing a neutral charge at physiological pH286 and ionizable lipid
nanoparticles consisting of ionizable lipid, cholesterol (hydrophobic),
helper lipid (DOPE or 1,2-distearoyl-sn-glycero-3-phosphocholine
[DSPC]), and PEG lipids. DOPE enhances efficacy by promoting
membrane fusion (cell and endosomal), and PEG lipids prevent retic-
uloendothelial clearance and reduce opsonization by serum proteins.
LNP-mediated mRNA delivery has been extensively used in protein
replacement therapies, vaccines, and cancer immunotherapies.276
Earlier work by Litzinger et al.287 showed that cationic liposomes of
size 2.0 mmare transiently taken up by the lung, followed by rapid dis-
tribution to the liver. Similarly, efficient pulmonary endothelial deliv-
ery of plasmid was achieved with a lipid vector consisting of DOTAP
liposomes, protamine, and oligo deoxynucleotides,288 with minimum
cytotoxicity and release of proinflammatory cytokines. The landmark
clinical trial of CFTR gene therapy with pGM169179 and multiple
other clinical trials with nasal delivery tested lipid nanoparticle
cholest-5-en-3-ol(3b)-,3-[(3-aminopropyl)[4-[(3-aminopropyl)amino]
butyl] carbamate] (GL67A) due to its desirable stability during aero-
solization,289 gene transfer potency,290 and well-characterized safety
parameters.291 The Wendel group292 has shown DOPE liposomes
as potential transfection agents for AAT mRNA, resulting in pro-
longed protein production of AAT in vitro with improved stability
of mRNA in liposomes for up to 80 days, without the loss of transfec-
tion efficacy. Alexion Pharmaceuticals has shown human AAT
expression in both mouse liver and lung upon i.v. injection of
mRNA-ionizable LNP complex after 24 h.21 Both approaches require
further testing on knockout mouse models293 to check its efficiency as
a therapy for AATD.
Lipid-enabled and unlocked nucleomonomer agent-modified RNA
(LUNAR) technology of Arcturus Therapeutics employs biodegrad-
able ionizable lipids (ATX, Arcturus Therapeutics’s proprietary
lipid) that have shown no adverse events, hepatotoxicity, weight
loss, or innate or adaptive immune reactions in response to treat-
ment with repeated dosing of up to 4 months.294 Ramaswamy
et al.294 observed faster translation (within 6 h) and major deposition
of LUNAR-encapsulated mRNA in mouse liver with i.v. injection.
Arcturus holds multiple patents on nanoparticles for RNA delivery
with the potential of lung epithelial delivery via nebulization. Trans-
late Bio holds a patent on multiple lipid nanoparticles with its collab-
orator at Massachusetts Institute of Technology (MIT) and Imperial
College London, and it is the first one to enter clinical trials with
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LNPs (ClinicalTrials.gov: NCT03375047) for mRNA-based CF ther-
apy. Valera (by Moderna) has reported efficacy of modified hemag-
glutinin mRNA-LNP-formulated vaccines against H7N9 andH10N8
influenza virus (presently at clinical phase I), when immunized
intradermally or intramuscularly in mice, ferrets, and non-human
primates293 (one must note that localization in lungs is not required
for immunization).
Though not as equally advanced as LNPs, polymer-based nanopar-
ticles have shown considerable potential in aiding therapeutics.
Cationic polymers (linear or branched) can enable nucleic acid shut-
tling across membranes by compactly packing them into nanoplexes,
and they can help in cellular uptake via endocytosis.295 PEI is the
vastly studied polymer for gene or oligonucleotide delivery,296,297
however, toxicity due to nondegradability, high molecular weight
(>20 kDa), and its highly branched formulations has limited its
clinical applications.298 The positive charge attributes to interaction
with serum proteins (negatively charged), resulting in their aggrega-
tion and increase in size that causes toxicity, similar to that of cationic
liposomes. Therefore, different groups have tried to modify PEI and
achieve higher transfection with lower toxicity, which includes
reducing size299 (mRNA release), reducing molecular weight,300 or
using additives.301
Poly (L-lysine) (PLL), poly(2-(dimethylamino)ethyl methacrylate)
(p[DMAEMA]), and PLGA are well known polymers, and diblock302
and triblock polymers303 have shown encouraging results for nucleic
acid transfection. As already discussed, mucus acts as a strong barrier,
and mucoadhesive particles can increase the residence time while
bulking up the nanoparticle. PEGylated NPs (diblock copolymer
composed of PLGA and PEG [PLGA-PEG], namely, PLGA-PEGmu-
cous penetrating particle [MPP]) of >200-nm size are known to pene-
trate mucus and CF sputum.304,305 Based on this, Schneider et al.305
and others have shown that MPP (%300 nm in diameter) exhibits
improved particle distribution and lung retention.150 Chitosan (mu-
coadhesive) coating20,306 of PLGA nanoparticles has shown successful
delivery of SP-BmRNA and hCFTRmRNA in mouse models, signif-
icantly improving survival307 and lung function,308 respectively. It is
possible that these enable deeper lung delivery instead of mere epithe-
lial delivery, due to which we could observe the survival of an SP-B-
deficient mouse model309 when corrected with zinc-finger nuclease
(ZFN)mRNA and donor template. In an attempt to develop nanopar-
ticles for pulmonary delivery, Ethris used mRNA complexed with a
polymer scaffold of poly (acrylic acid) of 20 kDa grafted with oligoal-
kylamines, which showed delivery in cranial parts of pig lung upon
nebulization.54 A study about the exact localization of developed
nanoparticles in different lung cell populations would benefit the
scientific society in moving toward disease-specific targeted therapy
for different lung diseases.
Further, combinations of lipids and polymers have been tested as
nanocarriers. These include self-assembling nano-micelles formed
by copolymer consisting of polyamino acid block and PEG
with mRNA at core. Commonly used polyamino blocks include
poly(Nʹ-(N-(2-aminoethyl)-2-aminoethyl) aspartamide (PAsp[DET]),
which has shown protein expression in nasal neurons with
mRNA coding for brain-derived neurotrophic factors (BDNFs).310
The complex also reduced apoptosis when injected with anti-
apoptotic protein B cell lymphoma (Bcl-2) mRNA in a fulminant
hepatitis mouse model.311 The group of Daniel G. Anderson has
developed various nanoparticles to be used in therapeutics,14,312
among which the polymer lipid combination of poly (b-amino
esters) (PBAEs) and PEG has shown greater potential in delivering
mRNA to lung via i.v. injection,313 aiding successful systemic deliv-
ery. Desrosiers et al.314 have developed amine-modified polyester-
based nanocarriers in combination with triblock copolymers, with
specific mRNA delivery to lung. Though degradable and optimized
for serum stability and reduced toxicity, these need to be further
tested for inflammatory reactions before clinical translation. Recent
publication by Patel et al.315 on hyperbranched PBAEs has shown
ease in nebulization and uniform distribution of mRNA in all 5
lobes of lung, with no measured local or systemic toxicity.
To further increase the specificity of nanocarrier-based delivery,
receptor-based technologies have been tested. Arrowhead Pharmaceu-
ticals developed an asialoglycoprotein receptor-targeting nanocarrier
to specifically administer an RNAi molecule (targeted RNAi molecule
[TRiM]) to reduce the accumulation of AAT protein230 for AAT-
related liver diseases. If combined with pulmonary delivery of AAT
mRNA, it can act as a complete therapy for diseases like AATD. A re-
ceptor-based method can also be developed for the lung epithelium,
but specific markers of lung epithelial cells have to be identified to
avoid cross-reactivity with other epithelial cell linings. In another
approach for enhancing translation and reducing the degradation of
mRNA upon entry, a delivery system has been tested that employs
translation initiation factor eIF4E with cationic polyamine. A study
showed that these nanoparticles induced mRNA expression in mouse
lung upon systemic delivery.316 Other nanoparticles developed for
lungs include gelatin nanocarriers crosslinked with genipin, monome-
thoxypoly(ethylene glycol)-poly(lactic-co-glycolic acid)-poly-l-lysine
(mPEG-PLGA-PLL) triblock copolymers, MUC-1 aptamer-function-
alized hybrid nanoparticles, drug-loaded liposomes, anionic PAMAM
dendrimers, and a recently developed virus-inspired polymer for
endosomal release (VIPER).215,230,238,240,250,252,317–320 However, as
discussed before, these must be extensively tested for compatibility
with mRNA.
Conclusions
This paper focused on respiratory diseases and associated cell popu-
lations of the lung. To understand the disease pathology and possible
countermeasures, the physiological aspects of various lung cells have
to be determined. This includes the awareness of connections of
epithelial cells with alveolar cells, serous cells (goblet cells), and also
stem and progenitor cells, as lung diseases may originate from a single
defect but can affect the whole lung. Recent developments already
produced major advancements in therapies such as chemical modu-
lators for CF, but they also produced therapy resistance or were only
effective for certain variants of a disease. This makes mRNA-based
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protein supplementation therapy a viable alternative for diseases such
as CF, SP-B deficiency, asthma, IPF, and COPD while offering a treat-
ment independent of the underlying mutational status. Furthermore,
stem cells of the lung can also be a target for mRNA-based CRISPR/
Cas therapies that hold the potential for permanent cures for mono-
genetic lung diseases, such as CF, SP-B deficiency, and AATD.
The therapeutic potential of mRNA for protein supplementation
therapy was widely unrecognized due to its instability for a long
time. Over the last decades, an appreciation of mRNA as the molecule
connecting the world of proteins and DNA is renewing the focus of
research on mRNA.9,20,215 The research focuses on the properties of
RNA to increase or modulate stability and evade immune recognition
as well as delivery of mRNA specifically to the lung and other organs.
The use of naturally occurring nucleoside modifications has dimin-
ished the recognition of mRNA by the innate immune system.230,235
These modifications also help in improving the stability and expres-
sion of mRNA. This is further promoted by modifications like
50-capping and the addition of a poly(A) tail as well as modifications
in the 30 and 50 UTRs. Sequence optimization increases expression
and lowers immunogenicity of mRNA therapeutics. The most opti-
mized RNA still needs to reach the target cell to be expressed into a
protein.
The problem of delivery consists of three main parts: (1) how to find
a suitable route of administration; (2) as mRNA for protein supple-
mentation therapy usually are of substantial size and negatively
charged, they will not cross cellular membranes unfacilitated; and
(3) the composition of mRNA and nanocarriers to maintain the
optimal stability of mRNA nanocarrier complexes. Looking at pro-
tein supplementation therapies for the lungs, i.t. delivery gives the
ability to apply mRNA therapeutics locally and concentrated in
the lungs. To overcome defense barriers like the respiratory mucus
and alveolar fluids as well as the cellular membranes, nanocarriers
developed into a favorable type of vehicle for mRNA. To date,
research indicates that small nanocarriers (100 nm) together
with a polymer coating and the potential application of a mucolytic
agent can improve the stability of the mRNA nanocarrier complex
and mRNA uptake into the target cell. Nonetheless, the mechanism
of how a nanocarrier facilitates the cellular uptake of mRNA is still
not fully understood.
All in all, the pieces needed for an effective protein supplementation
therapy in the lung are available in various preclinical and clinical
stages. The next task is to find a formulation to bring all of these com-
ponents together—route of administration, carrier, mRNA sequence
and modification—to form a working therapy for patients. The
first clinical trials in the slowly evolving field of protein supplementa-
tion therapy show that the concept is viable (ClinicalTrials.gov:
NCT02935712 and NCT03375047; see also Table 1).
AUTHOR CONTRIBUTIONS
I.S., A.K.M.A.H., and B.W. wrote the main parts of the article and
produced graphics. P.W. helped in the meticulous preparation of
the manuscript. M.S.D.K. drafted the final version of the manuscript.
All authors read and approved the final manuscript.
CONFLICTS OF INTEREST
M.S.D.K. holds a patent on RNA modification (EP2459231B1).
M.S.D.K. and A.K.M.A.H. hold a European patent on delivery of
hCFTR cmRNA complexed with nanoparticles (17169561.2-1401).
ACKNOWLEDGMENTS
This work was supported by the European Research Council (ERC
Starting Grant to M.S.D.K., 637752 “BREATHE”) and the HMZ
Privatstiftung to M.S.D.K. We thank Melanie Perreault for proof-
reading as a native English speaker.
REFERENCES
1. Robertson, M.P., and Joyce, G.F. (2012). The origins of the RNA world. Cold Spring
Harb. Perspect. Biol. 4, a003608.
2. Cech, T.R. (2012). The RNA worlds in context. Cold Spring Harb. Perspect. Biol. 4,
a006742.
3. Neveu, M., Kim, H.J., and Benner, S.A. (2013). The “strong” RNA world hypothesis:
fifty years old. Astrobiology 13, 391–403.
4. Murgola, E.J., Prather, N.E., Mims, B.H., Pagel, F.T., and Hijazi, K.A. (1983).
Anticodon shift in tRNA: a novel mechanism in missense and nonsense suppres-
sion. Proc. Natl. Acad. Sci. USA 80, 4936–4939.
5. Ellington, A.D., and Szostak, J.W. (1990). In vitro selection of RNA molecules that
bind specific ligands. Nature 346, 818–822.
6. Cogoni, C., Irelan, J.T., Schumacher, M., Schmidhauser, T.J., Selker, E.U., and
Macino, G. (1996). Transgene silencing of the al-1 gene in vegetative cells of
Neurospora is mediated by a cytoplasmic effector and does not depend on DNA-
DNA interactions or DNA methylation. EMBO J. 15, 3153–3163.
7. Chen, X., He, L., Zhao, Y., Li, Y., Zhang, S., Sun, K., So, K., Chen, F., Zhou, L., Lu, L.,
et al. (2017). Malat1 regulates myogenic differentiation and muscle regeneration
through modulating MyoD transcriptional activity. Cell Discov. 3, 17002.
8. Lundstrom, K. (2015). Special Issue: Gene Therapy with Emphasis on RNA
Interference. Viruses 7, 4482–4487.
9. Malone, R.W., Felgner, P.L., and Verma, I.M. (1989). Cationic liposome-mediated
RNA transfection. Proc. Natl. Acad. Sci. USA 86, 6077–6081.
10. Wolff, J.A., Malone, R.W., Williams, P., Chong, W., Acsadi, G., Jani, A., and
Felgner, P.L. (1990). Direct gene transfer into mouse muscle in vivo. Science
247, 1465–1468.
11. Jirikowski, G.F., Sanna, P.P., Maciejewski-Lenoir, D., and Bloom, F.E. (1992).
Reversal of diabetes insipidus in Brattleboro rats: intrahypothalamic injection of
vasopressin mRNA. Science 255, 996–998.
12. Newbury, S.F. (2006). Control of mRNA stability in eukaryotes. Biochem. Soc.
Trans. 34, 30–34.
13. Mockey, M., Gonçalves, C., Dupuy, F.P., Lemoine, F.M., Pichon, C., and Midoux, P.
(2006). mRNA transfection of dendritic cells: synergistic effect of ARCA mRNA
capping with Poly(A) chains in cis and in trans for a high protein expression level.
Biochem. Biophys. Res. Commun. 340, 1062–1068.
14. Holtkamp, S., Kreiter, S., Selmi, A., Simon, P., Koslowski, M., Huber, C., Türeci, O.,
and Sahin, U. (2006). Modification of antigen-encoding RNA increases stability,
translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood 108,
4009–4017.
15. Elango, N., Elango, S., Shivshankar, P., and Katz, M.S. (2005). Optimized transfec-
tion of mRNA transcribed from a d(A/T)100 tail-containing vector. Biochem.
Biophys. Res. Commun. 330, 958–966.
16. Rozenski, J., Crain, P.F., and McCloskey, J.A. (1999). The RNA Modification
Database: 1999 update. Nucleic Acids Res. 27, 196–197.
814 Molecular Therapy Vol. 27 No 4 April 2019
www.moleculartherapy.org
Review
17. Boccaletto, P., Machnicka, M.A., Purta, E., Piatkowski, P., Baginski, B., Wirecki,
T.K., de Crécy-Lagard, V., Ross, R., Limbach, P.A., Kotter, A., et al. (2018).
MODOMICS: a database of RNA modification pathways. 2017 update. Nucleic
Acids Res. 46, D303–D307.
18. Ishii, K.J., and Akira, S. (2005). TLR ignores methylated RNA? Immunity 23,
111–113.
19. Karikó, K., Ni, H., Capodici, J., Lamphier, M., and Weissman, D. (2004). mRNA is
an endogenous ligand for Toll-like receptor 3. J. Biol. Chem. 279, 12542–12550.
20. Haque, A.K.M.A., Dewerth, A., Antony, J.S., Riethmüller, J., Schweizer, G.R.,
Weinmann, P., Latifi, N., Yasar, H., Pedemonte, N., Sondo, E., et al. (2018).
Chemically modified hCFTR mRNAs recuperate lung function in a mouse model
of cystic fibrosis. Sci. Rep. 8, 16776.
21. Connolly, B., Isaacs, C., Cheng, L., Asrani, K.H., and Subramanian, R.R. (2018).
SERPINA1 mRNA as a Treatment for Alpha-1 Antitrypsin Deficiency. J. Nucleic
Acids 2018, 8247935.
22. Plasschaert, L.W., Zilionis, R., Choo-Wing, R., Savova, V., Knehr, J., Roma, G.,
Klein, A.M., and Jaffe, A.B. (2018). A single-cell atlas of the airway epithelium
reveals the CFTR-rich pulmonary ionocyte. Nature 560, 377–381.
23. Montoro, D.T., Haber, A.L., Biton, M., Vinarsky, V., Lin, B., Birket, S.E., Yuan, F.,
Chen, S., Leung, H.M., Villoria, J., et al. (2018). A revised airway epithelial hierarchy
includes CFTR-expressing ionocytes. Nature 560, 319–324.
24. Castranova, V., Rabovsky, J., Tucker, J.H., and Miles, P.R. (1988). The alveolar type
II epithelial cell: a multifunctional pneumocyte. Toxicol. Appl. Pharmacol. 93,
472–483.
25. Noguchi, A., Reddy, R., Kursar, J.D., Parks, W.C., andMecham, R.P. (1989). Smooth
muscle isoactin and elastin in fetal bovine lung. Exp. Lung Res. 15, 537–552.
26. Morrisey, E.E., and Hogan, B.L. (2010). Preparing for the first breath: genetic and
cellular mechanisms in lung development. Dev. Cell 18, 8–23.
27. Boström, H., Willetts, K., Pekny, M., Levéen, P., Lindahl, P., Hedstrand, H., Pekna,
M., Hellström, M., Gebre-Medhin, S., Schalling, M., et al. (1996). PDGF-A signaling
is a critical event in lung alveolar myofibroblast development and alveogenesis. Cell
85, 863–873.
28. Hilliard, T.N., Regamey, N., Shute, J.K., Nicholson, A.G., Alton, E.W., Bush, A., and
Davies, J.C. (2007). Airway remodelling in children with cystic fibrosis. Thorax 62,
1074–1080.
29. Adam, D., Roux-Delrieu, J., Luczka, E., Bonnomet, A., Lesage, J., Mérol, J.C., Polette,
M., Abély, M., and Coraux, C. (2015). Cystic fibrosis airway epithelium remodelling:
involvement of inflammation. J. Pathol. 235, 408–419.
30. Elias, J.A., Zhu, Z., Chupp, G., and Homer, R.J. (1999). Airway remodeling in
asthma. J. Clin. Invest. 104, 1001–1006.
31. Fehrenbach, H., Wagner, C., and Wegmann, M. (2017). Airway remodeling in
asthma: what really matters. Cell Tissue Res. 367, 551–569.
32. Knudsen, L., Ruppert, C., and Ochs, M. (2017). Tissue remodelling in pulmonary
fibrosis. Cell Tissue Res. 367, 607–626.
33. Wallace, W.A., Fitch, P.M., Simpson, A.J., and Howie, S.E. (2007). Inflammation-
associated remodelling and fibrosis in the lung - a process and an end point. Int.
J. Exp. Pathol. 88, 103–110.
34. Pain, M., Bermudez, O., Lacoste, P., Royer, P.J., Botturi, K., Tissot, A., Brouard, S.,
Eickelberg, O., and Magnan, A. (2014). Tissue remodelling in chronic bronchial dis-
eases: from the epithelial to mesenchymal phenotype. Eur. Respir. Rev. 23, 118–130.
35. Salazar, L.M., and Herrera, A.M. (2011). Fibrotic response of tissue remodeling in
COPD. Hai 189, 101–109.
36. Sato, M., and Keshavjee, S. (2008). Bronchiolitis obliterans syndrome: alloimmune-
dependent and -independent injury with aberrant tissue remodeling. Semin. Thorac.
Cardiovasc. Surg. 20, 173–182.
37. Ma, J., Rubin, B.K., and Voynow, J.A. (2018). Mucins, Mucus, and Goblet Cells.
Chest 154, 169–176.
38. Chen, G., Korfhagen, T.R., Xu, Y., Kitzmiller, J., Wert, S.E., Maeda, Y., Gregorieff, A.,
Clevers, H., and Whitsett, J.A. (2009). SPDEF is required for mouse pulmonary
goblet cell differentiation and regulates a network of genes associated with mucus
production. J. Clin. Invest. 119, 2914–2924.
39. Rajavelu, P., Chen, G., Xu, Y., Kitzmiller, J.A., Korfhagen, T.R., and Whitsett, J.A.
(2015). Airway epithelial SPDEF integrates goblet cell differentiation and pulmo-
nary Th2 inflammation. J. Clin. Invest. 125, 2021–2031.
40. De Rose, V., Molloy, K., Gohy, S., Pilette, C., and Greene, C.M. (2018). Airway
Epithelium Dysfunction in Cystic Fibrosis and COPD. Mediators Inflamm. 2018,
1309746.
41. Wynn, T.A., Cheever, A.W., Jankovic, D., Poindexter, R.W., Caspar, P., Lewis, F.A.,
and Sher, A. (1995). An IL-12-based vaccination method for preventing fibrosis
induced by schistosome infection. Nature 376, 594–596.
42. Whitsett, J.A. (2018). Airway Epithelial Differentiation and Mucociliary Clearance.
Ann. Am. Thorac. Soc. 15 (Suppl 3 ), S143–S148.
43. Gerbe, F., Sidot, E., Smyth, D.J., Ohmoto, M., Matsumoto, I., Dardalhon, V., Cesses,
P., Garnier, L., Pouzolles, M., Brulin, B., et al. (2016). Intestinal epithelial tuft cells
initiate type 2 mucosal immunity to helminth parasites. Nature 529, 226–230.
44. Tizzano, M., Gulbransen, B.D., Vandenbeuch, A., Clapp, T.R., Herman, J.P.,
Sibhatu, H.M., Churchill, M.E., Silver, W.L., Kinnamon, S.C., and Finger, T.E.
(2010). Nasal chemosensory cells use bitter taste signaling to detect irritants and
bacterial signals. Proc. Natl. Acad. Sci. USA 107, 3210–3215.
45. Krasteva, G., Canning, B.J., Hartmann, P., Veres, T.Z., Papadakis, T., Mühlfeld, C.,
Schliecker, K., Tallini, Y.N., Braun, A., Hackstein, H., et al. (2011). Cholinergic che-
mosensory cells in the trachea regulate breathing. Proc. Natl. Acad. Sci. USA 108,
9478–9483.
46. Gordon, E.D., Locksley, R.M., and Fahy, J.V. (2016). Cross-Talk between Epithelial
Cells and Type 2 Immune Signaling. The Role of IL-25. Am. J. Respir. Crit. Care
Med. 193, 935–936.
47. Zhang, Y.J., O’Neal, W.K., Randell, S.H., Blackburn, K., Moyer, M.B., Boucher, R.C.,
and Ostrowski, L.E. (2002). Identification of dynein heavy chain 7 as an inner arm
component of human cilia that is synthesized but not assembled in a case of primary
ciliary dyskinesia. J. Biol. Chem. 277, 17906–17915.
48. Ostrowski, L.E., Blackburn, K., Radde, K.M., Moyer, M.B., Schlatzer, D.M., Moseley,
A., and Boucher, R.C. (2002). A proteomic analysis of human cilia: identification of
novel components. Mol. Cell. Proteomics 1, 451–465.
49. Ostrowski, L.E., Dutcher, S.K., and Lo, C.W. (2011). Cilia and models for studying
structure and function. Proc. Am. Thorac. Soc. 8, 423–429.
50. Bustamante-Marin, X.M., and Ostrowski, L.E. (2017). Cilia and Mucociliary
Clearance. Cold Spring Harb. Perspect. Biol. 9, a028241.
51. Whitsett, J.A., and Alenghat, T. (2015). Respiratory epithelial cells orchestrate
pulmonary innate immunity. Nat. Immunol. 16, 27–35.
52. Sanderson, M.J., and Dirksen, E.R. (1986). Mechanosensitivity of cultured ciliated
cells from the mammalian respiratory tract: implications for the regulation of
mucociliary transport. Proc. Natl. Acad. Sci. USA 83, 7302–7306.
53. Shah, A.S., Ben-Shahar, Y., Moninger, T.O., Kline, J.N., and Welsh, M.J. (2009).
Motile cilia of human airway epithelia are chemosensory. Science 325, 1131–1134.
54. Horani, A., Ferkol, T.W., Dutcher, S.K., and Brody, S.L. (2016). Genetics and biology
of primary ciliary dyskinesia. Paediatr. Respir. Rev. 18, 18–24.
55. Yaghi, A., Zaman, A., Cox, G., and Dolovich, M.B. (2012). Ciliary beating is
depressed in nasal cilia from chronic obstructive pulmonary disease subjects.
Respir. Med. 106, 1139–1147.
56. Tamashiro, E., Xiong, G., Anselmo-Lima, W.T., Kreindler, J.L., Palmer, J.N., and
Cohen, N.A. (2009). Cigarette smoke exposure impairs respiratory epithelial cilio-
genesis. Am. J. Rhinol. Allergy 23, 117–122.
57. Simet, S.M., Sisson, J.H., Pavlik, J.A., Devasure, J.M., Boyer, C., Liu, X., Kawasaki, S.,
Sharp, J.G., Rennard, S.I., and Wyatt, T.A. (2010). Long-term cigarette smoke
exposure in a mouse model of ciliated epithelial cell function. Am. J. Respir. Cell
Mol. Biol. 43, 635–640.
58. Guichard, C., Harricane, M.C., Lafitte, J.J., Godard, P., Zaegel, M., Tack, V., Lalau,
G., and Bouvagnet, P. (2001). Axonemal dynein intermediate-chain gene
(DNAI1) mutations result in situs inversus and primary ciliary dyskinesia
(Kartagener syndrome). Am. J. Hum. Genet. 68, 1030–1035.
59. Olbrich, H., Häffner, K., Kispert, A., Völkel, A., Volz, A., Sasmaz, G., Reinhardt, R.,
Hennig, S., Lehrach, H., Konietzko, N., et al. (2002). Mutations in DNAH5 cause
Molecular Therapy Vol. 27 No 4 April 2019 815
www.moleculartherapy.org
Review
primary ciliary dyskinesia and randomization of left-right asymmetry. Nat. Genet.
30, 143–144.
60. Pifferi, M., Michelucci, A., Conidi, M.E., Cangiotti, A.M., Simi, P., Macchia, P., and
Boner, A.L. (2010). New DNAH11 mutations in primary ciliary dyskinesia with
normal axonemal ultrastructure. Eur. Respir. J. 35, 1413–1416.
61. Hjeij, R., Lindstrand, A., Francis, R., Zariwala, M.A., Liu, X., Li, Y., Damerla, R.,
Dougherty, G.W., Abouhamed, M., Olbrich, H., et al. (2013). ARMC4 mutations
cause primary ciliary dyskinesia with randomization of left/right body asymmetry.
Am. J. Hum. Genet. 93, 357–367.
62. Duriez, B., Duquesnoy, P., Escudier, E., Bridoux, A.M., Escalier, D., Rayet, I.,
Marcos, E., Vojtek, A.M., Bercher, J.F., and Amselem, S. (2007). A common
variant in combination with a nonsense mutation in a member of the thioredoxin
family causes primary ciliary dyskinesia. Proc. Natl. Acad. Sci. USA 104, 3336–
3341.
63. Horani, A., Druley, T.E., Zariwala, M.A., Patel, A.C., Levinson, B.T., Van Arendonk,
L.G., Thornton, K.C., Giacalone, J.C., Albee, A.J., Wilson, K.S., et al. (2012). Whole-
exome capture and sequencing identifies HEATR2 mutation as a cause of primary
ciliary dyskinesia. Am. J. Hum. Genet. 91, 685–693.
64. Olbrich, H., Schmidts, M., Werner, C., Onoufriadis, A., Loges, N.T., Raidt, J., Banki,
N.F., Shoemark, A., Burgoyne, T., Al Turki, S., et al.; UK10K Consortium (2012).
Recessive HYDIN mutations cause primary ciliary dyskinesia without randomiza-
tion of left-right body asymmetry. Am. J. Hum. Genet. 91, 672–684.
65. Merveille, A.C., Davis, E.E., Becker-Heck, A., Legendre, M., Amirav, I., Bataille, G.,
Belmont, J., Beydon, N., Billen, F., Clément, A., et al. (2011). CCDC39 is required for
assembly of inner dynein arms and the dynein regulatory complex and for normal
ciliary motility in humans and dogs. Nat. Genet. 43, 72–78.
66. Becker-Heck, A., Zohn, I.E., Okabe, N., Pollock, A., Lenhart, K.B., Sullivan-Brown,
J., McSheene, J., Loges, N.T., Olbrich, H., Haeffner, K., et al. (2011). The coiled-coil
domain containing protein CCDC40 is essential for motile cilia function and left-
right axis formation. Nat. Genet. 43, 79–84.
67. Horani, A., Brody, S.L., Ferkol, T.W., Shoseyov, D., Wasserman, M.G., Ta-shma, A.,
Wilson, K.S., Bayly, P.V., Amirav, I., Cohen-Cymberknoh, M., et al. (2013).
CCDC65 mutation causes primary ciliary dyskinesia with normal ultrastructure
and hyperkinetic cilia. PLoS ONE 8, e72299.
68. Panizzi, J.R., Becker-Heck, A., Castleman, V.H., Al-Mutairi, D.A., Liu, Y., Loges,
N.T., Pathak, N., Austin-Tse, C., Sheridan, E., Schmidts, M., et al. (2012).
CCDC103 mutations cause primary ciliary dyskinesia by disrupting assembly of
ciliary dynein arms. Nat. Genet. 44, 714–719.
69. Knowles, M.R., Leigh, M.W., Ostrowski, L.E., Huang, L., Carson, J.L., Hazucha,
M.J., Yin, W., Berg, J.S., Davis, S.D., Dell, S.D., et al.; Genetic Disorders of
Mucociliary Clearance Consortium (2013). Exome sequencing identifies mutations
in CCDC114 as a cause of primary ciliary dyskinesia. Am. J. Hum. Genet. 92,
99–106.
70. Hjeij, R., Onoufriadis, A., Watson, C.M., Slagle, C.E., Klena, N.T., Dougherty,
G.W., Kurkowiak, M., Loges, N.T., Diggle, C.P., Morante, N.F., et al.; UK10K
Consortium (2014). CCDC151 mutations cause primary ciliary dyskinesia by
disruption of the outer dynein arm docking complex formation. Am. J. Hum.
Genet. 95, 257–274.
71. Loges, N.T., Olbrich, H., Becker-Heck, A., Häffner, K., Heer, A., Reinhard, C.,
Schmidts, M., Kispert, A., Zariwala, M.A., Leigh, M.W., et al. (2009). Deletions
and point mutations of LRRC50 cause primary ciliary dyskinesia due to dynein
arm defects. Am. J. Hum. Genet. 85, 883–889.
72. Omran, H., Kobayashi, D., Olbrich, H., Tsukahara, T., Loges, N.T., Hagiwara, H.,
Zhang, Q., Leblond, G., O’Toole, E., Hara, C., et al. (2008). Ktu/PF13 is required
for cytoplasmic pre-assembly of axonemal dyneins. Nature 456, 611–616.
73. Mitchison, H.M., Schmidts, M., Loges, N.T., Freshour, J., Dritsoula, A., Hirst, R.A.,
O’Callaghan, C., Blau, H., Al Dabbagh, M., Olbrich, H., et al. (2012). Mutations in
axonemal dynein assembly factor DNAAF3 cause primary ciliary dyskinesia. Nat.
Genet. 44, 381–389.
74. Castleman, V.H., Romio, L., Chodhari, R., Hirst, R.A., de Castro, S.C., Parker, K.A.,
Ybot-Gonzalez, P., Emes, R.D., Wilson, S.W., Wallis, C., et al. (2009). Mutations
in radial spoke head protein genes RSPH9 and RSPH4A cause primary ciliary
dyskinesia with central-microtubular-pair abnormalities. Am. J. Hum. Genet. 84,
197–209.
75. Tarkar, A., Loges, N.T., Slagle, C.E., Francis, R., Dougherty, G.W., Tamayo, J.V.,
Shook, B., Cantino, M., Schwartz, D., Jahnke, C., et al.; UK10K (2013). DYX1C1
is required for axonemal dynein assembly and ciliary motility. Nat. Genet. 45,
995–1003.
76. Horani, A., Ferkol, T.W., Shoseyov, D., Wasserman, M.G., Oren, Y.S., Kerem, B.,
Amirav, I., Cohen-Cymberknoh, M., Dutcher, S.K., Brody, S.L., et al. (2013).
LRRC6 mutation causes primary ciliary dyskinesia with dynein arm defects. PLoS
ONE 8, e59436.
77. Zariwala, M.A., Gee, H.Y., Kurkowiak, M., Al-Mutairi, D.A., Leigh, M.W., Hurd,
T.W., Hjeij, R., Dell, S.D., Chaki, M., Dougherty, G.W., et al. (2013). ZMYND10
is mutated in primary ciliary dyskinesia and interacts with LRRC6. Am. J. Hum.
Genet. 93, 336–345.
78. Wallmeier, J., Al-Mutairi, D.A., Chen, C.T., Loges, N.T., Pennekamp, P., Menchen,
T., Ma, L., Shamseldin, H.E., Olbrich, H., Dougherty, G.W., et al. (2014). Mutations
in CCNO result in congenital mucociliary clearance disorder with reduced genera-
tion of multiple motile cilia. Nat. Genet. 46, 646–651.
79. Boon, M., Wallmeier, J., Ma, L., Loges, N.T., Jaspers, M., Olbrich, H., Dougherty,
G.W., Raidt, J., Werner, C., Amirav, I., et al. (2014). MCIDAS mutations result in
a mucociliary clearance disorder with reduced generation of multiple motile cilia.
Nat. Commun. 5, 4418.
80. Rokicki, W., Rokicki, M., Wojtacha, J., and D_zeljijli, A. (2016). The role and impor-
tance of club cells (Clara cells) in the pathogenesis of some respiratory diseases.
Kardiochir. Torakochirurgia Pol. 13, 26–30.
81. Zheng, D., Limmon, G.V., Yin, L., Leung, N.H., Yu, H., Chow, V.T., and Chen, J.
(2012). Regeneration of alveolar type I and II cells from Scgb1a1-expressing cells
following severe pulmonary damage induced by bleomycin and influenza. PLoS
ONE 7, e48451.
82. Zheng, D., Soh, B.S., Yin, L., Hu, G., Chen, Q., Choi, H., Han, J., Chow, V.T., and
Chen, J. (2017). Differentiation of Club Cells to Alveolar Epithelial Cells In Vitro.
Sci. Rep. 7, 41661.
83. Guseh, J.S., Bores, S.A., Stanger, B.Z., Zhou, Q., Anderson, W.J., Melton, D.A., and
Rajagopal, J. (2009). Notch signaling promotes airway mucous metaplasia and
inhibits alveolar development. Development 136, 1751–1759.
84. Roy, M.G., Rahmani, M., Hernandez, J.R., Alexander, S.N., Ehre, C., Ho, S.B., and
Evans, C.M. (2011). Mucin production during prenatal and postnatal murine
lung development. Am. J. Respir. Cell Mol. Biol. 44, 755–760.
85. Watson, J.K., Rulands, S., Wilkinson, A.C., Wuidart, A., Ousset, M., Van
Keymeulen, A., Göttgens, B., Blanpain, C., Simons, B.D., and Rawlins, E.L. (2015).
Clonal Dynamics Reveal Two Distinct Populations of Basal Cells in Slow-
Turnover Airway Epithelium. Cell Rep. 12, 90–101.
86. Boers, J.E., Ambergen, A.W., and Thunnissen, F.B. (1999). Number and prolifera-
tion of clara cells in normal human airway epithelium. Am. J. Respir. Crit. Care
Med. 159, 1585–1591.
87. Melton, K.R., Nesslein, L.L., Ikegami, M., Tichelaar, J.W., Clark, J.C., Whitsett, J.A.,
and Weaver, T.E. (2003). SP-B deficiency causes respiratory failure in adult mice.
Am. J. Physiol. Lung Cell. Mol. Physiol. 285, L543–L549.
88. Boers, J.E., den Brok, J.L., Koudstaal, J., Arends, J.W., and Thunnissen, F.B. (1996).
Number and proliferation of neuroendocrine cells in normal human airway epithe-
lium. Am. J. Respir. Crit. Care Med. 154, 758–763.
89. Noguchi, M., Sumiyama, K., and Morimoto, M. (2015). Directed Migration of
Pulmonary Neuroendocrine Cells toward Airway Branches Organizes the
Stereotypic Location of Neuroepithelial Bodies. Cell Rep. 13, 2679–2686.
90. Youngson, C., Nurse, C., Yeger, H., and Cutz, E. (1993). Oxygen sensing in airway
chemoreceptors. Nature 365, 153–155.
91. Livermore, S., Zhou, Y., Pan, J., Yeger, H., Nurse, C.A., and Cutz, E. (2015).
Pulmonary neuroepithelial bodies are polymodal airway sensors: evidence for
CO2/H+ sensing. Am. J. Physiol. Lung Cell. Mol. Physiol. 308, L807–L815.
92. Branchfield, K., Nantie, L., Verheyden, J.M., Sui, P., Wienhold, M.D., and Sun, X.
(2016). Pulmonary neuroendocrine cells function as airway sensors to control
lung immune response. Science 351, 707–710.
816 Molecular Therapy Vol. 27 No 4 April 2019
www.moleculartherapy.org
Review
93. Nevel, R.J., Garnett, E.T., Worrell, J.A., Morton, R.L., Nogee, L.M., Blackwell, T.S.,
and Young, L.R. (2016). Persistent Lung Disease in Adults with NKX2.1 Mutation
and Familial Neuroendocrine Cell Hyperplasia of Infancy. Ann. Am. Thorac. Soc.
13, 1299–1304.
94. Quigley, I.K., Stubbs, J.L., and Kintner, C. (2011). Specification of ion transport cells
in the Xenopus larval skin. Development 138, 705–714.
95. Esaki, M., Hoshijima, K., Nakamura, N., Munakata, K., Tanaka, M., Ookata, K.,
Asakawa, K., Kawakami, K., Wang, W., Weinberg, E.S., and Hirose, S. (2009).
Mechanism of development of ionocytes rich in vacuolar-type H(+)-ATPase in
the skin of zebrafish larvae. Dev. Biol. 329, 116–129.
96. Schoch, K.G., Lori, A., Burns, K.A., Eldred, T., Olsen, J.C., and Randell, S.H. (2004).
A subset of mouse tracheal epithelial basal cells generates large colonies in vitro. Am.
J. Physiol. Lung Cell. Mol. Physiol. 286, L631–L642.
97. Borthwick, D.W., Shahbazian, M., Krantz, Q.T., Dorin, J.R., and Randell, S.H.
(2001). Evidence for stem-cell niches in the tracheal epithelium. Am. J. Respir.
Cell Mol. Biol. 24, 662–670.
98. Randell, S.H., Comment, C.E., Ramaekers, F.C., and Nettesheim, P. (1991).
Properties of rat tracheal epithelial cells separated based on expression of cell surface
alpha-galactosyl end groups. Am. J. Respir. Cell Mol. Biol. 4, 544–554.
99. Siebel, C., and Lendahl, U. (2017). Notch Signaling in Development, Tissue
Homeostasis, and Disease. Physiol. Rev. 97, 1235–1294.
100. Morimoto, M., Nishinakamura, R., Saga, Y., and Kopan, R. (2012). Different assem-
blies of Notch receptors coordinate the distribution of the major bronchial Clara,
ciliated and neuroendocrine cells. Development 139, 4365–4373.
101. Morimoto, M., Liu, Z., Cheng, H.T., Winters, N., Bader, D., and Kopan, R. (2010).
Canonical Notch signaling in the developing lung is required for determination of
arterial smooth muscle cells and selection of Clara versus ciliated cell fate. J. Cell
Sci. 123, 213–224.
102. Hong, K.U., Reynolds, S.D., Watkins, S., Fuchs, E., and Stripp, B.R. (2004).
In vivo differentiation potential of tracheal basal cells: evidence for multipotent
and unipotent subpopulations. Am. J. Physiol. Lung Cell. Mol. Physiol. 286,
L643–L649.
103. Rock, J.R., Randell, S.H., and Hogan, B.L. (2010). Airway basal stem cells: a perspec-
tive on their roles in epithelial homeostasis and remodeling. Dis. Model. Mech. 3,
545–556.
104. Araya, J., Cambier, S., Markovics, J.A., Wolters, P., Jablons, D., Hill, A., Finkbeiner,
W., Jones, K., Broaddus, V.C., Sheppard, D., et al. (2007). Squamous metaplasia
amplifies pathologic epithelial-mesenchymal interactions in COPD patients.
J. Clin. Invest. 117, 3551–3562.
105. Williams, M.C. (2003). Alveolar type I cells: molecular phenotype and development.
Annu. Rev. Physiol. 65, 669–695.
106. Féréol, S., Fodil, R., Pelle, G., Louis, B., and Isabey, D. (2008). Cell mechanics of
alveolar epithelial cells (AECs) and macrophages (AMs). Respir. Physiol.
Neurobiol. 163, 3–16.
107. Hsu, H.S., Liu, C.C., Lin, J.H., Hsu, T.W., Su, K., and Hung, S.C. (2014). Repair of
naphthalene-induced acute tracheal injury by basal cells depends on b-catenin.
J. Thorac. Cardiovasc. Surg. 148, 322–332.
108. Hussein, O., Walters, B., Stroetz, R., Valencia, P., McCall, D., and Hubmayr, R.D.
(2013). Biophysical determinants of alveolar epithelial plasma membrane wounding
associated with mechanical ventilation. Am. J. Physiol. Lung Cell. Mol. Physiol. 305,
L478–L484.
109. Moldoveanu, B., Otmishi, P., Jani, P., Walker, J., Sarmiento, X., Guardiola, J., Saad,
M., andYu, J. (2009). Inflammatorymechanisms in the lung. J. Inflamm. Res. 2, 1–11.
110. Krick, S., Eul, B.G., Hänze, J., Savai, R., Grimminger, F., Seeger, W., and Rose,
F. (2005). Role of hypoxia-inducible factor-1alpha in hypoxia-induced apoptosis
of primary alveolar epithelial type II cells. Am. J. Respir. Cell Mol. Biol. 32,
395–403.
111. Clark, J.C., Wert, S.E., Bachurski, C.J., Stahlman, M.T., Stripp, B.R., Weaver, T.E.,
and Whitsett, J.A. (1995). Targeted disruption of the surfactant protein B gene
disrupts surfactant homeostasis, causing respiratory failure in newborn mice.
Proc. Natl. Acad. Sci. USA 92, 7794–7798.
112. Glasser, S.W., Burhans, M.S., Korfhagen, T.R., Na, C.L., Sly, P.D., Ross, G.F.,
Ikegami, M., and Whitsett, J.A. (2001). Altered stability of pulmonary surfactant
in SP-C-deficient mice. Proc. Natl. Acad. Sci. USA 98, 6366–6371.
113. Korfhagen, T.R., Bruno, M.D., Ross, G.F., Huelsman, K.M., Ikegami, M., Jobe, A.H.,
Wert, S.E., Stripp, B.R., Morris, R.E., Glasser, S.W., et al. (1996). Altered surfactant
function and structure in SP-A gene targeted mice. Proc. Natl. Acad. Sci. USA 93,
9594–9599.
114. Botas, C., Poulain, F., Akiyama, J., Brown, C., Allen, L., Goerke, J., Clements, J.,
Carlson, E., Gillespie, A.M., Epstein, C., and Hawgood, S. (1998). Altered surfactant
homeostasis and alveolar type II cell morphology in mice lacking surfactant protein
D. Proc. Natl. Acad. Sci. USA 95, 11869–11874.
115. Korfhagen, T.R., Sheftelyevich, V., Burhans, M.S., Bruno, M.D., Ross, G.F., Wert,
S.E., Stahlman, M.T., Jobe, A.H., Ikegami, M., Whitsett, J.A., and Fisher, J.H.
(1998). Surfactant protein-D regulates surfactant phospholipid homeostasis in vivo.
J. Biol. Chem. 273, 28438–28443.
116. Greene, K.E., Wright, J.R., Steinberg, K.P., Ruzinski, J.T., Caldwell, E., Wong, W.B.,
Hull, W., Whitsett, J.A., Akino, T., Kuroki, Y., et al. (1999). Serial changes in surfac-
tant-associated proteins in lung and serum before and after onset of ARDS. Am. J.
Respir. Crit. Care Med. 160, 1843–1850.
117. Gregory, T.J., Longmore, W.J., Moxley, M.A., Whitsett, J.A., Reed, C.R., Fowler,
A.A., 3rd, Hudson, L.D., Maunder, R.J., Crim, C., and Hyers, T.M. (1991).
Surfactant chemical composition and biophysical activity in acute respiratory
distress syndrome. J. Clin. Invest. 88, 1976–1981.
118. Chung, M.-I., Bujnis, M., Barkauskas, C.E., Kobayashi, Y., and Hogan, B.L.M.
(2018). Niche-mediated BMP/SMAD signaling regulates lung alveolar stem cell
proliferation and differentiation. Development 145, dev163014.
119. El-Badrawy, M.K., Shalabi, N.M., Mohamed, M.A., Ragab, A., and Abdelwahab,
H.W. (2016). Stem Cells and Lung Regeneration. Int. J. Stem Cells 9, 31–35.
120. Yei, S., Bachurski, C.J., Weaver, T.E., Wert, S.E., Trapnell, B.C., and Whitsett, J.A.
(1994). Adenoviral-mediated gene transfer of human surfactant protein B to respi-
ratory epithelial cells. Am. J. Respir. Cell Mol. Biol. 11, 329–336.
121. Oh, E.J., Mazzone, S.B., Canning, B.J., andWeinreich, D. (2006). Reflex regulation of
airway sympathetic nerves in guinea-pigs. J. Physiol. 573, 549–564.
122. Lynch, T.J., Anderson, P.J., Rotti, P.G., Tyler, S.R., Crooke, A.K., Choi, S.H.,
Montoro, D.T., Silverman, C.L., Shahin, W., Zhao, R., et al. (2018). Submucosal
Gland Myoepithelial Cells Are Reserve Stem Cells That Can Regenerate Mouse
Tracheal Epithelium. Cell Stem Cell 22, 653–667.e5.
123. Tata, A., Kobayashi, Y., Chow, R.D., Tran, J., Desai, A., Massri, A.J., McCord, T.J.,
Gunn, M.D., and Tata, P.R. (2018). Myoepithelial Cells of Submucosal Glands
Can Function as Reserve Stem Cells to Regenerate Airways after Injury. Cell Stem
Cell 22, 668–683.e6.
124. Kim, C.F., Jackson, E.L., Woolfenden, A.E., Lawrence, S., Babar, I., Vogel, S.,
Crowley, D., Bronson, R.T., and Jacks, T. (2005). Identification of bronchioalveolar
stem cells in normal lung and lung cancer. Cell 121, 823–835.
125. Dovey, J.S., Zacharek, S.J., Kim, C.F., and Lees, J.A. (2008). Bmi1 is critical for lung
tumorigenesis and bronchioalveolar stem cell expansion. Proc. Natl. Acad. Sci. USA
105, 11857–11862.
126. Zacharek, S.J., Fillmore, C.M., Lau, A.N., Gludish, D.W., Chou, A., Ho, J.W.,
Zamponi, R., Gazit, R., Bock, C., Jäger, N., et al. (2011). Lung stem cell self-renewal
relies on BMI1-dependent control of expression at imprinted loci. Cell Stem Cell 9,
272–281.
127. Tropea, K.A., Leder, E., Aslam, M., Lau, A.N., Raiser, D.M., Lee, J.H.,
Balasubramaniam, V., Fredenburgh, L.E., Alex Mitsialis, S., Kourembanas, S., and
Kim, C.F. (2012). Bronchioalveolar stem cells increase after mesenchymal stromal
cell treatment in a mouse model of bronchopulmonary dysplasia. Am. J. Physiol.
Lung Cell. Mol. Physiol. 302, L829–L837.
128. Rock, J.R., Barkauskas, C.E., Cronce, M.J., Xue, Y., Harris, J.R., Liang, J., Noble, P.W.,
and Hogan, B.L. (2011). Multiple stromal populations contribute to pulmonary
fibrosis without evidence for epithelial to mesenchymal transition. Proc. Natl.
Acad. Sci. USA 108, E1475–E1483.
129. Barkauskas, C.E., Cronce, M.J., Rackley, C.R., Bowie, E.J., Keene, D.R., Stripp, B.R.,
Randell, S.H., Noble, P.W., and Hogan, B.L. (2013). Type 2 alveolar cells are stem
cells in adult lung. J. Clin. Invest. 123, 3025–3036.
Molecular Therapy Vol. 27 No 4 April 2019 817
www.moleculartherapy.org
Review
130. Rawlins, E.L., Okubo, T., Xue, Y., Brass, D.M., Auten, R.L., Hasegawa, H., Wang, F.,
and Hogan, B.L. (2009). The role of Scgb1a1+ Clara cells in the long-term mainte-
nance and repair of lung airway, but not alveolar, epithelium. Cell Stem Cell 4,
525–534.
131. Whitsett, J.A., and Weaver, T.E. (2002). Hydrophobic surfactant proteins in lung
function and disease. N. Engl. J. Med. 347, 2141–2148.
132. Nogee, L.M. (2004). Alterations in SP-B and SP-C expression in neonatal lung
disease. Annu. Rev. Physiol. 66, 601–623.
133. Hartl, D., and Griese, M. (2005). Interstitial lung disease in children – genetic back-
ground and associated phenotypes. Respir. Res. 6, 32.
134. Hamvas, A. (2006). Inherited surfactant protein-B deficiency and surfactant pro-
tein-C associated disease: clinical features and evaluation. Semin. Perinatol. 30,
316–326.
135. Hallman, M., and Haataja, R. (2007). Genetic basis of respiratory distress syndrome.
Front. Biosci. 12, 2670–2682.
136. Veldhuizen, R., Nag, K., Orgeig, S., and Possmayer, F. (1998). The role of lipids in
pulmonary surfactant. Biochim. Biophys. Acta 1408, 90–108.
137. Vorbroker, D.K., Profitt, S.A., Nogee, L.M., andWhitsett, J.A. (1995). Aberrant pro-
cessing of surfactant protein C in hereditary SP-B deficiency. Am. J. Physiol. 268,
L647–L656.
138. Li, J., Ikegami, M., Na, C.L., Hamvas, A., Espinassous, Q., Chaby, R., Nogee, L.M.,
Weaver, T.E., and Johansson, J. (2004). N-terminally extended surfactant protein
(SP) C isolated from SP-B-deficient children has reduced surface activity and
inhibited lipopolysaccharide binding. Biochemistry 43, 3891–3898.
139. Polin, R.A., and Carlo, W.A.; Committee on Fetus and Newborn; American
Academy of Pediatrics (2014). Surfactant replacement therapy for preterm and
term neonates with respiratory distress. Pediatrics 133, 156–163.
140. Jobe, A., and Ikegami, M. (1987). Surfactant for the treatment of respiratory distress
syndrome. Am. Rev. Respir. Dis. 136, 1256–1275.
141. Hamvas, A., Cole, F.S., deMello, D.E., Moxley, M., Whitsett, J.A., Colten, H.R., and
Nogee, L.M. (1994). Surfactant protein B deficiency: antenatal diagnosis and
prospective treatment with surfactant replacement. J. Pediatr. 125, 356–361.
142. Kendig, J.W., Notter, R.H., Cox, C., Aschner, J.L., Benn, S., Bernstein, R.M.,
Hendricks-Munoz, K., Maniscalco, W.M., Metlay, L.A., Phelps, D.L., et al. (1988).
Surfactant replacement therapy at birth: final analysis of a clinical trial and compar-
isons with similar trials. Pediatrics 82, 756–762.
143. Soll, R.F., Hoekstra, R.E., Fangman, J.J., Corbet, A.J., Adams, J.M., James, L.S.,
Schulze, K., Oh, W., Roberts, J.D., Jr., Dorst, J.P., et al.; Ross Collaborative
Surfactant Prevention Study Group (1990). Multicenter trial of single-dose modified
bovine surfactant extract (Survanta) for prevention of respiratory distress syndrome.
Pediatrics 85, 1092–1102.
144. Walther, F.J., Hernández-Juviel, J.M., Gordon, L.M., and Waring, A.J. (2014).
Synthetic surfactant containing SP-B and SP-C mimics is superior to single-peptide
formulations in rabbits with chemical acute lung injury. PeerJ 2, e393.
145. Pfister, R.H., and Soll, R.F. (2005). New synthetic surfactants: the next generation?
Biol. Neonate 87, 338–344.
146. van Eijk, M., De Haas, C.G., and Haagsman, H.P. (1995). Quantitative analysis of
pulmonary surfactant proteins B and C. Anal. Biochem. 232, 231–237.
147. Seeger, W., Grube, C., Günther, A., and Schmidt, R. (1993). Surfactant inhibition by
plasma proteins: differential sensitivity of various surfactant preparations. Eur.
Respir. J. 6, 971–977.
148. Lukovic, D., Plasencia, I., Taberner, F.J., Salgado, J., Calvete, J.J., Pérez-Gil, J., and
Mingarro, I. (2006). Production and characterisation of recombinant forms of
human pulmonary surfactant protein C (SP-C): Structure and surface activity.
Biochim. Biophys. Acta 1758, 509–518.
149. Barnett, R.C., Lin, X., Barravecchia, M., Norman, R.A., de Mesy Bentley, K.L., Fazal,
F., Young, J.L., and Dean, D.A. (2017). Featured Article: Electroporation-mediated
gene delivery of surfactant protein B (SP-B) restores expression and improves
survival in mouse model of SP-B deficiency. Exp. Biol. Med. (Maywood) 242,
1345–1354.
150. Kormann, M.S., Hasenpusch, G., Aneja, M.K., Nica, G., Flemmer, A.W., Herber-
Jonat, S., Huppmann, M., Mays, L.E., Illenyi, M., Schams, A., et al. (2011).
Expression of therapeutic proteins after delivery of chemically modified mRNA in
mice. Nat. Biotechnol. 29, 154–157.
151. AstraZeneca. (2017). AstraZeneca and MedImmune enter strategic collaboration
with Ethris to develop mRNA therapies for respiratory diseases. https://www.
astrazeneca.com/media-centre/articles/2017/astrazeneca-and-medimmune-enter-
strategic-collaboration-with-ethris-to-develop-mrna-therapies-for-respirator-
diseases-17082017.html.
152. Robinson, D.S., Hamid, Q., Ying, S., Tsicopoulos, A., Barkans, J., Bentley, A.M.,
Corrigan, C., Durham, S.R., and Kay, A.B. (1992). Predominant TH2-like bron-
choalveolar T-lymphocyte population in atopic asthma. N. Engl. J. Med. 326,
298–304.
153. Rubin, B.K., Priftis, K.N., Schmidt, H.J., and Henke, M.O. (2014). Secretory hyper-
responsiveness and pulmonary mucus hypersecretion. Chest 146, 496–507.
154. Locksley, R.M. (2010). Asthma and allergic inflammation. Cell 140, 777–783.
155. Hellings, P.W., Kasran, A., Liu, Z., Vandekerckhove, P., Wuyts, A., Overbergh, L.,
Mathieu, C., and Ceuppens, J.L. (2003). Interleukin-17 orchestrates the granulocyte
influx into airways after allergen inhalation in a mouse model of allergic asthma.
Am. J. Respir. Cell Mol. Biol. 28, 42–50.
156. Wilson, R.H., Whitehead, G.S., Nakano, H., Free, M.E., Kolls, J.K., and Cook, D.N.
(2009). Allergic sensitization through the airway primes Th17-dependent neutro-
philia and airway hyperresponsiveness. Am. J. Respir. Crit. Care Med. 180, 720–730.
157. Barnes, P.J. (2008). Immunology of asthma and chronic obstructive pulmonary dis-
ease. Nat. Rev. Immunol. 8, 183–192.
158. Finkelman, F.D., Hogan, S.P., Hershey, G.K., Rothenberg, M.E., and Wills-Karp, M.
(2010). Importance of cytokines in murine allergic airway disease and human
asthma. J. Immunol. 184, 1663–1674.
159. Hartl, D., Koller, B., Mehlhorn, A.T., Reinhardt, D., Nicolai, T., Schendel, D.J.,
Griese, M., and Krauss-Etschmann, S. (2007). Quantitative and functional impair-
ment of pulmonary CD4+CD25hi regulatory T cells in pediatric asthma.
J. Allergy Clin. Immunol. 119, 1258–1266.
160. Karagiannidis, C., Akdis, M., Holopainen, P., Woolley, N.J., Hense, G., Rückert, B.,
Mantel, P.Y., Menz, G., Akdis, C.A., Blaser, K., and Schmidt-Weber, C.B. (2004).
Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma.
J. Allergy Clin. Immunol. 114, 1425–1433.
161. Zuany-Amorim, C., Sawicka, E., Manlius, C., Le Moine, A., Brunet, L.R., Kemeny,
D.M., Bowen, G., Rook, G., and Walker, C. (2002). Suppression of airway eosino-
philia by killed Mycobacterium vaccae-induced allergen-specific regulatory T-cells.
Nat. Med. 8, 625–629.
162. Arnold, I.C., Dehzad, N., Reuter, S., Martin, H., Becher, B., Taube, C., andMüller, A.
(2011). Helicobacter pylori infection prevents allergic asthma in mouse models
through the induction of regulatory T cells. J. Clin. Invest. 121, 3088–3093.
163. Doganci, A., Eigenbrod, T., Krug, N., De Sanctis, G.T., Hausding, M., Erpenbeck,
V.J., Haddad, B., Lehr, H.A., Schmitt, E., Bopp, T., et al. (2005). The IL-6R alpha
chain controls lung CD4+CD25+ Treg development and function during allergic
airway inflammation in vivo. J. Clin. Invest. 115, 313–325.
164. Hammad, H., Kool, M., Soullié, T., Narumiya, S., Trottein, F., Hoogsteden, H.C., and
Lambrecht, B.N. (2007). Activation of the D prostanoid 1 receptor suppresses
asthma by modulation of lung dendritic cell function and induction of regulatory
T cells. J. Exp. Med. 204, 357–367.
165. Schreiber, T.H., Wolf, D., Tsai, M.S., Chirinos, J., Deyev, V.V., Gonzalez, L., Malek,
T.R., Levy, R.B., and Podack, E.R. (2010). Therapeutic Treg expansion in mice by
TNFRSF25 prevents allergic lung inflammation. J. Clin. Invest. 120, 3629–3640.
166. Mays, L.E., Ammon-Treiber, S., Mothes, B., Alkhaled, M., Rottenberger, J., Müller-
Hermelink, E.S., Grimm, M., Mezger, M., Beer-Hammer, S., von Stebut, E., et al.
(2013). Modified Foxp3 mRNA protects against asthma through an IL-10-depen-
dent mechanism. J. Clin. Invest. 123, 1216–1228.
167. Curiel, T.J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-
Hogan, M., Conejo-Garcia, J.R., Zhang, L., Burow, M., et al. (2004). Specific recruit-
ment of regulatory T cells in ovarian carcinoma fosters immune privilege and
predicts reduced survival. Nat. Med. 10, 942–949.
818 Molecular Therapy Vol. 27 No 4 April 2019
www.moleculartherapy.org
Review
168. Belkaid, Y., Piccirillo, C.A., Mendez, S., Shevach, E.M., and Sacks, D.L. (2002).
CD4+CD25+ regulatory T cells control Leishmania major persistence and immu-
nity. Nature 420, 502–507.
169. Kormann, M.S., Depner, M., Hartl, D., Klopp, N., Illig, T., Adamski, J., Vogelberg,
C., Weiland, S.K., von Mutius, E., and Kabesch, M. (2008). Toll-like receptor heter-
odimer variants protect from childhood asthma. J. Allergy Clin. Immunol. 122,
86–92.
170. Zeyer, F., Mothes, B., Will, C., Carevic, M., Rottenberger, J., Nürnberg, B., Hartl, D.,
Handgretinger, R., Beer-Hammer, S., and Kormann, M.S. (2016). mRNA-Mediated
Gene Supplementation of Toll-Like Receptors as Treatment Strategy for Asthma
In Vivo. PLoS ONE 11, e0154001.
171. Kreda, S.M., Davis, C.W., and Rose, M.C. (2012). CFTR, mucins, and mucus
obstruction in cystic fibrosis. Cold Spring Harb. Perspect. Med. 2, a009589.
172. Masood, A., Yi, M., Belcastro, R., Li, J., Lopez, L., Kantores, C., Jankov, R.P., and
Tanswell, A.K. (2015). Neutrophil elastase-induced elastin degradation mediates
macrophage influx and lung injury in 60% O2-exposed neonatal rats. Am. J.
Physiol. Lung Cell. Mol. Physiol. 309, L53–L62.
173. Du, M., Liu, X., Welch, E.M., Hirawat, S., Peltz, S.W., and Bedwell, D.M. (2008).
PTC124 is an orally bioavailable compound that promotes suppression of the
human CFTR-G542X nonsense allele in a CF mouse model. Proc. Natl. Acad. Sci.
USA 105, 2064–2069.
174. Aslam, A.A., Higgins, C., Sinha, I.P., and Southern, K.W. (2017). Ataluren and
similar compounds (specific therapies for premature termination codon class I
mutations) for cystic fibrosis. Cochrane Database Syst. Rev. 1, CD012040.
175. Mayer, M. (2016). Lumacaftor-ivacaftor (Orkambi) for cystic fibrosis: behind the
‘breakthrough’. Evid. Based Med. 21, 83–86.
176. Rowe, S.M., Daines, C., Ringshausen, F.C., Kerem, E., Wilson, J., Tullis, E., Nair, N.,
Simard, C., Han, L., Ingenito, E.P., et al. (2017). Tezacaftor-Ivacaftor in Residual-
Function Heterozygotes with Cystic Fibrosis. N. Engl. J. Med. 377, 2024–2035.
177. Sermet-Gaudelus, I., Clancy, J.P., Nichols, D.P., Nick, J.A., De Boeck, K., Solomon,
G.M., Mall, M.A., Bolognese, J., Bouisset, F., den Hollander, W., et al. (2018).
Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic
fibrosis. J. Cyst. Fibros. , Published online November 19, 2018. https://doi.org/10.
1016/j.jcf.2018.10.015.
178. Ramjeesingh,M., Huan, L.J., Wilschanski, M., Durie, P., Li, C., Gyomorey, K.,Wang,
Y., Kent, G., Tanswell, K.A., Cutz, E., et al. (1998). Assessment of the efficacy of
in vivo CFTR protein replacement therapy in CFmice. Hum. Gene Ther. 9, 521–528.
179. Alton, E.W.F.W., Armstrong, D.K., Ashby, D., Bayfield, K.J., Bilton, D., Bloomfield,
E.V., Boyd, A.C., Brand, J., Buchan, R., Calcedo, R., et al.; UK Cystic Fibrosis Gene
Therapy Consortium (2015). Repeated nebulisation of non-viral CFTR gene therapy
in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled,
phase 2b trial. Lancet Respir. Med. 3, 684–691.
180. Alton, E.W.F.W., Armstrong, D.K., Ashby, D., Bayfield, K.J., Bilton, D., Bloomfield,
E.V., Boyd, A.C., Brand, J., Buchan, R., Calcedo, R., et al. (2016). A randomised, dou-
ble-blind, placebo-controlled trial of repeated nebulisation of non-viral cystic
fibrosis transmembrane conductance regulator (CFTR) gene therapy in patients
with cystic fibrosis. Efficacy and Mechanism Evaluation 3, 1–240.
181. Robinson, E., MacDonald, K.D., Slaughter, K., McKinney, M., Patel, S., Sun, C., and
Sahay, G. (2018). Lipid Nanoparticle-Delivered Chemically Modified mRNA
Restores Chloride Secretion in Cystic Fibrosis. Mol. Ther. 26, 2034–2046.
182. Bangel-Ruland, N., Tomczak, K., Fernández Fernández, E., Leier, G., Leciejewski, B.,
Rudolph, C., Rosenecker, J., and Weber, W.M. (2013). Cystic fibrosis transmem-
brane conductance regulator-mRNA delivery: a novel alternative for cystic fibrosis
gene therapy. J. Gene Med. 15, 414–426.
183. Suzuki, M., Sze, M.A., Campbell, J.D., Brothers, J.F., 2nd, Lenburg, M.E.,
McDonough, J.E., Elliott, W.M., Cooper, J.D., Spira, A., and Hogg, J.C. (2017).
The cellular and molecular determinants of emphysematous destruction in
COPD. Sci. Rep. 7, 9562.
184. Laurell, C.B., and Eriksson, S. (2013). The electrophoretic a1-globulin pattern of
serum in a1-antitrypsin deficiency. 1963. COPD 10 (Suppl 1 ), 3–8.
185. Gadek, J.E., Fells, G.A., Zimmerman, R.L., Rennard, S.I., and Crystal, R.G. (1981).
Antielastases of the human alveolar structures. Implications for the protease-
antiprotease theory of emphysema. J. Clin. Invest. 68, 889–898.
186. Lomas, D.A., Evans, D.L., Finch, J.T., and Carrell, R.W. (1992). The mechanism of Z
alpha 1-antitrypsin accumulation in the liver. Nature 357, 605–607.
187. Escribano, A., Amor, M., Pastor, S., Castillo, S., Sanz, F., Codoñer-Franch, P., and
Dasí, F. (2015). Decreased glutathione and low catalase activity contribute to oxida-
tive stress in children with a-1 antitrypsin deficiency. Thorax 70, 82–83.
188. Escribano, A., Pastor, S., Reula, A., Castillo, S., Vicente, S., Sanz, F., Casas, F., Torres,
M., Fernández-Fabrellas, E., Codoñer-Franch, P., and Dasí, F. (2016). Accelerated
telomere attrition in children and teenagers with a1-antitrypsin deficiency. Eur.
Respir. J. 48, 350–358.
189. Alam, S., Li, Z., Janciauskiene, S., and Mahadeva, R. (2011). Oxidation of Z a1-anti-
trypsin by cigarette smoke induces polymerization: a novel mechanism of early-
onset emphysema. Am. J. Respir. Cell Mol. Biol. 45, 261–269.
190. Ronzoni, R., Berardelli, R., Medicina, D., Sitia, R., Gooptu, B., and Fra, A.M. (2016).
Aberrant disulphide bonding contributes to the ER retention of alpha1-antitrypsin
deficiency variants. Hum. Mol. Genet. 25, 642–650.
191. Pittschieler, K. (1993). Vitamin E and liver damage inMZ heterozygous infants with
alpha 1-antitrypsin deficiency. Acta Paediatr. 82, 228–232.
192. Kode, A., Rajendrasozhan, S., Caito, S., Yang, S.R., Megson, I.L., and Rahman, I.
(2008). Resveratrol induces glutathione synthesis by activation of Nrf2 and protects
against cigarette smoke-mediated oxidative stress in human lung epithelial cells.
Am. J. Physiol. Lung Cell. Mol. Physiol. 294, L478–L488.
193. Novoradovsky, A., Brantly, M.L., Waclawiw, M.A., Chaudhary, P.P., Ihara, H., Qi,
L., Eissa, N.T., Barnes, P.M., Gabriele, K.M., Ehrmantraut, M.E., et al. (1999).
Endothelial nitric oxide synthase as a potential susceptibility gene in the pathogen-
esis of emphysema in alpha1-antitrypsin deficiency. Am. J. Respir. Cell Mol. Biol. 20,
441–447.
194. Topic, A., Nagorni-Obradovic, L., Francuski, D., Ljujic, M.,Malic, Z., and Radojkovic,
D. (2016). Oxidative Stress and Polymorphism of Xenobiotic-Metabolizing Enzymes
in Two Patients with Severe Alpha-1-Antitrypsin Deficiency. Biochem. Genet. 54,
746–752.
195. Wood, A.M., Simmonds, M.J., Bayley, D.L., Newby, P.R., Gough, S.C., and Stockley,
R.A. (2008). The TNFalpha gene relates to clinical phenotype in alpha-1-antitrypsin
deficiency. Respir. Res. 9, 52.
196. Kim, W.J., Wood, A.M., Barker, A.F., Brantly, M.L., Campbell, E.J., Eden, E.,
McElvaney, G., Rennard, S.I., Sandhaus, R.A., Stocks, J.M., et al. (2012).
Association of IREB2 and CHRNA3 polymorphisms with airflow obstruction in
severe alpha-1 antitrypsin deficiency. Respir. Res. 13, 16.
197. Wewers, M.D., Gadek, J.E., Keogh, B.A., Fells, G.A., and Crystal, R.G. (1986).
Evaluation of danazol therapy for patients with PiZZ alpha-1-antitrypsin deficiency.
Am. Rev. Respir. Dis. 134, 476–480.
198. Mallya, M., Phillips, R.L., Saldanha, S.A., Gooptu, B., Brown, S.C., Termine, D.J.,
Shirvani, A.M., Wu, Y., Sifers, R.N., Abagyan, R., and Lomas, D.A. (2007). Small
molecules block the polymerization of Z alpha1-antitrypsin and increase the clear-
ance of intracellular aggregates. J. Med. Chem. 50, 5357–5363.
199. Mahadeva, R., Dafforn, T.R., Carrell, R.W., and Lomas, D.A. (2002). 6-mer peptide
selectively anneals to a pathogenic serpin conformation and blocks polymerization.
Implications for the prevention of Z alpha(1)-antitrypsin-related cirrhosis. J. Biol.
Chem. 277, 6771–6774.
200. Hidvegi, T., Ewing, M., Hale, P., Dippold, C., Beckett, C., Kemp, C., Maurice, N.,
Mukherjee, A., Goldbach, C., Watkins, S., et al. (2010). An autophagy-enhancing
drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic
fibrosis. Science 329, 229–232.
201. Maurice, N., and Perlmutter, D.H. (2012). Novel treatment strategies for liver
disease due to a1-antitrypsin deficiency. Clin. Transl. Sci. 5, 289–294.
202. Kaushal, S., Annamali, M., Blomenkamp, K., Rudnick, D., Halloran, D., Brunt, E.M.,
and Teckman, J.H. (2010). Rapamycin reduces intrahepatic alpha-1-antitrypsin
mutant Z protein polymers and liver injury in a mouse model. Exp. Biol. Med.
(Maywood) 235, 700–709.
203. Hassan, T., Carroll, T.P., Buckley, P.G., Cummins, R., O’Neill, S.J., McElvaney, N.G.,
and Greene, C.M. (2014). miR-199a-5p silencing regulates the unfolded protein
response in chronic obstructive pulmonary disease and a1-antitrypsin deficiency.
Am. J. Respir. Crit. Care Med. 189, 263–273.
Molecular Therapy Vol. 27 No 4 April 2019 819
www.moleculartherapy.org
Review
204. Nana-Sinkam, S.P., and Choi, A.M. (2014). Epigenetics and the unfolded protein
response in the lung: emerging role for microRNAs. Am. J. Respir. Crit. Care
Med. 189, 239–240.
205. Esquinas, C., Janciauskiene, S., Gonzalo, R., Mas de Xaxars, G., Olejnicka, B.,
Belmonte, I., Barrecheguren, M., Rodriguez, E., Nuñez, A., Rodriguez-Frias, F.,
and Miravitlles, M. (2017). Gene and miRNA expression profiles in PBMCs from
patients with severe and mild emphysema and PiZZ alpha1-antitrypsin deficiency.
Int. J. Chron. Obstruct. Pulmon. Dis. 12, 3381–3390.
206. Stoller, J.K., Rouhani, F., Brantly, M., Shahin, S., Dweik, R.A., Stocks, J.M., Clausen,
J., Campbell, E., and Norton, F. (2002). Biochemical efficacy and safety of a new
pooled human plasma alpha(1)-antitrypsin, Respitin. Chest 122, 66–74.
207. Sandhaus, R.A. (1993). Alpha 1-antitrypsin augmentation therapy. Agents Actions
Suppl. 42, 97–102.
208. Chapman, K.R., Burdon, J.G., Piitulainen, E., Sandhaus, R.A., Seersholm, N., Stocks,
J.M., Stoel, B.C., Huang, L., Yao, Z., Edelman, J.M., and McElvaney, N.G.; RAPID
Trial Study Group (2015). Intravenous augmentation treatment and lung density
in severe a1 antitrypsin deficiency (RAPID): a randomised, double-blind, pla-
cebo-controlled trial. Lancet 386, 360–368.
209. Chiuchiolo, M.J., and Crystal, R.G. (2016). Gene Therapy for Alpha-1 Antitrypsin
Deficiency Lung Disease. Ann. Am. Thorac. Soc. 13 (Suppl 4 ), S352–S369.
210. Chiuchiolo, M.J., Kaminsky, S.M., Sondhi, D., Mancenido, D., Hollmann, C., and
Crystal, R.G. (2014). Phase I/II study of intrapleural administration of a serotype
rh.10 replication-deficient adeno-associated virus gene transfer vector expressing
the human a1-antitrypsin cDNA to individuals with a1-antitrypsin deficiency.
Hum. Gene Ther. Clin. Dev. 25, 112–133.
211. Michel, T., Kankura, A., Salinas Medina, M.L., Kurz, J., Behring, A., Avci-Adali, M.,
Nolte, A., Schlensak, C., Wendel, H.P., and Krajewski, S. (2015). In Vitro Evaluation
of a Novel mRNA-Based Therapeutic Strategy for the Treatment of Patients
Suffering from Alpha-1-Antitrypsin Deficiency. Nucleic Acid Ther. 25, 235–244.
212. Karikó, K., Kuo, A., and Barnathan, E. (1999). Overexpression of urokinase receptor
in mammalian cells following administration of the in vitro transcribed encoding
mRNA. Gene Ther. 6, 1092–1100.
213. Kallen, K.J., and Theß, A. (2014). A development that may evolve into a revolution
in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs.
Ther. Adv. Vaccines 2, 10–31.
214. Svitkin, Y.V., Cheng, Y.M., Chakraborty, T., Presnyak, V., John, M., and Sonenberg,
N. (2017). N1-methyl-pseudouridine in mRNA enhances translation through
eIF2a-dependent and independent mechanisms by increasing ribosome density.
Nucleic Acids Res. 45, 6023–6036.
215. Vaidyanathan, S., Azizian, K.T., Haque, A.K.M.A., Henderson, J.M., Hendel, A.,
Shore, S., Antony, J.S., Hogrefe, R.I., Kormann, M.S.D., Porteus, M.H., and
McCaffrey, A.P. (2018). Uridine Depletion and Chemical Modification Increase
Cas9 mRNA Activity and Reduce Immunogenicity without HPLC Purification.
Mol. Ther. Nucleic Acids 12, 530–542.
216. Filipowicz, W., Furuichi, Y., Sierra, J.M., Muthukrishnan, S., Shatkin, A.J., and
Ochoa, S. (1976). A protein binding the methylated 50-terminal sequence,
m7GpppN, of eukaryotic messenger RNA. Proc. Natl. Acad. Sci. USA 73, 1559–
1563.
217. van Dijk, E., Cougot, N., Meyer, S., Babajko, S., Wahle, E., and Séraphin, B. (2002).
Human Dcp2: a catalytically active mRNA decapping enzyme located in specific
cytoplasmic structures. EMBO J. 21, 6915–6924.
218. Liu, H., Rodgers, N.D., Jiao, X., and Kiledjian, M. (2002). The scavenger mRNA de-
capping enzyme DcpS is a member of the HIT family of pyrophosphatases. EMBO J.
21, 4699–4708.
219. Mazza, C., Segref, A., Mattaj, I.W., and Cusack, S. (2002). Large-scale induced fit
recognition of an m(7)GpppG cap analogue by the human nuclear cap-binding
complex. EMBO J. 21, 5548–5557.
220. Stepinski, J., Waddell, C., Stolarski, R., Darzynkiewicz, E., and Rhoads, R.E. (2001).
Synthesis and properties of mRNAs containing the novel “anti-reverse” cap analogs
7-methyl(30-O-methyl)GpppG and 7-methyl (30-deoxy)GpppG. RNA 7, 1486–
1495.
221. Furuichi, Y., and Shatkin, A.J. (2000). Viral and cellular mRNA capping: past and
prospects. Adv. Virus Res. 55, 135–184.
222. Katibah, G.E., Qin, Y., Sidote, D.J., Yao, J., Lambowitz, A.M., and Collins, K. (2014).
Broad and adaptable RNA structure recognition by the human interferon-induced
tetratricopeptide repeat protein IFIT5. Proc. Natl. Acad. Sci. USA 111, 12025–12030.
223. Abbas, Y.M., Laudenbach, B.T., Martínez-Montero, S., Cencic, R., Habjan, M.,
Pichlmair, A., Damha, M.J., Pelletier, J., and Nagar, B. (2017). Structure of human
IFIT1 with capped RNA reveals adaptable mRNA binding and mechanisms for
sensing N1 and N2 ribose 20-O methylations. Proc. Natl. Acad. Sci. USA 114,
E2106–E2115.
224. Schoggins, J.W. (2015). A Sense of Self: RIG-I’s Tolerance to Host RNA. Immunity
43, 1–2.
225. Körner, C.G., and Wahle, E. (1997). Poly(A) tail shortening by a mammalian
poly(A)-specific 30-exoribonuclease. J. Biol. Chem. 272, 10448–10456.
226. Quabius, E.S., and Krupp, G. (2015). Synthetic mRNAs for manipulating cellular
phenotypes: an overview. N. Biotechnol. 32, 229–235.
227. Bergman, N., Moraes, K.C., Anderson, J.R., Zaric, B., Kambach, C., Schneider, R.J.,
Wilusz, C.J., andWilusz, J. (2007). Lsm proteins bind and stabilize RNAs containing
50 poly(A) tracts. Nat. Struct. Mol. Biol. 14, 824–831.
228. Chen, C.Y., and Shyu, A.B. (1995). AU-rich elements: characterization and impor-
tance in mRNA degradation. Trends Biochem. Sci. 20, 465–470.
229. Machnicka, M.A., Milanowska, K., Osman Oglou, O., Purta, E., Kurkowska, M.,
Olchowik, A., Januszewski, W., Kalinowski, S., Dunin-Horkawicz, S., Rother,
K.M., et al. (2013). MODOMICS: a database of RNA modification pathways–
2013 update. Nucleic Acids Res. 41, D262–D267.
230. Karikó, K., Buckstein, M., Ni, H., and Weissman, D. (2005). Suppression of RNA
recognition by Toll-like receptors: the impact of nucleoside modification and the
evolutionary origin of RNA. Immunity 23, 165–175.
231. Karikó, K., Muramatsu, H., Keller, J.M., and Weissman, D. (2012). Increased eryth-
ropoiesis in mice injected with submicrogram quantities of pseudouridine-contain-
ing mRNA encoding erythropoietin. Mol. Ther. 20, 948–953.
232. Huang, H.,Weng, H., Sun,W., Qin, X., Shi, H.,Wu, H., Zhao, B.S., Mesquita, A., Liu,
C., Yuan, C.L., et al. (2018). Recognition of RNA N6-methyladenosine by IGF2BP
proteins enhances mRNA stability and translation. Nat. Cell Biol. 20, 285–295.
233. Warren, L., Manos, P.D., Ahfeldt, T., Loh, Y.H., Li, H., Lau, F., Ebina, W., Mandal,
P.K., Smith, Z.D., Meissner, A., et al. (2010). Highly efficient reprogramming to
pluripotency and directed differentiation of human cells with synthetic modified
mRNA. Cell Stem Cell 7, 618–630.
234. Durbin, A.F., Wang, C., Marcotrigiano, J., and Gehrke, L. (2016). RNAs Containing
Modified Nucleotides Fail To Trigger RIG-I Conformational Changes for Innate
Immune Signaling. MBio 7, e00833-16.
235. Anderson, B.R., Muramatsu, H., Nallagatla, S.R., Bevilacqua, P.C., Sansing, L.H.,
Weissman, D., and Karikó, K. (2010). Incorporation of pseudouridine into
mRNA enhances translation by diminishing PKR activation. Nucleic Acids Res.
38, 5884–5892.
236. Yang, X., Yang, Y., Sun, B.-F., Chen, Y.-S., Xu, J.-W., Lai, W.-Y., Li, A., Wang, X.,
Bhattarai, D.P., Xiao, W., et al. (2017). 5-methylcytosine promotes mRNA export
- NSUN2 as the methyltransferase and ALYREF as an m5C reader. Cell Res. 27,
606–625.
237. Anderson, B.R., Muramatsu, H., Jha, B.K., Silverman, R.H., Weissman, D., and
Karikó, K. (2011). Nucleoside modifications in RNA limit activation of 20-50-oligoa-
denylate synthetase and increase resistance to cleavage by RNase L. Nucleic Acids
Res. 39, 9329–9338.
238. Andries, O., Mc Cafferty, S., De Smedt, S.C., Weiss, R., Sanders, N.N., and Kitada, T.
(2015). N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouri-
dine-incorporated mRNA by providing enhanced protein expression and reduced
immunogenicity in mammalian cell lines andmice. J. Control. Release 217, 337–344.
239. Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B.L., Tam, Y.K., Madden,
T.D., Hope, M.J., andWeissman, D. (2015). Expression kinetics of nucleoside-modi-
fied mRNA delivered in lipid nanoparticles to mice by various routes. J. Control.
Release 217, 345–351.
240. Thess, A., Grund, S., Mui, B.L., Hope, M.J., Baumhof, P., Fotin-Mleczek, M., and
Schlake, T. (2015). Sequence-engineered mRNA Without Chemical Nucleoside
820 Molecular Therapy Vol. 27 No 4 April 2019
www.moleculartherapy.org
Review
Modifications Enables an Effective Protein Therapy in Large Animals. Mol. Ther. 23,
1456–1464.
241. Ely, L., Roa,W., Finlay,W.H., and Löbenberg, R. (2007). Effervescent dry powder for
respiratory drug delivery. Eur. J. Pharm. Biopharm. 65, 346–353.
242. Grenha, A., Seijo, B., and Remuñán-López, C. (2005). Microencapsulated chitosan
nanoparticles for lung protein delivery. Eur. J. Pharm. Sci. 25, 427–437.
243. Yamamoto, H., Kuno, Y., Sugimoto, S., Takeuchi, H., and Kawashima, Y. (2005).
Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery
of calcitonin by mucoadhesion and opening of the intercellular tight junctions.
J. Control. Release 102, 373–381.
244. McConville, J.T., Overhoff, K.A., Sinswat, P., Vaughn, J.M., Frei, B.L., Burgess, D.S.,
Talbert, R.L., Peters, J.I., Johnston, K.P., and Williams, R.O., 3rd (2006). Targeted
high lung concentrations of itraconazole using nebulized dispersions in a murine
model. Pharm. Res. 23, 901–911.
245. Kreuter, J., Täuber, U., and Illi, V. (1979). Distribution and elimination of poly
(methyl-2-14C-methacrylate) nanoparticle radioactivity after injection in rats and
mice. J. Pharm. Sci. 68, 1443–1447.
246. Green, M.R., Manikhas, G.M., Orlov, S., Afanasyev, B., Makhson, A.M., Bhar, P., and
Hawkins, M.J. (2006). Abraxane, a novel Cremophor-free, albumin-bound particle
form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann.
Oncol. 17, 1263–1268.
247. Kreuter, J. (1983). Evaluation of nanoparticles as drug-delivery systems. III: mate-
rials, stability, toxicity, possibilities of targeting, and use. Pharm. Acta Helv. 58,
242–250.
248. Shalgunov, V., Zaytseva-Zotova, D., Zintchenko, A., Levada, T., Shilov, Y.,
Andreyev, D., Dzhumashev, D., Metelkin, E., Urusova, A., Demin, O., et al.
(2017). Comprehensive study of the drug delivery properties of poly(l-lactide)-
poly(ethylene glycol) nanoparticles in rats and tumor-bearing mice. J. Control.
Release 261, 31–42.
249. Wang, T., Upponi, J.R., and Torchilin, V.P. (2012). Design of multifunctional non-
viral gene vectors to overcome physiological barriers: dilemmas and strategies. Int. J.
Pharm. 427, 3–20.
250. Sahin, U., Karikó, K., and Türeci, Ö. (2014). mRNA-based therapeutics–developing
a new class of drugs. Nat. Rev. Drug Discov. 13, 759–780.
251. Sanders, N., Rudolph, C., Braeckmans, K., De Smedt, S.C., and Demeester, J. (2009).
Extracellular barriers in respiratory gene therapy. Adv. Drug Deliv. Rev. 61,
115–127.
252. Bosquillon, C., Lombry, C., Préat, V., and Vanbever, R. (2001). Influence of formu-
lation excipients and physical characteristics of inhalation dry powders on their
aerosolization performance. J. Control. Release 70, 329–339.
253. Newman, S.P. (1985). Aerosol deposition considerations in inhalation therapy.
Chest 88 (2, Suppl), 152S–160S.
254. Wine, J.J. (1999). The genesis of cystic fibrosis lung disease. J. Clin. Invest. 103,
309–312.
255. Widdicombe, J.G. (1997). Airway liquid: a barrier to drug diffusion? Eur. Respir. J.
10, 2194–2197.
256. Button, B., Cai, L.H., Ehre, C., Kesimer, M., Hill, D.B., Sheehan, J.K., Boucher, R.C.,
and Rubinstein, M. (2012). A periciliary brush promotes the lung health by sepa-
rating the mucus layer from airway epithelia. Science 337, 937–941.
257. Yeates, D.B., Aspin, N., Levison, H., Jones, M.T., and Bryan, A.C. (1975).
Mucociliary tracheal transport rates in man. J. Appl. Physiol. 39, 487–495.
258. Sanders, N.N., De Smedt, S.C., Van Rompaey, E., Simoens, P., De Baets, F., and
Demeester, J. (2000). Cystic fibrosis sputum: a barrier to the transport of nano-
spheres. Am. J. Respir. Crit. Care Med. 162, 1905–1911.
259. Dawson, M., Wirtz, D., and Hanes, J. (2003). Enhanced viscoelasticity of human
cystic fibrotic sputum correlates with increasing microheterogeneity in particle
transport. J. Biol. Chem. 278, 50393–50401.
260. Broughton-Head, V.J., Smith, J.R., Shur, J., and Shute, J.K. (2007). Actin limits
enhancement of nanoparticle diffusion through cystic fibrosis sputum by muco-
lytics. Pulm. Pharmacol. Ther. 20, 708–717.
261. Stern, M., Caplen, N.J., Browning, J.E., Griesenbach, U., Sorgi, F., Huang, L.,
Gruenert, D.C., Marriot, C., Crystal, R.G., Geddes, D.M., and Alton, E.W. (1998).
The effect of mucolytic agents on gene transfer across a CF sputum barrier
in vitro. Gene Ther. 5, 91–98.
262. Kitson, C., Angel, B., Judd, D., Rothery, S., Severs, N.J., Dewar, A., Huang, L.,
Wadsworth, S.C., Cheng, S.H., Geddes, D.M., and Alton, E.W. (1999). The extra-
and intracellular barriers to lipid and adenovirus-mediated pulmonary gene transfer
in native sheep airway epithelium. Gene Ther. 6, 534–546.
263. Ferrari, S., Kitson, C., Farley, R., Steel, R., Marriott, C., Parkins, D.A., Scarpa, M.,
Wainwright, B., Evans, M.J., Colledge, W.H., et al. (2001). Mucus altering agents
as adjuncts for nonviral gene transfer to airway epithelium. Gene Ther. 8, 1380–
1386.
264. Ernst, N., Ulrichskötter, S., Schmalix, W.A., Rädler, J., Galneder, R., Mayer, E.,
Gersting, S., Plank, C., Reinhardt, D., and Rosenecker, J. (1999). Interaction of
liposomal and polycationic transfection complexes with pulmonary surfactant.
J. Gene Med. 1, 331–340.
265. Kukowska-Latallo, J.F., Chen, C., Eichman, J., Bielinska, A.U., and Baker, J.R., Jr.
(1999). Enhancement of dendrimer-mediated transfection using synthetic lung sur-
factant exosurf neonatal in vitro. Biochem. Biophys. Res. Commun. 264, 253–261.
266. Sanders, N.N., Van Rompaey, E., De Smedt, S.C., and Demeester, J. (2002). On the
transport of lipoplexes through cystic fibrosis sputum. Pharm. Res. 19, 451–456.
267. King, M., and Rubin, B.K. (2002). Pharmacological approaches to discovery and
development of new mucolytic agents. Adv. Drug Deliv. Rev. 54, 1475–1490.
268. Rubin, B.K. (2007). Mucolytics, expectorants, and mucokinetic medications. Respir.
Care 52, 859–865.
269. Sanders, N.N., De Smedt, S.C., Cheng, S.H., and Demeester, J. (2002). Pegylated
GL67 lipoplexes retain their gene transfection activity after exposure to components
of CF mucus. Gene Ther. 9, 363–371.
270. Maisel, K., Reddy, M., Xu, Q., Chattopadhyay, S., Cone, R., Ensign, L.M., and Hanes,
J. (2016). Nanoparticles coated with high molecular weight PEG penetrate mucus
and provide uniform vaginal and colorectal distribution in vivo. Nanomedicine
(Lond.) 11, 1337–1343.
271. Neumann, E., Schaefer-Ridder, M., Wang, Y., and Hofschneider, P.H. (1982). Gene
transfer into mouse lyoma cells by electroporation in high electric fields. EMBO J. 1,
841–845.
272. Mattozzi, M.D., Voges, M.J., Silver, P.A., and Way, J.C. (2014). Transient gene
expression in tobacco using Gibson assembly and the Gene Gun. J. Vis. Exp. (86),
51234.
273. Celis, J.E. (1984). Expression of mRNAs microinjected into somatic cells. Ciba
Found. Symp. 103, 220–238.
274. Dewitte, H., Van Lint, S., Heirman, C., Thielemans, K., De Smedt, S.C., Breckpot, K.,
and Lentacker, I. (2014). The potential of antigen and TriMix sonoporation using
mRNA-loaded microbubbles for ultrasound-triggered cancer immunotherapy.
J. Control. Release 194, 28–36.
275. Islam, M.A., Reesor, E.K., Xu, Y., Zope, H.R., Zetter, B.R., and Shi, J. (2015).
Biomaterials for mRNA delivery. Biomater. Sci. 3, 1519–1533.
276. Hajj, K.A., and Whitehead, K.A. (2017). Tools for translation: non-viral materials
for therapeutic mRNA delivery. Nat. Rev. Mater. 2, 17056.
277. Yin, H., Kanasty, R.L., Eltoukhy, A.A., Vegas, A.J., Dorkin, J.R., and Anderson, D.G.
(2014). Non-viral vectors for gene-based therapy. Nat. Rev. Genet. 15, 541–555.
278. Deering, R.P., Kommareddy, S., Ulmer, J.B., Brito, L.A., and Geall, A.J. (2014).
Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines. Expert
Opin. Drug Deliv. 11, 885–899.
279. Phua, K.K., Leong, K.W., and Nair, S.K. (2013). Transfection efficiency and trans-
gene expression kinetics of mRNA delivered in naked and nanoparticle format.
J. Control. Release 166, 227–233.
280. Khalil, I.A., Kogure, K., Akita, H., and Harashima, H. (2006). Uptake pathways and
subsequent intracellular trafficking in nonviral gene delivery. Pharmacol. Rev. 58,
32–45.
281. Lonez, C., Vandenbranden, M., and Ruysschaert, J.M. (2012). Cationic lipids
activate intracellular signaling pathways. Adv. Drug Deliv. Rev. 64, 1749–1758.
Molecular Therapy Vol. 27 No 4 April 2019 821
www.moleculartherapy.org
Review
282. Noble, G.T., Stefanick, J.F., Ashley, J.D., Kiziltepe, T., and Bilgicer, B. (2014). Ligand-
targeted liposome design: challenges and fundamental considerations. Trends
Biotechnol. 32, 32–45.
283. Zangi, L., Lui, K.O., von Gise, A., Ma, Q., Ebina,W., Ptaszek, L.M., Später, D., Xu, H.,
Tabebordbar, M., Gorbatov, R., et al. (2013). Modified mRNA directs the fate of
heart progenitor cells and induces vascular regeneration after myocardial infarction.
Nat. Biotechnol. 31, 898–907.
284. Phua, K.K., Staats, H.F., Leong, K.W., and Nair, S.K. (2014). Intranasal mRNA nano-
particle vaccination induces prophylactic and therapeutic anti-tumor immunity. Sci.
Rep. 4, 5128.
285. Antony, J.S., Dewerth, A., Haque, A., Handgretinger, R., and Kormann, M.S. (2015).
Modified mRNA as a new therapeutic option for pediatric respiratory diseases and
hemoglobinopathies. Mol. Cell Pediatr. 2, 11.
286. Semple, S.C., Akinc, A., Chen, J., Sandhu, A.P., Mui, B.L., Cho, C.K., Sah, D.W.,
Stebbing, D., Crosley, E.J., Yaworski, E., et al. (2010). Rational design of cationic
lipids for siRNA delivery. Nat. Biotechnol. 28, 172–176.
287. Litzinger, D.C., Brown, J.M., Wala, I., Kaufman, S.A., Van, G.Y., Farrell, C.L., and
Collins, D. (1996). Fate of cationic liposomes and their complex with oligonucleo-
tide in vivo. Biochim. Biophys. Acta 1281, 139–149.
288. Ma, Z., Zhang, J., Alber, S., Dileo, J., Negishi, Y., Stolz, D., Watkins, S., Huang, L.,
Pitt, B., and Li, S. (2002). Lipid-mediated delivery of oligonucleotide to pulmonary
endothelium. Am. J. Respir. Cell Mol. Biol. 27, 151–159.
289. Eastman, S.J., Lukason, M.J., Tousignant, J.D., Murray, H., Lane, M.D., St George,
J.A., Akita, G.Y., Cherry, M., Cheng, S.H., and Scheule, R.K. (1997). A concentrated
and stable aerosol formulation of cationic lipid:DNA complexes giving high-level
gene expression in mouse lung. Hum. Gene Ther. 8, 765–773.
290. Lee, E.R., Marshall, J., Siegel, C.S., Jiang, C., Yew, N.S., Nichols, M.R., Nietupski, J.B.,
Ziegler, R.J., Lane, M.B.,Wang, K.X., et al. (1996). Detailed analysis of structures and
formulations of cationic lipids for efficient gene transfer to the lung. Hum. Gene
Ther. 7, 1701–1717.
291. Scheule, R.K., St George, J.A., Bagley, R.G., Marshall, J., Kaplan, J.M., Akita, G.Y.,
Wang, K.X., Lee, E.R., Harris, D.J., Jiang, C., et al. (1997). Basis of pulmonary toxicity
associated with cationic lipid-mediated gene transfer to the mammalian lung. Hum.
Gene Ther. 8, 689–707.
292. Michel, T., Luft, D., Abraham, M.K., Reinhardt, S., Salinas Medina, M.L., Kurz, J.,
Schaller, M., Avci-Adali, M., Schlensak, C., Peter, K., et al. (2017). Cationic
Nanoliposomes Meet mRNA: Efficient Delivery of Modified mRNA Using
Hemocompatible and Stable Vectors for Therapeutic Applications. Mol. Ther.
Nucleic Acids 8, 459–468.
293. Borel, F., Sun, H., Zieger, M., Cox, A., Cardozo, B., Li, W., Oliveira, G., Davis, A.,
Gruntman, A., Flotte, T.R., et al. (2018). Editing out five Serpina1 paralogs to create
a mouse model of genetic emphysema. Proc. Natl. Acad. Sci. USA 115, 2788–2793.
294. Ramaswamy, S., Tonnu, N., Tachikawa, K., Limphong, P., Vega, J.B., Karmali, P.P.,
Chivukula, P., and Verma, I.M. (2017). Systemic delivery of factor IX messenger
RNA for protein replacement therapy. Proc. Natl. Acad. Sci. USA 114, E1941–
E1950.
295. Akinc, A., Thomas, M., Klibanov, A.M., and Langer, R. (2005). Exploring polyethy-
lenimine-mediated DNA transfection and the proton sponge hypothesis. J. Gene
Med. 7, 657–663.
296. Boussif, O., Lezoualc’h, F., Zanta, M.A., Mergny, M.D., Scherman, D., Demeneix, B.,
and Behr, J.P. (1995). A versatile vector for gene and oligonucleotide transfer into
cells in culture and in vivo: polyethylenimine. Proc. Natl. Acad. Sci. USA 92,
7297–7301.
297. Lungwitz, U., Breunig, M., Blunk, T., and Göpferich, A. (2005). Polyethylenimine-
based non-viral gene delivery systems. Eur. J. Pharm. Biopharm. 60, 247–266.
298. Lv, H., Zhang, S., Wang, B., Cui, S., and Yan, J. (2006). Toxicity of cationic lipids and
cationic polymers in gene delivery. J. Control. Release 114, 100–109.
299. Schaffer, D.V., Fidelman, N.A., Dan, N., and Lauffenburger, D.A. (2000). Vector
unpacking as a potential barrier for receptor-mediated polyplex gene delivery.
Biotechnol. Bioeng. 67, 598–606.
300. Zhao, M., Li, M., Zhang, Z., Gong, T., and Sun, X. (2016). Induction of HIV-1 gag
specific immune responses by cationic micelles mediated delivery of gag mRNA.
Drug Deliv. 23, 2596–2607.
301. Convertine, A.J., Benoit, D.S., Duvall, C.L., Hoffman, A.S., and Stayton, P.S. (2009).
Development of a novel endosomolytic diblock copolymer for siRNA delivery.
J. Control. Release 133, 221–229.
302. Cheng, C., Convertine, A.J., Stayton, P.S., and Bryers, J.D. (2012). Multifunctional
triblock copolymers for intracellular messenger RNA delivery. Biomaterials 33,
6868–6876.
303. Suk, J.S., Lai, S.K., Wang, Y.Y., Ensign, L.M., Zeitlin, P.L., Boyle, M.P., and Hanes, J.
(2009). The penetration of fresh undiluted sputum expectorated by cystic fibrosis
patients by non-adhesive polymer nanoparticles. Biomaterials 30, 2591–2597.
304. Schuster, B.S., Suk, J.S., Woodworth, G.F., and Hanes, J. (2013). Nanoparticle diffu-
sion in respiratory mucus from humans without lung disease. Biomaterials 34,
3439–3446.
305. Schneider, C.S., Xu, Q., Boylan, N.J., Chisholm, J., Tang, B.C., Schuster, B.S.,
Henning, A., Ensign, L.M., Lee, E., Adstamongkonkul, P., et al. (2017).
Nanoparticles that do not adhere to mucus provide uniform and long-lasting
drug delivery to airways following inhalation. Sci. Adv. 3, e1601556.
306. Mahiny, A.J., Dewerth, A., Mays, L.E., Alkhaled, M., Mothes, B., Malaeksefat, E.,
Loretz, B., Rottenberger, J., Brosch, D.M., Reautschnig, P., et al. (2015). In vivo
genome editing using nuclease-encoding mRNA corrects SP-B deficiency. Nat.
Biotechnol. 33, 584–586.
307. Baba, M., Itaka, K., Kondo, K., Yamasoba, T., and Kataoka, K. (2015). Treatment of
neurological disorders by introducing mRNA in vivo using polyplex nanomicelles.
J. Control. Release 201, 41–48.
308. Matsui, A., Uchida, S., Ishii, T., Itaka, K., and Kataoka, K. (2015). Messenger RNA-
based therapeutics for the treatment of apoptosis-associated diseases. Sci. Rep. 5,
15810.
309. Kaczmarek, J.C., Patel, A.K., Kauffman, K.J., Fenton, O.S., Webber, M.J., Heartlein,
M.W., DeRosa, F., and Anderson, D.G. (2016). Polymer-Lipid Nanoparticles for
Systemic Delivery of mRNA to the Lungs. Angew. Chem. Int. Ed. Engl. 55,
13808–13812.
310. Hao, Z., Qu, B., Wang, Y., Tang, S., Wang, G., Qiu, M., Zhang, R., Liu, Y., and Xiao,
X. (2011). Preparation and characterization of lung-targeting ceftiofur-loaded
gelatin microspheres. Drug Dev. Ind. Pharm. 37, 1422–1428.
311. Youngren-Ortiz, S.R., Hill, D.B., Hoffmann, P.R., Morris, K.R., Barrett, E.G., Forest,
M.G., and Chougule, M.B. (2017). Development of Optimized, Inhalable,
Gemcitabine-Loaded Gelatin Nanocarriers for Lung Cancer. J. Aerosol Med.
Pulm. Drug Deliv. 30, 299–321.
312. Kozak, M. (1987). An analysis of 50-noncoding sequences from 699 vertebrate
messenger RNAs. Nucleic Acids Res. 15, 8125–8148.
313. Lai, E.C., and Posakony, J.W. (1997). The Bearded box, a novel 30 UTR sequence
motif, mediates negative post-transcriptional regulation of Bearded and Enhancer
of split Complex gene expression. Development 124, 4847–4856.
314. Desrosiers, R., Friderici, K., and Rottman, F. (1974). Identification of methylated
nucleosides in messenger RNA from Novikoff hepatoma cells. Proc. Natl. Acad.
Sci. USA 71, 3971–3975.
315. Patel, A.K., Kaczmarek, J.C., Bose, S., Kauffman, K.J., Mir, F., Heartlein, M.W.,
DeRosa, F., Langer, R., and Anderson, D.G. (2019). Inhaled Nanoformulated
mRNA Polyplexes for Protein Production in Lung Epithelium. Adv. Mater. 31,
e1805116.
316. Li, J., Wang,W., He, Y., Li, Y., Yan, E.Z., Zhang, K., Irvine, D.J., and Hammond, P.T.
(2017). Structurally Programmed Assembly of Translation Initiation Nanoplex for
Superior mRNA Delivery. ACS Nano 11, 2531–2544.
317. Wang, X., Lu, Z., Gomez, A., Hon, G.C., Yue, Y., Han, D., Fu, Y., Parisien, M., Dai,
Q., Jia, G., et al. (2014). N6-methyladenosine-dependent regulation of messenger
RNA stability. Nature 505, 117–120.
318. Agu, R.U., Ugwoke, M.I., Armand, M., Kinget, R., and Verbeke, N. (2001). The lung
as a route for systemic delivery of therapeutic proteins and peptides. Respir. Res. 2,
198–209.
822 Molecular Therapy Vol. 27 No 4 April 2019
www.moleculartherapy.org
Review
319. Kreyling, W.G., Hirn, S., and Schleh, C. (2010). Nanoparticles in the lung. Nat.
Biotechnol. 28, 1275–1276.
320. Sijts, A.J.A.M., Standera, S., Toes, R.E.M., Ruppert, T., Beekman, N.J.C.M., van
Veelen, P.A., Ossendorp, F.A., Melief, C.J., and Kloetzel, P.M. (2000). MHC class
I antigen processing of an adenovirus CTL epitope is linked to the levels of immu-
noproteasomes in infected cells. J. Immunol. 164, 4500–4506.
321. Kaczmarek, J.C., Kowalski, P.S., and Anderson, D.G. (2017). Advances in the deliv-
ery of RNA therapeutics: from concept to clinical reality. Genome Med. 9, 60.
322. Muthukrishnan, S., Both, G.W., Furuichi, Y., and Shatkin, A.J. (1975). 50-Terminal
7-methylguanosine in eukaryotic mRNA is required for translation. Nature 255,
33–37.
323. Vachon, V.K., Calderon, B.M., and Conn, G.L. (2015). A novel RNA molecular
signature for activation of 20-50 oligoadenylate synthetase-1. Nucleic Acids Res.
43, 544–552.
324. Luthra, P., Sun, D., Silverman, R.H., and He, B. (2011). Activation of IFN-b expres-
sion by a viral mRNA through RNase L and MDA5. Proc. Natl. Acad. Sci. USA 108,
2118–2123.
Molecular Therapy Vol. 27 No 4 April 2019 823
www.moleculartherapy.org
Review
